
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c793a546-8000-4ef3-b463-2f3103d5b0bb,g:76bc2861-d437-4803-aadf-f81ff54c4e7d,d:de71da3b0d1e4a41a1afea061e2d3dd6--><meta http-equiv="Content-Type" content="text/html">


<title>blcm-20211231</title><div style="display:none"><ix:header><ix:hidden><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityCentralIndexKey" id="fact-identifier-0" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl80L2ZyYWc6MjMwZTg2YzQxYWYzNDA4ZDg0YzBkY2M0MGIxZDI3ODIvdGFibGU6ZTYwMDI3YzBhZmY5NGE1YmJkODhkYTNhM2MyMTAwMTUvdGFibGVyYW5nZTplNjAwMjdjMGFmZjk0YTViYmQ4OGRhM2EzYzIxMDAxNV8zLTEtMS0xLTE2Njg0_7c035524-baa3-4063-9c51-7e4a97a131f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001358403</ix:nonnumeric></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="fact-identifier-1" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl80L2ZyYWc6MjMwZTg2YzQxYWYzNDA4ZDg0YzBkY2M0MGIxZDI3ODIvdGFibGU6ZTYwMDI3YzBhZmY5NGE1YmJkODhkYTNhM2MyMTAwMTUvdGFibGVyYW5nZTplNjAwMjdjMGFmZjk0YTViYmQ4OGRhM2EzYzIxMDAxNV85LTEtMS0xLTE2Njg0_e3cde059-d356-4407-9f57-6460e59cbc03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="fact-identifier-2" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl80L2ZyYWc6MjMwZTg2YzQxYWYzNDA4ZDg0YzBkY2M0MGIxZDI3ODIvdGFibGU6ZTYwMDI3YzBhZmY5NGE1YmJkODhkYTNhM2MyMTAwMTUvdGFibGVyYW5nZTplNjAwMjdjMGFmZjk0YTViYmQ4OGRhM2EzYzIxMDAxNV8xMC0xLTEtMS0xNjY4NA_8448285a-f327-4711-88ae-356ccb42cdfa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:AmendmentFlag" id="fact-identifier-3" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl80L2ZyYWc6MjMwZTg2YzQxYWYzNDA4ZDg0YzBkY2M0MGIxZDI3ODIvdGFibGU6ZTYwMDI3YzBhZmY5NGE1YmJkODhkYTNhM2MyMTAwMTUvdGFibGVyYW5nZTplNjAwMjdjMGFmZjk0YTViYmQ4OGRhM2EzYzIxMDAxNV8xMS0xLTEtMS0xNjY4NA_009eaaa0-7f3e-4b4b-a3b8-262a6a6c2b2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span><span><ix:nonfraction unitref="number" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="fact-identifier-4" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83OS9mcmFnOjQ2OTI0NmU4ZDZkNTRmZDg5MzhjZDEwY2MzNDJhMzRmL3RhYmxlOmY0OTY1NmFmMTBmODRmNDM5ODViZGY2ODRiMjYzOWViL3RhYmxlcmFuZ2U6ZjQ5NjU2YWYxMGY4NGY0Mzk4NWJkZjY4NGIyNjM5ZWJfMS0xLTEtMS0xNjY4NA_3684b844-9318-43dd-b128-cb3e5286dd67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span><span><ix:nonfraction unitref="number" contextref="i5589153f75b14902b004fd798ed3215d_D20200205-20200205" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="fact-identifier-5" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85MS9mcmFnOmJmYjEyYmZhZGNiNDQyMmZhMTIwYWExMTZmZDY3YmIwL3RleHRyZWdpb246YmZiMTJiZmFkY2I0NDIyZmExMjBhYTExNmZkNjdiYjBfMTcx_5d62d2e7-245f-4603-afc2-0e6f042b6148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span><span><ix:nonfraction unitref="shares" contextref="ice8621cd26cf4fdc9966ac003cf1f721_D20211204-20211204" decimals="INF" name="blcm:ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight" scale="0" id="fact-identifier-6" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMzQxL2ZyYWc6MzQ1Mzc2NGU4NTllNGEzZDhjNjJiZjA0ZjRmZmRmZDMvdGV4dHJlZ2lvbjozNDUzNzY0ZTg1OWU0YTNkOGM2MmJmMDRmNGZmZGZkM185MzQ1ODQ4ODM2NDAw_76636ea6-6440-49fa-b88b-f9e33b28bc2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span><span><ix:nonnumeric contextref="i036f43da78cd4d5a9a447a47f85acaf6_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="fact-identifier-7" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMzQxL2ZyYWc6MzQ1Mzc2NGU4NTllNGEzZDhjNjJiZjA0ZjRmZmRmZDMvdGV4dHJlZ2lvbjozNDUzNzY0ZTg1OWU0YTNkOGM2MmJmMDRmNGZmZGZkM18yMTk5MDIzMjU1NjQw_eaf8b34c-0e86-4ffd-84df-5b096399e9df" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">P0Y</ix:nonnumeric></span><span><ix:nonnumeric contextref="if0a2e56672544f4d9720011d110ec46e_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="fact-identifier-8" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMzQxL2ZyYWc6MzQ1Mzc2NGU4NTllNGEzZDhjNjJiZjA0ZjRmZmRmZDMvdGV4dHJlZ2lvbjozNDUzNzY0ZTg1OWU0YTNkOGM2MmJmMDRmNGZmZGZkM18yMTk5MDIzMjU1NjMz_54daca09-d299-4260-8fe7-18d332646b81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">P0Y</ix:nonnumeric></span><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzM4NDgyOTA3MDcwMTk_a17e1c62-af41-44b8-899c-87995b64e5c6">P2Y</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzY5OTE_632c5823-5f58-4cb2-b266-e4f4f5e012c1">P10D</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcwNzc_e759e84a-050d-439c-80a0-b78dabfbc676">P10D</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="blcm-20211231.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5468f81bfcb4c6886b6263e39acc5bd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie9fc543d6d5940cd8d5b55dc2f927647_I20220321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236c04c5165044769887aa3cb89df57a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4a78daf18e4d4444a873de7ad4b3dff5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f2df821c7c74542bdf0f02561b57bfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8197c47b53244633b86290ed0d8a0a9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:SupplyAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14fbc315d00d4cfb8bcf75d8905f7337_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:SupplyAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i49e41a9785be4a358abf336c5012c31d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:LicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0d6f31c6fa964fcab52a7a4bf2b34862_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:LicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1e39ffd71a84496a0777d73585f2ad6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:SupplyAgreementAndLicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic52559a7a1de41bdb34aac1e042e3fd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">blcm:SupplyAgreementAndLicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6005e4e2600496eacd7133e6cbbc6b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270ba8e9980b47baa9945d3afc7b23ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda9d2641e7847b792e2baa55f098195_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f4fd14058040819142b3a3682c7815_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdf7ac618464cdc87976bf10e6ba688_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3390ec76a6b040df98b7edab94eaaec0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae66221f10e47949897a952036d7680_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab5298264bba49d687b45d538a946669_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc4aff4354f7407693da8140420899ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06446714655e44b0bbcc02310f59a608_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36dcd997b73b408e8f6d2cd5f014ef7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib607e68aa1b24b61906b8997c1b81421_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia124e39a89294e649f6c2fcc64b9d47a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba061572fbc45989dc245feefe6e544_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44415b809fe84311823510ac1a664238_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43455d9c6bc2493caf9ac4680bf8aecb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc165ec32d85465d96eaf628fdb7c81e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb5f34373434fef8ec9f96f55451803_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i564e615d88a24980a0e4df003a5382ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0bf8488c873418a99609b6fd35b3885_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1b42b25f0734d2490e534472aa95f9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7642c00ae4f4ec583c78dbcc8782679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50315a911ef84b559894ae80afb809f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b41e8f7657434289c92793a055c713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e05e74e201143acb0c1666360398d67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9289f5e30d4f61870d1098c203861e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f897c7d761462aabf05ee0c0b28959_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>blcm:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>blcm:segment</xbrli:measure></xbrli:unit><xbrli:context id="i47fea5ad8abd4bbf9f75e99524a4d163_I20200204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17a5142cdcc4ce8a220db71d648fa86_I20200205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cf2b55430f4019b410337d7717d334_I20200614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733849ef74504c28964019582a43ef48_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf9fa5695b941d99db8c96d059ea1fb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">blcm:TakedaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iecb1e483333a485ab9ecce6be458637d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:MDAndersonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d15b7b6d1e94bde9ac536c88a06851f_D20200414-20200414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:A2130W.HolcombeBlvd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-14</xbrli:startdate><xbrli:enddate>2020-04-14</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f20fc086b374ccdb6df517498fff915_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:ResearchAndDevelopmentFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cdbd9b9b188403f93314e3343a81afa_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:ResearchAndDevelopmentFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:ReedRoadHoustonTXMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idceb87b2e4bc48a592ea6f325e3399eb_D20210315-20210315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-03-15</xbrli:startdate><xbrli:enddate>2021-03-15</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i807426abce39417e85c2b2d54aace245_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6991c90827564c2aabd5fe8e3909b9c2_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066342492db944de806136139abade48_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d68d2cea79442d8f597ee73ada01a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3f40d22d071427d81353598d6cac168_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i88aa024e2d884c569e5cf292f8f5372e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e2a121b78854d30be8796f794388932_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59ae1df39ae145e0863c07163a179c3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7450386338cb40fa9c82c4a56156dea0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca56416361c44eabf0c13b56e7d74c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9acce5a3a0534092b158ed744a273675_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ac7473376540ce8ca91a46bf14add5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6615dadd0c4d8fb3e5dc94cfcbaa51_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">blcm:ManufacturingEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4cb9807f5ef549269fe62572a5c7f78d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">blcm:ManufacturingEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf4b7646dbf4d5aa825c03ca6c9affa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">blcm:ManufacturingEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28527a1ff1aa4559a4d40897a6dc1a39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80cefc192e1149ccb3c4ebf1a7e7274a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i850ab4078f234749b4e9b46d0b852d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741e89e6497945fdb9b592b0c23595fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcdea42408f740b8894840014d5aaa60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabb2e91846094a18b7b7195eeef64f56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife363db7ddbd448c8b52d37166de46e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550c48074d4a4c6e9f46c274eca07adf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42cd2bebc534723abfd2794b121dd10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3fd3938d544841399a920cc75b84c1f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6fd0f81e5de6497ab96125c754b1a270_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idcc9d1f406f1468bab9d96585ee49ac6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85c43e0099974f2c96d8d65176b416cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80c09730973e494d9604a078ae0789c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7291d40f8b8d4a35bb5a7844a02d6d84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i51e2c4cb965f49568b7ddf3cf4034629_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7554edb959f2477ca9152b14a5ea59a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i820931bfd608449387c86d23ddb78592_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5589153f75b14902b004fd798ed3215d_D20200205-20200205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-05</xbrli:startdate><xbrli:enddate>2020-02-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaadf80ff2fb843c8b7b5ad1b8d24a7bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be28a1b69b140a4a0d42e31e606cdc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2bea2442214cd58a87bd1dd9e0eb5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd1576642634498a3ae399ffb58e423_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie416e19ccd7e4d1180a83271076fdd2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38bb9b6283364f49a44f66c8336eb323_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib520ab89d65b43428caf3691f4a0223d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if59a539aa3a84094875ebf2288f7f698_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2591ba79d8b44645880b208c04c4dfd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6c6baf87684479a4f330127176a713_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d4ab66f78a4b0189a572ce60b43ef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff90f34369747d99cc5527c2de360e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152d7bd2d2244bbb8e164ea87a6cb427_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:WarrantDerivativeLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0346bc06dc7b4c1197eed20af6fc7913_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:WarrantDerivativeLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i42ed175dd0fa4ee5a08aa7cf7f205e52_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">blcm:HoustonTexasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1367724e706543e0ac1a58c9c3c5444c_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:ResearchAndDevelopmentFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2928d70a4c294b5cbb91813850f56d81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:ResearchAndDevelopmentFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba0c172ad2c64a8c8f5d8eea1dd744f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">blcm:SanFranciscoOfficeSpaceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0e2813a3ee0e4e2f99d15c8285718655_I20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">blcm:OxfordLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64d051bd51d4728a00d89379ea857ac_D20171221-20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">blcm:HerculesLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-12-21</xbrli:startdate><xbrli:enddate>2017-12-21</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46fd340b112349708dde16636df6e630_D20171221-20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">blcm:OxfordLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-12-21</xbrli:startdate><xbrli:enddate>2017-12-21</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i779b010644c2422ab46cb955249d0ba0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">blcm:OxfordLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1f2c6a642de4c239e41f6c1faaee71f_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">blcm:OxfordLoanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-11-01</xbrli:startdate><xbrli:enddate>2020-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1933ec3b38aa4fccacd6f69a9fa72567_I20211204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:December2021PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8621cd26cf4fdc9966ac003cf1f721_D20211204-20211204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:December2021PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-04</xbrli:startdate><xbrli:enddate>2021-12-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4670d1c5aa28403ca34a064c8e31781d_D20211204-20211204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:December2021PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-04</xbrli:startdate><xbrli:enddate>2021-12-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9082828cad6b4405a8d40811842239b4_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:November2020UnderwrittenOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:November2020UnderwrittenOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-11-02</xbrli:startdate><xbrli:enddate>2020-11-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98ea0b692bea4b2aad6645d7dc7fe076_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:November2020UnderwrittenOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-11-02</xbrli:startdate><xbrli:enddate>2020-11-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6aef2c2186c4f2da748dd183f26a8eb_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:November2020UnderwrittenOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-11-02</xbrli:startdate><xbrli:enddate>2020-11-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9ba5bd43a4f4124b8dc1624a7ec8aa1_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-16</xbrli:startdate><xbrli:enddate>2019-08-16</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i382a6ed5a2094a409a6c38ff25e8b573_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637e568e11f54af08fb024dea2b251ab_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd5d8e93865417f8b7913f3e4f8a9de_D20190821-20190821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-21</xbrli:startdate><xbrli:enddate>2019-08-21</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib147d3c88f894b2dbefc3315da0f987e_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i713c3cce74c84a89861e978700f74605_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919b66337c4e44b7a245422d8aec0b2d_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">blcm:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0959896ecc7431e959b752d3863f8d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">blcm:WarrantDerivativeLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4eb1cd202340b4bc735a8b464e862b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">blcm:WarrantDerivativeLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e00fcfd10ee4a5b99fdd49917102609_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">blcm:WarrantDerivativeLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0893334e832a4c4c952688a563749369_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series2PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-16</xbrli:startdate><xbrli:enddate>2019-08-16</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2d6bd600428941e3bba159d84401718f_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series2PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49d16349f5874275a7532fef1b358c0c_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series3PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-16</xbrli:startdate><xbrli:enddate>2019-08-16</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20dbd00730a8427da42a70ff8a5695bd_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d8309509e674155b9d4f0c57e5668c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:A2019IssuedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e11c30f7584f0dbd95e510b96aef8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:A2020IssuedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i036f43da78cd4d5a9a447a47f85acaf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:IssuedOnNovember22020Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:A2021IssuedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a2e56672544f4d9720011d110ec46e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">blcm:IssuedOnDecember72021Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccaf58778004b12a0b950fb7ac915bc_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d0f94167d6416480140728dba0a23b_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if439c35e57f84f8198941723e0bb891e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series2PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa898288c1094519b1b2a863aebd2629_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series3PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i162a4a2602074271bd15a1bff826ea96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec2cb72cd6c4787a50a1c0b755892f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1322c0bf879f4b78ab0cd5d18b363cb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series2PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741ac74c96474994908a43a0dd00cbe5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series3PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf8f1df9f314548bbe07dc3661f75f8_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">blcm:Series2PreferredStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>blcm:plan</xbrli:measure></xbrli:unit><xbrli:context id="i1c15b69bc95943e99465b595082081eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8015dbb7c1574fcba04a45a6e113ddd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06813ca5a85147509b9b8c6443b909f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51fd5ec5af4430f978c4e71af75c33f_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d02271004464836a18b9b40a78284ce_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-06-01</xbrli:startdate><xbrli:enddate>2020-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69a898e7a0584ba28886035348e44ad7_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd00764da8f34e98a98f83a0dab746dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcbf9a3391e948e48670553130152f59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c45a21c3d0472ab6ea23a4f224cfbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd51add8d0a94eeaa9c011e415bbac4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">blcm:InducementEmployeeStockOptionsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530c634326904ca2a7f8ffa95df1bbd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">blcm:InducementEmployeeStockOptionsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9831a006f77b4237af44fc5389d816f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1febabe6349142acb0a8f83cf9916ba9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179edf8ed8864615a3d50b23fcd54cc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">blcm:InducementRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2202e685554aa7b28f5aff7494df0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">blcm:InducementRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd89d8fbf2c2419cb132f0458660da5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2019EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i74121680cdef41be8bf7bf100d5a65ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9884a3e5eb4975a054f6c2b8dcaea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470cd8b3357a46c09250fbdf29b03991_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a57fe3b57954d4c83f03d8769a5af5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321a29f91052497988a21cbd5d4abe98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i71368a124d1f420287367ea7de54c757_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f1d90f3233446581331846a4699635_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeThreeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2ec28ce16ad543e2bf23db163827b093_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeThreeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee826079f8e4f15bdce1faa3872a89b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeFourMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id2d02bf18ec4491188894537f5978a65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeFourMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4159706212924c2db71ce2e3fecb58db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeFiveMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i055b3841f68346ef8dadf5be51362c5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">blcm:ExercisePriceRangeFiveMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idefb4e4db80f469dabd2ece3778621d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5064785f80634863b0f4c9c2673da546_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i62438e1ebbc54cda81f31f2e249e5cc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5948a95daefa4444a028a32b389dd760_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9837e2de40444a3da4cc7744f165c7fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b53d27909f47cbab2d407eeb884583_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd2fa016ad5485bb7b1576710652c92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idbf131eb73fd45b19f335f6d7c85f619_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5577f5996ca64249bfb81900a55916d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">blcm:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8242ed350741b8bf827bd154cc8de6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i081fe2a72cb64249bb7119c9e82e2a6e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1c7fe4824dc40a385728be9a468220f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaebebeee6aed41b6a12ed261796cc1ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6c97dd59b684f59ae717bfca06c038a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:BaylorMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6bbc842116f4dadb9175bdacc0aeb63_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:BaylorMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4490bf4fd09f4f5e83e18a46e04d0ec0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:BaylorMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:AgensysInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2015-12-10</xbrli:startdate><xbrli:enddate>2015-12-10</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i850e911b14374e8896439c73c6dd8959_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">blcm:BioVecPharmaIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2015-06-10</xbrli:startdate><xbrli:enddate>2015-06-10</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>blcm:product</xbrli:measure></xbrli:unit><xbrli:context id="ieaf683b96ef84367851ace784f569fdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9cac21fa3564560b6a11612f4f5157e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992c81554c22419c9fb83c9319dba987_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95535ea4bdc14a92b088e61d0092bc8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12df86319c3c4b788412c7e1c9748209_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8b1692698a4f07b46ede7dd7e20ae0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001358403</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_1"></div><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentType" id="fact-identifier-9" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQy_7ed5058e-b7e4-4ab6-8120-9459f54fdb19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark&nbsp;One)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="fact-identifier-10" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTUz_5ec36985-5662-43b7-86f1-91d5a3274da6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="fact-identifier-11" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8xNTk0MjkxODYwODUyNg_54833806-c4b5-4ff9-a681-91f1f8ee634b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="fact-identifier-12" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8xNTk0MjkxODYwODUyNg_51443186-62a1-4f71-b417-1a10ae366447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December&nbsp;31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="fact-identifier-13" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ5_316f917f-101c-40b8-9f17-1ff8b0b848aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityFileNumber" id="fact-identifier-14" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ0_16359769-0e1d-4432-8ef5-32737370dd16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-36783</ix:nonnumeric></span> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityRegistrantName" id="fact-identifier-15" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQz_04bd3431-0093-4a24-8cd5-5c363b05a0b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Bellicum Pharmaceuticals, Inc.</ix:nonnumeric></span> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="padding-left:216pt;padding-right:216pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="fact-identifier-16" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6NzA1YWE4ODQyYjUyNGRiNmJiYzkwZDE1NDhmMzJjMTgvdGFibGVyYW5nZTo3MDVhYTg4NDJiNTI0ZGI2YmJjOTBkMTU0OGYzMmMxOF8wLTAtMS0xLTE2Njg0_606fb654-118b-4118-9732-0ec04c479184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="fact-identifier-17" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6NzA1YWE4ODQyYjUyNGRiNmJiYzkwZDE1NDhmMzJjMTgvdGFibGVyYW5nZTo3MDVhYTg4NDJiNTI0ZGI2YmJjOTBkMTU0OGYzMmMxOF8wLTItMS0xLTE2Njg0_c636e497-501b-40c9-a9f3-306037044bd0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20-1450200</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center;text-indent:36pt"><span><br></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="fact-identifier-18" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ1_87c06d01-f1ea-4777-bc9c-66d74804f70b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3730 Kirby Drive, Suite 1200</ix:nonnumeric></span>, <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="fact-identifier-19" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTU1_500bc1fd-5222-4941-8230-7599b08cbe88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Houston</ix:nonnumeric></span>, <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="fact-identifier-20" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQw_c010907e-242f-499e-a63b-1f9b9e418f55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">TX</ix:nonnumeric></span> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="fact-identifier-21" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTUw_24687e98-0116-4ddd-afbf-a2692ce9d33c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77098</ix:nonnumeric></span></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">    (Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Zip code)</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:CityAreaCode" id="fact-identifier-22" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl85MzQ1ODQ4ODQxNzky_96f12912-3b2e-479a-9260-7f7506bcfa7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">281</ix:nonnumeric></span>) <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:LocalPhoneNumber" id="fact-identifier-23" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ2_97921e1d-caa5-48e1-9279-5f0c7e5b9f10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">454-3424</ix:nonnumeric></span></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrants telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4pt;text-align:center"><span><br></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Act: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:Security12bTitle" id="fact-identifier-24" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6MzkyMWQxZmViOWYzNGFlNjk2MDRlYjZkNzE4ZGEzOTUvdGFibGVyYW5nZTozOTIxZDFmZWI5ZjM0YWU2OTYwNGViNmQ3MThkYTM5NV8xLTAtMS0xLTE2Njg0_c988b732-d199-43e8-a751-1ad6a022c5b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, par value $0.01&nbsp;per share</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:TradingSymbol" id="fact-identifier-25" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6MzkyMWQxZmViOWYzNGFlNjk2MDRlYjZkNzE4ZGEzOTUvdGFibGVyYW5nZTozOTIxZDFmZWI5ZjM0YWU2OTYwNGViNmQ3MThkYTM5NV8xLTEtMS0xLTE2Njg0_6c4d4a4b-7639-4f70-8a6a-cf8a609be1ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">BLCM</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">The <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="fact-identifier-26" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6MzkyMWQxZmViOWYzNGFlNjk2MDRlYjZkNzE4ZGEzOTUvdGFibGVyYW5nZTozOTIxZDFmZWI5ZjM0YWU2OTYwNGViNmQ3MThkYTM5NV8xLTItMS0xLTIwNzM1L3RleHRyZWdpb246NmJkMzU2YzE1NDkxNGNiYmE0NGZjYTFlNzJkZDA1YjZfMTQ4NDM0MDY5NzUwMTE_9e792789-c177-48e3-9ba7-08a417c47572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span> Capital Market</span></div></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(g) of the Act: None </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-27" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ3_f31fb3e0-ad1c-4eff-ab56-1b600f1e374a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="fact-identifier-28" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTQ4_381aaae6-3849-47f6-8ca8-0f71bfc3a179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="fact-identifier-29" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTM4_2e536342-51f5-4fd1-bb33-4960d8cb52cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (229.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-30" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTUx_837373ee-220c-4910-bad7-eee1414a3c85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule&nbsp;12b-2 of the Exchange Act. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&nbsp;accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="fact-identifier-31" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6ZTdhMWU2MDdjNTZhNDIzZTlhNWVlNDk2YTg4YjEzOGIvdGFibGVyYW5nZTplN2ExZTYwN2M1NmE0MjNlOWE1ZWU0OTZhODhiMTM4Yl8yLTAtMS0xLTE2Njg0_0527d878-fc02-49cb-950e-a597443eba8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&nbsp;reporting&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="fact-identifier-32" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6ZTdhMWU2MDdjNTZhNDIzZTlhNWVlNDk2YTg4YjEzOGIvdGFibGVyYW5nZTplN2ExZTYwN2M1NmE0MjNlOWE1ZWU0OTZhODhiMTM4Yl8yLTQtMS0xLTE2Njg0_fc82c195-3d4c-4627-8ba4-4134386af9e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span><br></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="fact-identifier-33" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGFibGU6ZTdhMWU2MDdjNTZhNDIzZTlhNWVlNDk2YTg4YjEzOGIvdGFibGVyYW5nZTplN2ExZTYwN2M1NmE0MjNlOWE1ZWU0OTZhODhiMTM4Yl8zLTQtMS0xLTE2Njg0_cbdc4f9e-cf55-4ab3-a404-d98c92997aab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span><br></span></td></tr></tbody></table></div><div style="text-indent:24.75pt"><span><br></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="fact-identifier-34" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTUy_05d53e72-4044-4160-bf89-cee4aa65e422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="fact-identifier-35" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTM5_d2efc118-288f-45ee-a9ee-63df27d23975" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br></span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">The approximate aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based upon the last sale price of the common stock as reported on The Nasdaq Capital Market as of June 30, 2021 was $<span><ix:nonfraction unitref="usd" contextref="ie5468f81bfcb4c6886b6263e39acc5bd_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-36" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zMTEx_5997a4bb-0998-4d25-9c55-25e09de11576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,796,617</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Shares of the Registrant's common stock held by each executive officer, director and stockholder that the registrant concluded were affiliates of the registrant have been excluded from such calculation . This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">As of March&nbsp;21, 2022, there were <span><ix:nonfraction unitref="shares" contextref="ie9fc543d6d5940cd8d5b55dc2f927647_I20220321" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-37" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zNDgw_0cecf139-e316-4cd1-98c2-be24d09cad09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,552,207</ix:nonfraction></span> shares of the Registrant's common stock, par value $0.01 per share, outstanding.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:174%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="fact-identifier-38" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xL2ZyYWc6MWRlZmZlZGNmZWNhNGE5NmE4YzhlNGRkY2Q0MWM4MDYvdGV4dHJlZ2lvbjoxZGVmZmVkY2ZlY2E0YTk2YThjOGU0ZGRjZDQxYzgwNl8zOTU0_9e5cc1a6-9a9c-4085-a795-fe713ec64aa7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Portions of the Registrants Definitive Proxy Statement relating to its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days following the Registrants fiscal year ended December 31, 2021.</ix:nonnumeric></span></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BELLICUM PHARMACEUTICALS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form&nbsp;10-K </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December 31, 2021 </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_10" tabindex="18">PART&nbsp;I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_16" tabindex="18">Item&nbsp;1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_16" tabindex="18">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_16" tabindex="18">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_19" tabindex="18">Item&nbsp;1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_19" tabindex="18">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_19" tabindex="18">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_22" tabindex="18">Item 1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_22" tabindex="18">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_22" tabindex="18">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_25" tabindex="18">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_25" tabindex="18">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_25" tabindex="18">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_28" tabindex="18">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_28" tabindex="18">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_28" tabindex="18">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_31" tabindex="18">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_31" tabindex="18">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_31" tabindex="18">54</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_34" tabindex="18">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_37" tabindex="18">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_37" tabindex="18">Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_37" tabindex="18">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_40" tabindex="18">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_40" tabindex="18">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_40" tabindex="18">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_43" tabindex="18">Item 7.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_43" tabindex="18">Managements Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_43" tabindex="18">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_58" tabindex="18">Item 7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_58" tabindex="18">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_58" tabindex="18">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_61" tabindex="18">Item 8.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_61" tabindex="18">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_61" tabindex="18">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_127" tabindex="18">Item 9.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_127" tabindex="18">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_127" tabindex="18">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_130" tabindex="18">Item 9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_130" tabindex="18">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_130" tabindex="18">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_133" tabindex="18">Item 9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_133" tabindex="18">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_133" tabindex="18">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_1331" tabindex="18">Item 9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_1331" tabindex="18">C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_1331" tabindex="18">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_1331" tabindex="18">91</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_136" tabindex="18">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_139" tabindex="18">Item 10.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_139" tabindex="18">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_139" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_142" tabindex="18">Item 11.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_142" tabindex="18">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_142" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_145" tabindex="18">Item 12.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_145" tabindex="18">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_145" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_148" tabindex="18">Item 13.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_148" tabindex="18">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_148" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_151" tabindex="18">Item 14.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_151" tabindex="18">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_151" tabindex="18">92</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_154" tabindex="18">PART&nbsp;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_157" tabindex="18">Item 15.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_154" tabindex="18">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_154" tabindex="18">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_157" tabindex="18">Item 16.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_157" tabindex="18">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_157" tabindex="18">97</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_13"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections entitled Business, Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations, may contain forward-looking statements. We may, in some cases, use words such as anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, will, would or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about: </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the success, cost and timing of our product development activities and clinical trials; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to advance Chemical Induction of Dimerization, or CID, CID-based technologies, including CaspaCIDe and GoCAR-T;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the commercialization of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our plans to research, develop and commercialize our product candidates; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to attract collaborators with development, regulatory and commercialization expertise and the success of any such collaborations; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">future agreements with third parties in connection with the commercialization of our product candidates and any other approved product; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the rate and degree of market acceptance of our product candidates; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">regulatory developments in the United States, or U.S., and foreign countries; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the success of competing therapies that are or may become available; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to attract and retain key scientific or management personnel; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to grow our organization and increase the size of our facilities to meet our anticipated growth; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our use of cash and other resources; and </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements reflect our managements beliefs and views with respect to future events and are based on estimates and assumptions as of the filing date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under the heading Risk Factors. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Annual Report by these cautionary statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update these forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise specifically indicated, all information in this Annual Report on Form 10-K has been retroactively adjusted to give effect to a 1-for-10 reverse stock-split that was effective on February 5, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span><br></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our business and our securities. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found in this report on Form 10-K in Item 1A entitled "Risk Factors"</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have incurred net losses from operations in every year since our inception and anticipate that we will continue to incur net losses in the future.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require significant funding to complete the development and commercialization of our product candidates. If we fail to obtain additional financing, we may have to delay, reduce or eliminate our development programs or commercialization efforts.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our current product candidates are in early stage clinical trials, and we may experience unfavorable results in the future.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 outbreak, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to satisfy applicable listing standards, our common stock may be delisted from the Nasdaq Capital Market.</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&nbsp;&nbsp;Business </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company focused on discovering and developing novel, controllable cellular immunotherapies for the treatment of various forms of cancer. We are advancing CAR-T cell therapies, which are an innovative approach in which a patients or donors T cells are genetically modified to carry chimeric antigen receptors, or CARs. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better efficacy and safety outcomes than are seen with current cellular immunotherapies.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell behavior is controlled by cascades of specialized signaling proteins. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. We genetically introduce these molecular switches into immune cells and deliver the cells to the patient in the manner of conventional cellular immunotherapy. We have developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the CAR-T cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the CAR-T cells. Each of our product candidates incorporates one or both switches, for enhanced, real-time control of efficacy and safety:</span></div><div><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inducible MyD88/CD40 (iMC) activation switch that is incorporated into our GoCAR-T product candidates is designed to enhance CAR-T therapies by augmenting multiple mechanisms of action, including: 1) boosting effector cell proliferation; 2) enhancing functional persistence by resisting exhaustion and inhibitory signals found in the tumor microenvironment; and 3) stimulating the cancer patients own immune system to intensify tumor killing. Unlike other CAR-T therapies that can behave unpredictably due to their autonomous activity, GoCAR-T antitumor effects are controlled through scheduled administration of rimiducid. In the event of severe side effects, GoCAR-T activity can be attenuated by extending the interval between rimiducid doses or suspending further rimiducid administration.</span></div><div><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our CaspaCIDe safety switch (also known as inducible Caspase-9, or iC9) is designed to be inactive unless the patient experiences a serious side effect (e.g., CRS, neurologic toxicities or off-tumor / on-target toxicities). In that event, rimiducid or temsirolimus (depending on the design of the product candidate) is administered to induce Caspase-9 and eliminate the cells, with the goal of attenuating the therapy and resolving the serious side effect.</span></div><div><span><br></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of our product candidates are dual-switch GoCAR-Ts that are designed to provide a user-controlled system for managing proliferation, persistence and safety of tumor antigen-specific CAR-T cells by incorporating both our iMC and CaspaCIDe switches.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By incorporating our novel switch technologies, we are developing product candidates with the potential to elicit positive clinical outcomes and ultimately change the treatment paradigm in various areas of cellular immunotherapy. Our most advanced programs are described below.</span></div><div><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">BPX-601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an autologous GoCAR-T product candidate containing our proprietary iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen, or PSCA. We believe iMC enhances T cell proliferation and persistence, enhances host immune activity, and modulates the tumor microenvironment to improve the potential to treat solid tumors compared to traditional CAR-T therapies. A Phase 1/2 clinical trial, called BP-012, in patients with metastatic castration-resistant prostate cancer and metastatic pancreatic cancer expressing PSCA is ongoing.</span></div><div><span><br></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">BPX-603</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an autologous dual-switch GoCAR-T product candidate containing both the iMC activation and CaspaCIDe safety switches. BPX-603 is our first dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2. A Phase 1/2 clinical trial, called BPX603-201A, in patients with metastatic HER2+ solid tumors is ongoing.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed efficient and scalable processes to manufacture genetically modified T cells of high quality, which are currently being used to generate products for our clinical trials. We are leveraging this know how in combination with our proprietary cellular control technologies, resources, capabilities and expertise for the manufacture of CAR-T product candidates to create and develop first and best-in-class product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cellular Immunotherapy </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cellular immunotherapy harnesses immune cells to attack and eliminate harmful diseased cells in the body. The immune system is the bodys defense network. It consists of a number of cells (e.g., leukocytes) and organs that, working together, recognize and respond to threats in the form of pathogens-modified or transformed cells. T cells are a type of white blood cell that recognize pathogens and can target and eliminate them upon full activation through the addition of appropriate co-stimulatory signals. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-T approaches entail collecting a patients or donors T cells, genetically modifying them ex vivo, or outside of the body, to incorporate specific receptors which target cancer cells and then infusing the modified cells into the patient. CARs are designed to target antigens on the surface of cancer cells. In early human clinical trials, CAR-T cell therapies have demonstrated an unprecedented ability to achieve complete responses in some hematological cancers, even in patients who have suffered multiple relapses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While high objective response rates have been reported in some hematological malignancies, CAR-T therapy has shown limited clinical efficacy in solid tumors.  This is likely due to poor proliferation and persistence of these cells and to immune suppressive factors found in the tumor microenvironment. In addition, patients treated with CAR-T cell therapies can have serious and sometimes fatal toxicities, which can be caused by high levels of activation of the CAR-T therapy, which can lead to severe cytokine release syndrome, or CRS, and neurologic toxicities. Furthermore, CAR-T therapies have the potential to attack healthy tissues (i.e., on-target/off-tumor toxicities) which can also result in death. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Our Proprietary CID Technology Platform</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary CID technology platform is designed to address the challenges of current cellular immunotherapies. Cellular activities and functions, such as growth, activation, proliferation and cell death, are controlled by signaling cascades following aggregation of specific proteins. Our CID platform consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, rimiducid or temsirolimus, instead of by natural upstream signals. Our current product candidates are based on either an activation switch, a safety switch, or a dual switch which contains both activation and safety switches.  After the small molecule is administered, the safety switch is designed to lead to apoptosis, and the activation switch is designed to lead to proliferation, activation and enhanced persistence of immune cells. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate the molecular switches in the appropriate immune cells through genetic manipulation and administer them to the patient. After the gene-modified immune cells are inside the patients body, specific functions of these cells may be controlled by administration of small molecule ligands (rimiducid or temsirolimus). The CID switch proteins have been designed to specifically bind to rimiducid or temsirolimus.  Once introduced, these ligands couple, or aggregate, CID switch proteins together to create a cluster that triggers the signaling cascade. Aside from its impact on CID-modified immune cells bearing switch proteins, rimiducid is bioinert and has no other known effect on the body. In dual-switch applications, temsirolimus can be used to activate a safety switch, if severe, treatment-related toxicities occur. Temsirolimus is a kinase inhibitor approved for the treatment of advanced renal cell carcinoma that has a well-characterized safety profile.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary CID-based product candidates depend on the following signaling molecules to trigger signaling cascades, resulting in different cell activities:</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15pt">iMC: Signaling Molecules for Activation and Proliferation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> iMC is also known as inducible MyD88 and CD40.  Myeloid differentiation primary response 88, or MyD88, is a protein that has functions in cellular responses to stimuli such as stress, cytokines and bacteria or viruses. CD40 is a co-stimulatory protein found on antigen-presenting cells, such as dendritic cells and B cells and is required for their full activation. Activation of iMC in immune cells, such as T lymphocytes, provides inducible co-stimulation, leading to enhanced cell proliferation and survival. In addition, activation of iMC causes immune cells to secrete pro-inflammatory cytokines and chemokines, and to express co-stimulatory cell surface molecules to potentially modulate the tumor microenvironment and stimulate the patients own immune system. </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our GoCAR-T technology incorporates our proprietary iMC activation switch that activates CAR-T cells when triggered by both rimiducid and the targeted antigen expressed on the surface of the cancer cells. Current generation CAR-T constructs consist of a CD3 domain and one or more co-stimulatory molecules that are both activated when the CAR-T binds to the cancer antigen, and therefore, function autonomously following infusion.  While current generation CAR-T cells have been effective in some hematologic malignancies, this reliance on an antigen for activation of the CAR-T cell results in an unpredictable and inherently uncontrollable therapeutic effect and potential associated toxicity. Further, in solid tumor settings, current generation CAR-T cells often fail to proliferate or persist for more than a few days or weeks and have been largely ineffective. In each situation, the physician has no effective way to intervene to achieve greater consistency once the cells have been administered.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GoCAR-T technology is designed to change the current paradigm by placing our proprietary co-activation domain, MC, under rimiducid control. GoCAR-T cells are designed to only be fully activated when exposed to both the cancer cells expressing the target antigen and rimiducid. This separation is designed to control the degree of activation of the CAR-T cells through adjustments to the schedule of rimiducid dosing.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.44pt">CaspaCIDe: Signaling Molecule for Apoptosis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CaspaCIDe is also known as inducible Caspase-9. Caspase-9 is the initiating enzyme in the apoptosis pathway. When activated, the dimerization of CaspaCIDe leads to rapid apoptosis of gene-modified T cells. Because CaspaCIDe is designed to be permanently integrated into our cellular therapies, the safety switch has the potential to be available for use long after the initial therapy is delivered. Moreover, preclinical animal studies demonstrate the ability to modulate the elimination of cells containing CaspaCIDe by different rimiducid doses and schedules (i.e., titrated elimination).</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-4.5pt"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CaspaCIDe has been incorporated into several clinical programs. At the American Society of Hematology Annual Meeting in 2018, we presented data on the administration of rimiducid to trigger CaspaCIDe in 24 patients experiencing graft versus host disease (GvHD) refractory to standard treatments after receiving rivo-cel following stem cell transplantation. The best overall GvHD clinical response after rimiducid administration was 70%, with a median time to response of one day.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-4.5pt"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2021, we announced the first reported case of the use of CaspaCIDe to mitigate a severe CAR T-mediated adverse event refractory to standard of care treatment. The report in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Blood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a journal published by the American Society of Hematology, detailed a case from an investigator sponsored trial at the University of North Carolina Lineberger Comprehensive Cancer Center of a CD19 CAR-T containing CaspaCIDe. A patient in the study experienced grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) for 72 hours despite standard care. Within 12 hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to being incorporated in some of our product candidates, CaspaCIDe has been licensed to several entities for use in their CAR-T and CAR-NK programs. Under these agreements, Bellicum grants license to the use of CaspaCIDe and access to supply of rimiducid in exchange for a proportion of the economics of these programs as they advance and generate revenue for the licensee, including a single-digit-percent royalty on global net sales should they be approved by regulators. Currently, these agreements cover seven CAR-T or CAR-NK programs, with the option to expand to additional programs over time.</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Active Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BPX-601: GoCAR-T for PSCA+ Solid Tumors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are developing BPX-601, an autologous GoCAR-T product candidate containing our proprietary iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen, or PSCA. PSCA is an antigen expressed in several solid tumor indications, including prostate and pancreatic cancer. Pre-clinical data show iMC enhances T cell proliferation and persistence, enhances host immune activity, and modulates the tumor microenvironment to improve the potential to treat solid tumors compared to traditional CAR-T therapies. A Phase 1/2 clinical trial, called BP-012, in patients with metastatic castration-resistance prostate, or mCRPC, and pancreatic cancer expressing PSCA is ongoing. In December, 2021, we announced that one of the first three mCPRC patients treated in the study achieved a confirmed Partial Response by RECIST v1.1 criteria. Additionally, no dose-limiting toxicities were observed.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BPX-603: Dual-Switch GoCAR-T for HER2+ Solid Tumors</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing BPX-603, which is our first controllable dual-switch autologous GoCAR-T product candidate and incorporates both the iMC activation switch and the CaspaCIDe safety switch. BPX-603 is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2. HER2 is a validated antigen for cancer therapies, and academic HER2 CAR-T cell clinical studies have shown evidence of anti-tumor activity. These academic HER2 CAR-T approaches targeting HER2 have been limited by modest clinical efficacy and off-tumor/on-target toxicity. We believe that our dual-switch GoCAR-T technology may be uniquely suited to improve upon these earlier efforts, by driving greater efficacy through iMC activation while enabling clinicians to manage any treatment-emergent toxicities with CaspaCIDe. A Phase 1/2 clinical trial, called BPX603-201A, in patients with metastatic HER2+ solid tumors is ongoing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing, Processing and Delivering to Patients</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed efficient and scalable processes to manufacture genetically modified T cells of high quality.  We are leveraging the processes we have developed for BPX-601 in combination with our proprietary cellular control technologies, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, capabilities and expertise for the manufacture of our product candidates to create and develop first and best-in-class product candidates.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require a combination of three critical components: (1)&nbsp;viral vectors with DNA content encoded for our proprietary switch proteins and co-stimulatory and other accessory molecules, (2)&nbsp;patient-derived T cells that are genetically modified by our viral vectors, and (3)&nbsp;the small molecules rimiducid and/or temsirolimus, which activate the switch proteins. Each of these components requires a separate supply chain and shares the same regulatory requirements applicable for biological or chemical materials suitable for human use. Details on each of these components are described below:</span></div><div style="text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15.57pt">Viral Vectors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use gamma retrovirus to transduce our product candidates. We believe that gamma retrovirus is optimal for cell transduction given that it is an integrating vector that induces long-term gene expression, exhibits high transduction efficiency, has sufficient capacity for DNA content, and has been extensively and safely used in clinical trials. </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15pt">Genetically Modified Cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have designed and refined a proprietary process for cell engineering that has been improved from lab-based open procedures used in academic and research settings to a functionally closed system that is more appropriate for large-scale clinical trials and commercialization. Our systems are designed to be compliant with current guidelines and regulations for cell-based manufacturing in the U.S. and Europe and have been successfully implemented by our third-party manufacturers.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15.57pt">Small Molecules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rimiducid is a synthetic small molecule that has been rationally designed to trigger the proprietary switch proteins in our CID platform. We have separate third-party manufacturers for the active pharmaceutical ingredient, or API, and the finished drug product. Manufacturers of both the API and finished drug product are licensed to manufacture a variety of marketed drugs worldwide and have been selected based on their ability to provide supplies for our clinical trials and future commercialization. In our dual-switch constructs, the small molecule temsirolimus can be used to trigger one of the two switches. Temsirolimus is an approved and commercially available product manufactured and distributed by Pfizer Inc. under the trade name TORISEL.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on continuously refining our overall cell therapy supply chain, manufacturing, processing and delivery to patients to be more efficient. Our current process cycles for our autologous product candidates, from collection of white blood cells to infusion of the final product, can be completed in as little as four weeks and are customized to be complementary to the treatment procedure of interest in order to prevent delays or complications.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect proprietary technology, inventions, and improvements that are commercially important to our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also seek to rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity and patent term extensions where available as well as contractual agreements with our academic and commercial partners.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A strategic focus for us has been to identify and license key patents and patent applications that serve to enhance our intellectual property and technology position. Our intellectual property estate includes: (1)&nbsp;claims directed to core CID technologies and components used in our products; (2)&nbsp;claims directed to methods of treatment for therapeutic indications; (3)&nbsp;claims directed to specific products; and (4)&nbsp;claims directed to innovative methods for generating new constructs for genetically engineering T&nbsp;cells. We believe our patent estate, together with our efforts to develop and patent next generation technologies, provides us with a substantial intellectual property position. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, to our knowledge, our patent estate, on a worldwide basis, includes 187 issued patents, 26 of which are in the U.S., and 67 pending patent applications, 16 of which are in the U.S., which we own or for which we have an exclusive, either in its entirety or within our field of use, commercial license. The provisional and pending patent applications and issued patents include composition of matter and method of use claims.</span></div><div style="margin-top:6pt;padding-left:60.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We have internally developed technology disclosed in seven pending utility patent applications in the U.S., one European granted patent validated in eight countries, and 25 pending foreign patent applications that relate to our GoCAR-T technology. If U.S. patents issue from the U.S. applications, the estimated expiration date of the last to expire patent is in 2039. If patents are issued in foreign jurisdictions, the anticipated expiration dates will be in 2039.</span></div><div style="margin-top:6pt;padding-left:60.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pursuant to our licenses from Baylor and Ariad, we have exclusive commercial rights to 12 issued U.S. patents expiring in 2024 or later, four pending U.S. utility patent applications, two European granted patents (the first </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:60.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">validated in three countries, the second validated in ten countries), four issued foreign patents expiring in 2024 or later and two pending patent applications in foreign jurisdictions that relate to our GoCAR-T, rivo-cel and certain of our other technologies. If U.S. patents issue from the currently pending U.S. patent applications, the estimated expiration date of the last to expire patent is 2031. If patents from the currently pending patent applications are issued in foreign jurisdictions, the estimated expiration dates range from 2024 to 2029. </span></div><div style="margin-top:6pt;padding-left:60.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pursuant to our license agreement with Agensys we have exclusive commercial rights for technology to target certain cancer-specific antigens.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the U.S., a patents term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or the USPTO, in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. The term of a patent that covers an FDA-approved drug or biologic may also be eligible for a patent term restoration of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term restoration is calculated based on the length of time the drug or biologic is under regulatory review. A patent term restoration under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug or biologic may be restored. Moreover, a patent can only be restored once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug or biologic. When possible, depending upon the length of clinical trials and other factors involved in the filing of a Biologics License Application, or BLA, we expect to apply for patent term extensions for patents covering our product candidates and their methods of use.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaboration and License Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development and Co-Commercialization Agreement - Adaptimmune</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we and Adaptimmune Therapeutics plc, or Adaptimmune, entered into a Co-Development and Co-Commercialization Agreement, or the Adaptimmune Agreement, in order to facilitate a staged collaboration to evaluate, develop and commercialize next generation T cell therapies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Adaptimmune Agreement, the parties agreed to evaluate our GoTCR technology, iMC co-stimulation, with Adaptimmune's affinity-optimized SPEAR</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells for the potential to create enhanced TCR product candidates. Depending on results of the preclinical proof-of-concept phase, the agreement may progress to a two-target co-development and co-commercialization phase. To the extent necessary, and in furtherance of the parties proof-of-concept and co-development efforts, the parties granted each other a royalty-free, non-transferable, non-exclusive license covering their respective technologies for purposes of facilitating such proof-of-concept and co-development efforts. In addition, as to covered therapies developed under the Adaptimmune Agreement, the parties granted each other a reciprocal exclusive license for the commercialization of such therapies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any joint commercialization of a covered therapy, the parties agreed to negotiate in good faith the commercially reasonable terms of a co-commercialization agreement. The parties also agreed that any such agreement shall provide for, among other things, equal sharing of the costs of any such joint commercialization and the calculation of profit shares as set forth in the Adaptimmune Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Adaptimmune Agreement will expire on a country-by-country basis once the parties cease commercialization of the T cell therapies covered by the Adaptimmune Agreement, unless earlier terminated by either party for material breach, non-performance or cessation of development, bankruptcy/insolvency, or failure to progress to co-development phase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - Agensys</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&nbsp;2015, we and Agensys, Inc., or Agensys, entered into a license agreement, or the Agensys Agreement, pursuant to which (i)&nbsp;Agensys granted us, within the field of cell and gene therapy of diseases in humans, an exclusive, worldwide license and sublicense to its patent rights directed to PSCA and related antibodies, and (ii)&nbsp;we granted Agensys a non-exclusive, fully paid license to our patents directed to inventions that were made by us in the course of developing our licensed products, solely for use with Agensys therapeutic products containing a soluble antibody that binds to PSCA or, to the extent not based upon our other proprietary technology, to non-therapeutic applications of antibodies not used within the field.</span></div><div style="margin-top:13.2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the rights granted to us under the Agensys Agreement, we agreed to pay to Agensys a non-refundable upfront fee of $3.0 million. We are also required to make aggregate milestone payments to Agensys of up to (i)&nbsp;$5.0 million upon the first achievement of certain specified clinical milestones for its licensed products, (ii)&nbsp;$50.0 million upon the achievement of certain specified clinical milestones for each licensed product, and (iii)&nbsp;$75.0 million upon the achievement of certain sales milestones for each licensed product. The Agensys Agreement additionally provides that we will pay to Agensys a royalty percentage that ranges from the mid to high single digits based on the level of annual net sales of licensed products by us, our affiliates or permitted sublicensees. The royalty payments are subject to reduction under specified circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agensys Agreement, Agensys also was granted the option to obtain an exclusive license, on a product-by-product basis, from us to commercialize in Japan each licensed product developed under the Agensys Agreement that has completed a phase 2 clinical trial. As to each such licensed product, if Agensys or its affiliate, Astellas Pharma, Inc., exercises the option, the Agensys Agreement provides that we will be paid an option exercise fee of $5.0 million. In addition, the Agensys Agreement provides that we will be paid a royalty that ranges from the mid to high single digits based on the level of annual net sales in Japan of each such licensed product. If the option is exercised, the aggregate milestone payments payable by us to Agensys, described above with respect to each licensed product, would be reduced by up to an aggregate of $65.0 million upon the achievement of certain specified clinical and sales milestones.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agensys Agreement will terminate upon the expiration of the last royalty term for the products covered by the Agensys Agreement, which is the earlier of (i)&nbsp;the date of expiration or abandonment of the last valid claim within the licensed patent rights covering any licensed products under the Agensys Agreement, (ii)&nbsp;the expiration of regulatory exclusivity as to a licensed product, and (iii)&nbsp;10 years after the first commercial sale of a licensed product. Either party may terminate the Agensys Agreement upon a material breach by the other party that remains uncured following 60 days after the date of written notice of such breach (or 30 days if such material breach is related to failure to make payment of amounts due under the Agensys Agreement) or upon certain insolvency events. In addition, Agensys may terminate the Agensys Agreement immediately upon written notice to us if we or any of our affiliates or permitted sublicensees commence an interference proceeding or challenge the validity or enforceability of any of Agensys patent rights.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - BioVec</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we and BioVec Pharma, Inc., or BioVec, entered into a license agreement, or the BioVec Agreement, pursuant to which BioVec agreed to supply us with certain proprietary cell lines and granted us a non-exclusive, worldwide license to certain of its patent rights and related know-how related to such proprietary cell lines.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the products supplied and rights granted to us under the BioVec Agreement, we agreed to pay to BioVec an upfront fee of $100,000 within ten business days of the effective date of the BioVec Agreement and a fee of $300,000 within ten business days of its receipt of the first release of GMP lot of the products licensed under the BioVec Agreement. In addition, we agreed to pay to BioVec an annual fee of $150,000, commencing 30 days following the first filing of an IND, or its foreign equivalent, for a product covered by the license; with such annual fees being creditable against any royalties payable by us to BioVec under the BioVec Agreement. We also are required to make a $250,000 milestone payment to BioVec for each of the first three licensed products to enter into a clinical phase trial and one-time milestone payments of $2.0 million upon receipt of a registration granted by the FDA or EMA on each of our first three licensed products. The BioVec Agreement additionally provides that we will pay to BioVec a royalty in the low single digits on net sales of products covered by the BioVec Agreement. We may also grant sub licenses under the licensed patent rights and know-how to third parties for limited purposes related to the use, sale and other exploitation of the products licensed under the BioVec Agreement. The BioVec Agreement will continue until terminated. The BioVec Agreement may be terminated by us, in our sole discretion, at any time upon 90 days written notice to BioVec. Either party may terminate the BioVec Agreement in the event of a breach by the other party of any material provision of the BioVec Agreement that remains uncured on the date that is 60 days after written notice of such failure or upon certain insolvency events that remain uncured following the date that is 30 days after the date of written notice to a party regarding such insolvency event.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements - Baylor College of Medicine</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2008 Baylor License Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an Exclusive License Agreement with Baylor College of Medicine, or Baylor, dated March&nbsp;20, 2008, or the 2008 Baylor license agreement, we obtained an exclusive, worldwide and fully paid up license to certain intellectual property, including intellectual property related to methods for activating antigen presenting cells and to genetic constructs coding for membrane bound inducible cytoplasmic CD40.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the 2008 Baylor license agreement, we issued to Baylor 23,529 shares of our common stock and assumed responsibility for all legal fees and expenses, filing or maintenance fees, assessments and all other costs and expenses related to prosecuting, obtaining and maintaining patent protection on the patents subject to the 2008 Baylor license agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2008 Baylor license agreement is subject to certain restrictions and is nonexclusive with respect to (1)&nbsp;the making or use of the licensed intellectual property for use in non-commercial research, patient care, teaching, and other educational purposes; (2)&nbsp;any non-exclusive license covering the licensed intellectual property that Baylor grants to other academic or research institutions for noncommercial research purposes; (3)&nbsp;any non-exclusive licenses that Baylor is required to grant to the U.S. or foreign state pursuant to an existing or future treaty with the U.S.; and (4)&nbsp;a non-exclusive license granted to ARIAD Pharmaceuticals, Inc. or ARIAD under the terms of a materials transfer agreement between Baylor and ARIAD.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylor may terminate or modify the 2008 Baylor license agreement in the event of a material breach by us that remains uncured following the date that is 90 days after written notice of such breach or upon certain insolvency events that remain uncured following the date that is 30 days following written notice of such insolvency event. We may terminate the 2008 Baylor license agreement, or any portion thereof, at our sole discretion at any time upon 30 days written notice to Baylor. Upon termination of the 2008 Baylor license agreement, all rights to the intellectual property immediately revert to Baylor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2010 Baylor License Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an Exclusive License Agreement with Baylor, dated June&nbsp;27, 2010, or the 2010 Baylor license agreement, we obtained an exclusive, worldwide license to certain intellectual property, including intellectual property related to methods for treating prostate cancer, methods of administering T cells to a patient, and methods of activating antigen presenting cells with constructs comprising MyD88 and CD40.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2010 Baylor license agreement we are required to pay a low annual maintenance fee on each anniversary of the agreement date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2010 Baylor license agreement also require us to make royalty payments of less than one percent, subject to certain annual minimums, on net sales of products covered by the license. In addition, to the extent we enter into a sublicensing agreement relating to a licensed product, we are required to pay Baylor a percentage in the mid-single digits on all non-royalty income received from sublicensing revenue. Bellicum is required to make milestone payments, of up to $735,000 in aggregate, upon successful completion of clinical and regulatory milestones regarding the first two products covered by this license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Baylor license agreement will expire upon expiration of the last patent contained in the licensed patent rights, on a country-by-country basis, upon which we will have a perpetual, paid-in-full license in such country. Baylor may terminate or modify the 2010 Baylor license agreement in the event of a material breach by us that remains uncured following the date that is 90 days after written notice of such breach or upon certain insolvency events that remain uncured following the date that is 30 days following written notice of such insolvency event. We may terminate the 2010 Baylor license agreement, or any portion thereof, at our sole discretion at any time upon 60 days written notice to Baylor. Upon termination of the 2010 Baylor license agreement for any reason prior to expiration, we must assign to Baylor each authorized sublicense agreement that is currently in effect on the date of termination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Baylor License Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an Exclusive License Agreement with Baylor, effective November&nbsp;1, 2014, or the 2014 Baylor license agreement, we obtained an exclusive, worldwide license to certain intellectual property, including intellectual property related to methods for inducing selective apoptosis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2014 Baylor license agreement we are required to pay Baylor a low annual maintenance fee on each anniversary of the agreement date. The terms of the 2014 Baylor license agreement also require us to make royalty payments in the low single digits, subject to certain annual minimums, on net sales of products covered by the license. To the extent we enter into a sublicensing agreement relating to a licensed product, Bellicum is also required to pay Baylor a percentage in the low </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">double-digits on all non-royalty income received from sublicensing revenue. We are required to make milestone payments, of up to $275,000 in aggregate, upon successful completion of clinical and regulatory milestones regarding the first product covered by this license. The 2014 Baylor license agreement will expire upon expiration of the last patent contained in the licensed patent rights, on a country-by-country basis, upon which we will have a perpetual, paid-in-full license in each such country.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baylor may terminate or modify the 2014 Baylor license agreement in the event of a material breach by us that remains uncured following the date that is 90 days after written notice of such breach or upon certain insolvency events that remain uncured following the date that is 30 days following written notice of such insolvency event. We may terminate the 2014 Baylor license agreement, or any portion thereof, at our sole discretion at any time upon 60 days written notice to Baylor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Baylor License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we and Baylor entered into two additional license agreements pursuant to which we obtained exclusive rights to technologies and patent rights owned by Baylor.  We could incur additional payments upon the achievement of certain milestone events as set forth in the agreements.  If we are successful in developing any of the licensed technologies under either agreement, resulting sales would be subject to a royalty payment in the low single digits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Agreements with Cancer Prevention and Research Institute of Texas</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2011, we entered into a Cancer Research Grant Contract, or the First Grant Contract, with the Cancer Prevention and Research Institute of Texas, or CPRIT, under which CPRIT awarded a grant not to exceed approximately $5.7 million to be used for the execution of defined clinical development of rivo-cel. To date, we have received approximately $4.9 million under the grant. The First Grant Contract terminated on June 30, 2014, but obligations exist as to licensing, royalty payments, and indemnification provisions.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, we announced that the Company received notice of a product development award totaling approximately $16.9 million from CPRIT. The CPRIT award was expected to fund a portion of a three-year global clinical program comprising clinical trials for adult and pediatric patients with high-risk and intermediate-risk AML, and potentially other hematologic cancers. The proposed studies are designed to evaluate the benefit of rivo-cel and rimiducid in the context of in vivo and ex vivo T cell depleted haploidentical HSCT. The CPRIT oversight committee met in February 2017 and agreed to move forward with the proposed terms of the grant agreement, and a second grant, or the Second Grant Contract was entered into in August 2017. Additionally, the First Grant Contract was amended in order to align revenue sharing terms, discussed below, with the Second Grant Contract. We initiated a pivotal randomized Phase 2/3 clinical trial (THRIVE) supported in part by the CPRIT funding.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we terminated the Second Grant Contract based on our decision to cease enrollment of the THRIVE trial. A total of approximately $3.3 million in grant funds was received and used for the project. </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No additional funds will be disbursed under this grant, but the revenue share and other post-grant obligations described below survive the termination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of each of the Grant Contracts, we grant to CPRIT a non-exclusive, irrevocable, royalty-free, perpetual, worldwide license to any technology and intellectual property resulting from the grant-funded activities and any other intellectual property that is owned by us and necessary for the exploitation of the technology and intellectual property resulting from the grant-funded activities, or the Project Results, for and on behalf of CPRIT and other governmental entities and agencies of the State of Texas and private or independent institutions of higher education located in Texas for education, research and other non-commercial purposes only. The terms of each of the Grant Contracts require that we pay tiered royalties in the low- to mid-single digit percentages on revenues from sales and licenses of products or services that are based upon, utilize, are developed from or materially incorporate Project Results. Such royalties reduce to less than one percent after a mid-single-digit multiple of the grant funds have been repaid to CPRIT in royalties. Such royalties are payable for so long as we have marketing exclusivity or patents covering the applicable product or service (or twelve years from first commercial sale of such product or service in certain countries if there is no such exclusivity or patent protection).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we abandon patent applications or patents covering Project Results in certain major market countries, CPRIT can, at its own cost, take over the prosecution and maintenance of such patents and is granted a non-exclusive, irrevocable, royalty-free, perpetual license with right to sublicense in such country to the applicable Project Results. We are required to use diligent and commercially reasonable efforts to commercialize at least one commercial product or service or otherwise bring to practical application the Project Results. If CPRIT notifies us of our failure with respect to the foregoing, and such failure is not owing to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material safety concerns, then, at CPRITs option, the applicable Project Results would be transferred to CPRIT and CPRIT would be granted a non-exclusive license to any other intellectual property that is owned by us and necessary for the exploitation of the Project Results, and CPRIT, at its own cost, can commercialize products or services that are based upon, utilize, are developed from or materially incorporate Project Results. CPRITs option is subject to our ability to cure any failures identified by CPRIT within 60 days and a requirement to negotiate in good faith with us with respect to an alternative commercialization strategy for a period of 180 days</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary CID platform, differentiated product candidates and scientific expertise in the field of cellular immunotherapy provide us with competitive advantages, we face potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, governmental agencies and public and private research institutions.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell based treatments for cancer, such as CAR-T therapies, have recently been an area of significant research and development by academic institutions and biopharmaceutical companies. Our product candidates may compete with product candidates from a number of companies that are currently focused on this therapeutic modality, including 2seventy bio, Inc., Adaptimmune, Alaunos Therapeutics, Inc., Allogene Therapeutics, Inc., Amgen Inc., Atara Biotherapeutics, Inc., Athenex, Inc., Autolus Therapeutics plc, BioNTech Europe GmbH, Bristol-Meyer Squibb Co., Cellectis SA, Celyad S.A., CRISPR Therapeutics, Fate Therapeutics Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Immatics N.V., ImmunityBio, Inc., Iovance Biotherapeutics, Inc., Janssen Pharmaceutical, Legend Biotech, Lyell Immunopharma, Inc., Medigene AG, Mustang Bio, Inc., Novartis AG, Obsidian Therapeutics, Poseida Therapeutics, Precigen Inc., Precision Biosciences, Inc., Sana Biotechnology, Sorrento Therapeutics, Inc., and Takeda Pharmaceutical Co.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other cell based treatments, our product candidates may compete in their solid tumor indications with novel therapeutics of other modalities, including small molecules, monoclonal antibodies, bi-specific antibodies, antibody-drug conjugates, and targeted radionuclides.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance. Our competitors treatments may be more effective, or more effectively marketed and sold, than any treatment we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our treatments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and subject registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers. For example, if a third party is able to obtain a stand-alone new drug application for rimiducid, then potential generic manufacturers may be able to file abbreviated new drug applications for that product.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that our therapeutic products, if approved, will be priced at a significant premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company that operates in the U.S., we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered and licensed facilities in compliance with the current good manufacturing practice, or cGMP, for biologics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates human cells, tissues, and cellular and tissue-based products, or HCT/Ps, under a two-tiered framework, based on risk categorization. Higher-risk HCT/Ps are regulated as biologics. For example, such products must complete extensive clinical trials, which must be conducted pursuant to an effective IND. The FDA must review and approve a Biologics License Application, or BLA before a new biologic may be marketed.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA considers our investigational products to be combination products because our products involve a biologic, the engineered cells, that is intended to be used with a small molecule chemical drug, rimiducid. In general, biologics such as our engineered cells are regulated through the FDAs Center for Biologics Evaluation and Research, or CBER, while synthetic drugs are regulated through the FDAs Center for Drug Evaluation and Research. When the FDA encounters a combination product such as our products, the agency determines which of the two centers will have primary responsibility for regulating the product by determining the primary mode of action for the product. The cellular component of our combination contributes the primary mode of action and, as a result, the FDA will regulate our investigational products as biologics, through CBER.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S., at the federal, state and local levels, and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the U.S. and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Product Development Process</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates new drugs and biological products under the Federal Food, Drug and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process required by the FDA before a biological product may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:3pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.57pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.57pt">performance of adequate and well-controlled human clinical trials according to the FDAs regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use; </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials; </span></div><div style="padding-left:49.5pt;text-align:justify"><span><br></span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.57pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological products identity, strength, quality and purity and, if applicable, the FDAs current good tissue practices, or GTPs, for the use of HCT/Ps; </span></div><div style="padding-left:49.5pt"><span><br></span></div><div style="padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.67pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and </span></div><div style="padding-left:49.5pt"><span><br></span></div><div style="padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">FDA review and approval, or licensure, of the BLA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor must resolve FDAs outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsors control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDAs regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is independent from the trial sponsor and is charged with protecting the welfare and rights of clinical trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Clinical trials also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials for biologic products are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-bottom:3pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.57pt">Phase 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="margin-bottom:3pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="margin-bottom:3pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.57pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the progress of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in&nbsp;vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsors initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRBs requirements or if the biological product has been associated with unexpected serious harm to patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product, as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that we register all of our clinical trials on a publicly accessible website and provide results information for most of our clinical trials, other than Phase 1 clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Review and Approval Processes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of certain data or full or partial waivers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the application also includes a non-orphan indication.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the products identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require HCT/P establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To maintain compliance with CGMPs, GTPs, and GCPs, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS or other risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological products safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, the PREA does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s). Sponsors in satisfaction of this obligation may receive an additional six months of marketing exclusivity for all dosage forms and all indications with the same active moiety as the drug studied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug or biologic for this type of disease or condition will be recovered from sales in the U.S. for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not shorten the duration of the regulatory review or approval process, but does provide certain advantages, such as a waiver of PDUFA fees, enhanced access to FDA staff, and potential waiver of the PREA requirements discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs, or if the drug has been designated as a qualified infectious disease product. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Under Fast Track, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. Even if Fast Track designation is granted, it may be rescinded if the product no longer meets the qualifying criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product, submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product is eligible for priority review if it treats a serious condition and, if approved, would provide a significant improvement in safety and efficacy. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform appropriate post-marketing clinical studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. The FDCA also provides expedited procedures for FDA withdrawal of approval of a product approved through accelerated approval. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy Designation is intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation requires preliminary clinical evidence that may demonstrate substantial improvement on a clinically significant endpoint over available therapies. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance, organizational commitment, and other potential actions to expedite review. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same product if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will expedite the development and review of such product. Even if a Breakthrough Therapy Designation is granted, it may be rescinded if the product no longer meets the qualifying criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Health Care Laws and Compliance Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS, such as the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA, the sunshine provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, and similar state laws, each as amended.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for either the referral of an individual, or for the purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal health care programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biologic manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The Anti-Kickback Statute may be violated if only one purpose of the remuneration is to induce referrals.  In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The civil monetary penalties law imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims laws, including but not limited to the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government. Pharmaceutical and other health care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies marketing of the product for unapproved, that is, off-label, and thus non-reimbursable, uses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA created additional new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any health care benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAAs security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity, and their covered subcontractors. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Childrens Health Insurance Program, with certain exceptions, to report annually information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and require that certain manufacturers and group purchasing organizations report annually certain ownership and investment interests held by physicians and their immediate family members. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be required to begin satisfying the product tracing, verification, and reporting requirements set out in the Drug Supply Chain Security Act.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to distribute products commercially, we must also comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several states have enacted legislation requiring pharmaceutical and biotechnology companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other health care entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including significant administrative, civil and criminal penalties, damages, fines, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, exclusion from participation in government health care programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage, Pricing and Reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the U.S., third-party payors include federal and state health care programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payors determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on health care pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Reform</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States and some foreign jurisdictions, there have been, and we anticipate there will continue to be, several legislative and regulatory changes and proposed healthcare reform measures with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the PPACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, the PPACA has been subject to executive branch, judicial and Congressional challenges. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the PPACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. Moreover, payment methodologies may also be subject to changes in healthcare legislation and regulatory initiatives. In addition, there has been increasing legislative and executive branch interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries, Presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, Promoting Competition in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">American Economy, with multiple provisions aimed at prescription drugs. In response to Bidens executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. It is unclear whether these or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> had 7&nbsp;employees, al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l of whom were full-time, 5 of whom were engaged in research and development activities and 2 of whom were engaged in general and administrative activities. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve objectives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families. In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees, as well as the community in which we operate, and which comply with government regulations, including working from home.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in July 2004. Our principal executive office is located at 3730 Kirby Drive, Suite 1200, Houston, Texas and our telephone number is (281)&nbsp;454-3424. Our corporate website address is www.bellicum.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&nbsp;8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, will be made available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The contents of our website are not incorporated into this Annual Report and our reference to the URL for our website is intended to be an inactive textual reference only.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business and results of operations are subject to a number of risks and uncertainties. You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. </span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses from operations in every year since our inception and anticipate that we will continue to incur net losses in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company, have no products approved for commercial sale and have incurred significant losses since our inception in 2004. To date, we have financed our operations primarily through equity and debt financings. For the fiscal years ended December 31, 2021 and 2020, we reported a net loss of $9.7 million and $7.7 million, respectively. As of December 31, 2021, we had an accumulated deficit of $550.5 million. We expect to continue to incur significant losses from operations for the foreseeable future, and we expect these accumulated losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we obtain regulatory approval of and seek to commercialize any of our product candidates, we will likely incur significant sales, marketing and manufacturing expenses and may continue to incur substantial research and development expenses for additional post-marketing approval development requirements related to such product.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders equity and working capital.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require significant funding to complete the development and commercialization of our product candidates. If we fail to obtain additional financing, we may have to delay, reduce or eliminate our development programs or commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates and other research and development programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had cash, cash equivalents and restricted cash of approximately $47.7 million. We maintain our cash and cash equivalents with high quality, accredited financial institutions. These amounts at times may exceed federally insured limits. Cash, cash equivalents and restricted cash are expected to be sufficient to fund our operating expenses and capital expenditure requirements through at least one year from the financial statement issuance date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to finance future cash needs through public or private equity offerings, debt financings, strategic partnerships and alliances or licensing arrangements. We cannot be certain that additional funding will be available on acceptable terms, or at all. In addition, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the pandemic. If the disruption persists and/ or deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity to fund research and development programs, including discovery research, preclinical and clinical development activities. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will need to significantly delay, scale back or discontinue the development or commercialization of our product candidates. We also could be required to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek collaborators for one or more of our current or future product candidates on terms that are less favorable than might otherwise be available;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek a third party to acquire us or our assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to raise additional funds on a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment of our development programs, or implement further reduction of costs for facilities and administration beyond our October 2020 restructuring. Moreover, if we do not obtain such additional funds, there could be substantial doubt about our ability </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to our stockholders and other security holders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and future success depends, in part, on our ability to obtain regulatory authority assent to conduct human clinical trials, obtain regulatory approval to launch a product based on evidence of clinical safety and efficacy and then successfully commercialize our clinical product candidates. All of our product candidates will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, and access to sufficient commercial manufacturing capacity and significant marketing efforts before we can expect to generate any revenue from product sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA or comparable regulatory authority or an Institutional Review Board or comparable ethics oversight body may decline to clear the applicable Investigational New Drug Application (IND) or equivalent regulatory submission necessary to conduct human clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates have the necessary safety, purity, and potency for any of their proposed indications; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our product candidates clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter serious and unexpected adverse events during clinical trials that render our products unsafe for use in humans; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in Europe, the U.S. or elsewhere; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes and/or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources and efforts to developing our proprietary CID technology platform, identifying potential product candidates and conducting preclinical studies and clinical trials. We are in the early stages of developing our product candidates, and we have not completed development of any products. Our ability to generate revenue and achieve profitability depends in large part on our ability, alone or with partners, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future. Our ability to generate future revenues from product sales depends heavily on our success in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing requisite clinical trials through all phases of clinical development of our current product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials, if any; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing product candidates for which we obtain marketing approval, if any, with a partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying and developing new product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progressing our pre-clinical programs into human clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing new molecular switches based on our proprietary CID technology platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, expanding and enforcing our intellectual property; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biologic product development, we are unable to predict the likelihood or timing for when we may receive regulatory approval of any of our current or future product candidates or when we will be able to achieve or maintain profitability, if ever. If we do not receive regulatory approvals, our business, prospects, financial condition and results of operations will be adversely affected. Even if we obtain the regulatory approvals to market and sell one or more of our product candidates, we may never generate significant revenues from any commercial sales for several reasons, including because the market for our products may be smaller than we anticipate, or products may not be adopted by physicians and payors or because our products may not be as efficacious or safe as other treatment options. If we fail to successfully commercialize one or more products, we may be unable to generate sufficient revenues to sustain and grow our business and our business, prospects, financial condition and results of operations will be adversely affected. In addition, our expenses could increase beyond expectations if we are required by the FDA, or foreign regulatory agencies, to perform studies and clinical trials in addition to those that we currently anticipate for our product candidates, or if there are any delays in our or our partners completing clinical trials or the development of any of our product candidates. Further, if one or more of the product candidates that we independently develop is approved for commercial sale, we expect to incur significant costs associated with commercializing any such product candidates. Finally, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CID technology is novel and largely unproven.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary CID technology platform is novel and there are no approved products or third-party product candidates in late-stage clinical trials based on this technology. Additionally, the safety and efficacy profile of rimiducid has not been subject to large scale clinical testing. If rimiducid is found to have a poor safety profile in clinical trials, or if our technology is not effective, we may be required to redesign all of our product candidates, which would require significant time and expense. In addition, our CID platform technology may not be applicable or effective in the development of additional cellular immunotherapies beyond our current programs which would adversely affect our business and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell therapies are novel and present significant challenges.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-T and other cell therapy product candidates represent a relatively new field of cellular immunotherapy. Advancing this novel and personalized therapy creates significant challenges for us, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with commercial development of cell therapies for cancer; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing a consistent and reliable process, while limiting contamination risks, for engineering and manufacturing T cells ex vivo and infusing the engineered cells into the patient;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating medical personnel regarding the potential safety benefits, as well as the challenges, of incorporating our product candidates into their treatment regimens; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from third-party payors for our novel and personalized therapy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to successfully develop CAR-T and other cell therapies or develop processes related to the manufacture or commercialization of these therapies would adversely affect our business, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our product candidates are subject to the risks of failure inherent in biologic drug development. Success in early clinical trials does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing, even at statistically significant levels.  We will be required to demonstrate through clinical trials that our product candidates are safe and effective for use in the target indication before we can obtain regulatory approvals for commercial sale. Companies frequently suffer significant setbacks in late-stage clinical trials, even after earlier clinical trials have shown promising results and most product candidates that commence clinical trials are never approved as products. We expect there may be greater variability in results for cellular immunotherapy products processed and administered on a patient-by-patient basis like some of our CID technology-based development and product candidates than for off-the-shelf products, like many drugs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates fail to demonstrate sufficient safety or efficacy, we would experience potentially significant delays in, or be required to abandon our development of the product candidate, which would have a material and adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current product candidates are in early stage clinical trials, and we may experience unfavorable results in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2 clinical trial is ongoing for BPX-601 for the treatment of prostate and pancreatic cancer, and a Phase 1/2 clinical trial for BPX-603 in HER2-positive solid tumors. We may not be able to commence clinical trials in the time frames we expect or we may encounter delays. For example, in December 2020, we announced that the FDA had placed a clinical hold on our BPX-601 trial in pancreatic cancer due to the death of a patient in the trial. Although the FDA released the hold in January 2021, there can be no assurance that future patients deaths in this or any of our clinical trials will not trigger additional clinical holds. As these product candidates are in early stages of development, we face significant uncertainty regarding whether they will be effective and safe in human patients, and the results from preclinical studies, such as in vitro and in vivo studies, of BPX-601 and BPX-603 may not be indicative of the results of clinical trials of these product candidates. For example, in October 2020, we announced that the first four pancreatic cancer patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation but clinically meaningful efficacy as measured by RECIST criteria was not observed. Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if clinical trials are successfully completed, the FDA or foreign regulatory authorities may not interpret the results as we do, and more clinical trials could be required before we submit our product candidates for approval. To the extent that the results of our clinical trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our CID platform to build a pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our CID platform, which serves as the foundation of our CaspaCIDe and GoCAR-T technologies, can be further leveraged to discover other novel technologies, therapeutic applications and market opportunities. We are at an early stage of development and our platform has not yet, and may never lead to, approved or marketable products. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including for reasons related to their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not be able to obtain product or partnership revenues in future periods, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, and strategic partners to conduct our preclinical and clinical trials under agreements with us. Negotiations of budgets and contracts with study sites may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities could require us to perform additional clinical trials before approving our marketing applications. It is possible that, upon inspection, such regulatory authorities could determine that any of our clinical trials fail to comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under current good manufacturing practices, or cGMPs, and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with these third parties, we cannot control whether they devote sufficient time and resources to our ongoing preclinical, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Our business could be adversely affected by health epidemics in regions in which we have operations or conduct research activities or clinical trials. Such health epidemics could also affect the business or operations of contract manufacturers, raw material suppliers, clinical trial sites, and other third parties with whom we conduct business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">For example, the effects of government stay-at-home orders or related adjustments in our business are likely to negatively impact productivity, disrupt our business and delay our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Severe and/or long-term disruptions in our operations will negatively impact our business, operating results and financial condition. Specifically, COVID-19 related delays in clinical trial enrollment, patient care, data availability, or monitoring may delay the timeline to our integrity of data from our trials and could affect their acceptability to the FDA or other regulatory authorities, which would represent significant setbacks for the applicable program. To date, we have experienced COVID-19-related delays on patient screening and enrollment which may impact the speed of enrollment and the timing of data presentations from our ongoing studies. More significant disruptions may occur if the pandemic worsens in the geographies in which our study sites or manufacturing facilities are located. In addition, quarantines, stay-at-home, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, the effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely. In addition, to the extent the ongoing COVID-19 outbreak adversely affects our business, financial condition, results of operations and growth prospects, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this Risk Factors section.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria defined in the protocol; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the trials primary endpoints; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to study sites; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical trial; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing clinical trials and approved therapies available for patients. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, some of our clinical trials will look to enroll patients with characteristics which are found in a very small population, for example, patients with rare cancers with specific attributes that are targeted with our product candidates. Our clinical trials will compete with other companies' clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in these clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and antibody therapy, rather than enroll patients in any of our future clinical trials. Patients may also be unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology or gene therapy industries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any adverse developments that occur during any clinical trials conducted by academic investigators, our collaborators or other entities conducting clinical trials under independent INDs may affect our ability to obtain regulatory approval or commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rimiducid and CaspaCIDe-containing cell therapy constructs are being used by third parties in clinical trials for which we are collaborating or in clinical trials which are completely independent of our development programs. We have little to no control over the conduct of those clinical trials. If serious adverse events occur during these or any other clinical trials using our product candidates, the FDA and other regulatory authorities may delay, limit or deny approval of our product candidate or require us to conduct additional clinical trials as a condition to marketing approval, which would increase our costs. If we receive regulatory approval for any product candidate and a new and serious safety issue is identified in clinical trials conducted by third parties, the applicable regulatory authorities may withdraw their approval of the product or otherwise restrict our ability to market and sell our product. In addition, treating physicians may be less willing to administer our product due to concerns over such adverse events, which would limit our ability to commercialize our product.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoptive cell therapy with autologous T cells is associated with a range of potentially severe immune-mediated adverse effects. In third party clinical trials involving CAR-T cells, the most prominent acute toxicities included symptoms thought to be associated with the release of cytokines, such as fever, low blood pressure and kidney dysfunction. Some patients also experienced toxicity of the central nervous system, such as confusion, cranial nerve dysfunction and speech impairment. Adverse side effects attributed to CAR-T cells were severe and life-threatening in some patients. The life-threatening events were related to kidney dysfunction and toxicities of the central nervous system. Severe and life-threatening toxicities occurred primarily in the first two weeks after cell infusion and generally resolved within three weeks. In the past, several patients have also died in clinical trials by others involving CAR-T cells. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects observed in our clinical trials, whether or not they are caused by our product candidates, could result in the delay, suspension or termination of clinical trials by us, the FDA or other regulatory authorities for a number of reasons. In addition, because the patients in our clinical trials are suffering from life-threatening diseases, are often suffering from multiple complicating conditions and are in a position of extreme immune deficiency at the time that they receive our therapy, it may be difficult to accurately assess the relationship between our product candidates and adverse events experienced by very ill patients. If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on relatively new technology, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. Costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from therapies such as our current and future product candidates can be significant. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products. In addition, our proposed product candidates involve several complex and costly manufacturing and processing steps, the costs of which will be borne by us. The costs of our clinical trials may increase if the FDA does not agree with our clinical development plans or requires us to conduct additional clinical trials to demonstrate the safety and efficacy of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, genetically engineering T cells is a competitive endeavor. Multiple companies are engaged in the engineering of T cells, including (but not limited to): 2seventy bio, Inc., Adaptimmune, Alaunos Therapeutics, Inc., Allogene Therapeutics, Inc., Amgen Inc., Atara Biotherapeutics, Inc., Athenex, Inc., Autolus Therapeutics plc, BioNTech Europe GmbH, Bristol-Meyer Squibb Co., Cellectis SA, Celyad S.A., CRISPR Therapeutics, Fate Therapeutics Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Immatics N.V., ImmunityBio, Inc., Iovance Biotherapeutics, Inc., Janssen Pharmaceutical, Legend Biotech, Lyell Immunopharma, Inc., Medigene AG, Mustang Bio, Inc., Novartis AG, Obsidian Therapeutics, Poseida Therapeutics, Precigen Inc., Precision Biosciences, Inc., Sana Biotechnology, Sorrento Therapeutics, Inc., and Takeda Pharmaceutical Co.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other cell based treatments, our product candidates may compete in their solid tumor indications with novel therapeutics of other modalities, including small molecules, monoclonal antibodies, bi-specific antibodies, antibody-drug conjugates, and targeted radionuclides.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see Item 1. Business Competition under Part I of our Annual Report.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Workforce and expense reductions may have an adverse impact on our internal programs, our ability to hire and retain key personnel and may be distracting to management.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We currently employ a small number of employees and are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and substantially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We substantially decreased our workforce in October 2020 and, depending on our need for additional funding and expense control, we may be required to implement further workforce and expense reductions in the future. Further workforce and expense reductions may not result in efficiencies and anticipated savings and could result in reduced progress on our internal programs. In addition, employees, whether or not directly affected by a reduction, may seek future employment with our business partners or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors. Although our employees are required to sign a confidentiality agreement at the time of hire, the confidentiality of certain proprietary information and knowledge may not be maintained in the course of any such future employment. Further, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled personnel. We may have difficulty retaining and attracting such personnel as a result of a perceived risk of future workforce and expense reductions. In addition, the implementation of expense reduction programs may result in the diversion of efforts of our executive management team and other key employees, which could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Furthermore, we have identified and may continue to identify deficiencies in our internal control over financial reporting due in part to our limited staffing and resources. If we are unable to maintain effective controls over financial reporting, it is possible that a misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis. We have implemented and continue to implement measures designed to improve our internal control over financial reporting, including the retention of accounting consultants to assist in areas of complex accounting and financial reporting. However, if we are unsuccessful in maintaining the effectiveness of our internal control over financial reporting, the accuracy and timing of our financial reporting may be harmed, which could result in, among other things, restatements of our financial statements, failure to comply with SEC requirements, loss of investor confidence in our financial reporting, and a decline in our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock units, or RSUs, that vest over time. The value to employees of stock options and RSUs that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain key man insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled scientific and medical personnel.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our 2019 private placement of equity restrict our operating and financial flexibility, and give priority to certain investors, both of which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into an agreement with certain institutional investors providing for a private placement. Pursuant to the terms of the 2019 securities purchase agreement for the private placement transaction, the investors in the private placement transaction have consent rights over certain significant matters of our business. These include decisions to authorize or issue equity securities that are senior or pari passu to the Series 1 preferred stock with respect to liquidation preference, the occurrence of indebtedness in excess of $1,000,000, the sale or license of certain of our technology and the payment of dividends. As a result, these stockholders, acting together, will have significant influence over certain matters affecting our business.  The investors in the private placement may not exercise their rights to purchase additional tranches of preferred stock and may not consent to us seeking additional funds through debt or other equity financings. In addition, potential investors in the Company may decline to do so because of the preferential rights granted under the private placement agreement. Each of these factors could negatively impact our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are reliant on a third party to manufacture our clinical product candidates and may not be able to secure adequate manufacturing capacity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced the closing of the sale of our U.S. manufacturing facility to M.D. Anderson. When M.D. Anderson assumed ownership of the facility, we became reliant on M.D. Anderson to supply our current clinical product candidates. We have endeavored to structure the transaction in a manner that ensures availability of adequate capacity and priority access thereto for the continued clinical development of our product candidates. Given the complexity of the manufacturing processes for cellular therapies, M.D. Anderson may be unable to effectively manufacture or release our products in accordance with applicable cGMP standards, which could result in significant costs or delays to our programs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We oversee a complex manufacturing supply chain of cellular therapy product candidates, viral vectors and small molecule drugs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the complex nature of our cell therapy products, we need to oversee the manufacture of multiple components that require a diverse knowledge base and appropriate manufacturing personnel. The supply chain for these components is separate and distinct, and no single manufacturer can supply more than one component of each of our products. Additionally, it is likely that the cell therapy products will need to be made within an appropriate geographic location for the area in which the products will be utilized, so one cell therapy manufacturing facility may not be able to supply diverse geographic areas. Any lack of capabilities to store, freeze, thaw and infuse our cell therapies would adversely affect our business and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our autologous GoCAR-T product candidates, including BPX-601 and BPX-603 are manufactured on a patient-by-patient basis using each patients own cells. Efficient manufacturing of these products relies upon our ability to sufficiently expand and activate the cells of patients who have undergone multiple lines of prior therapy, often including immunosuppressive chemotherapy. Rimiducid, the small molecule drug used to activate both our iMC and iC9 switches, is a complex molecule to synthesize and is relatively insoluble and lipophilic, rendering it difficult to formulate. We have limited internal expertise in small molecule drug development and manufacturing, and we have identified specialty contract manufacturers to produce the rimiducid drug substance and drug product. It is uncertain whether the drug substance and drug product manufacturers will be able to manufacture sufficient quantity and quality of rimiducid to conduct the necessary non-clinical and clinical trials.</span></div><div><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet caused our product candidates to be manufactured or processed on a commercial scale. We may not be able to scale patient-by-patient manufacturing and processing to satisfy clinical or commercial demands for any of our product candidates. In addition, our anticipated reliance on a limited number of third-party manufacturers for manufacturing exposes us to the following risks:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and any replacement contractor must be approved by regulatory authorities. This approval would require new testing and compliance inspections. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory approval, if any.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by regulatory agencies to ensure strict compliance with cGMP and other government regulations and standards. We do not have control over third-party manufacturers compliance with these regulations and standards.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, the approval, if any of our product candidates or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited information available regarding the ultimate cost of our products, and cannot estimate what the cost of our products will be upon commercialization, should that occur.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product. Because of the patient-specific nature of our manufacturing process, it is not amenable to traditional scale up to manufacture larger lots as is performed for traditional drugs and biological agents.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene-modified cell therapy manufacture requires many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product. Some suppliers typically support biomedical researchers or blood-based hospital businesses and may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have commercial supply arrangements with many of these suppliers and may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the FCPA or comparable foreign regulations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; and  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, and the impact of the COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek strategic alliances, create joint ventures or collaborations and enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. It is possible that, following a strategic transaction or license, we may not achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to manufacture our drug substance and product, and because we collaborate with various organizations and academic institutions on the advancement of our technology platform, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitors discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors utilize hazardous materials in our business operations, and any claims relating to improper handling, storage, or disposal of these materials could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. governing the use, manufacture, storage, handling and disposal of medical and hazardous materials, and similar laws in other geographic regions. Although we believe that our manufacturers procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our clinical investigators, contractors or consultants, may fail or suffer security breaches.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">System outages, network disruptions and cyber-security threats could interrupt the operation of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the use of information technology systems for our operations. Outages, disruptions and threats could have an adverse impact on our ability to conduct operations. Cyber-security threats, such as malware, phishing and network attacks, are on the rise. These attacks can affect the availability of our information technology systems, including their data, as well as the confidentiality and integrity of these systems. A security breach poses a risk to confidential data, including but not limited to intellectual property and trade secrets resulting in financial, legal or reputational harm to us. Insider threats may exist if an individual authorized to access our technology systems improperly discloses sensitive data to unauthorized persons or the public. We also have outsourced elements of our operations, including elements of our information technology infrastructure, and thus manage several independent vendor relationships with third parties who may have access to our confidential information.  Confidentiality agreements are in place for authorized users and third parties to support the prevention of confidential information being improperly disclosed. We have policies and procedures in place, including controls around the access and activity of authorized users, active system monitoring, back-up and recovery, information technology security and mandatory annual information technology security awareness training to assist in the prevention and mitigation of an outage, disruption or threat. In addition, we have invested in high availability, redundant technologies that will reduce the risk of an outage, disruption or threat.  However, our efforts may not prevent an outage, disruption or threat that would materially adversely affect us. We also may not have sufficient liability insurance, either type or amount, to cover us against claims related to a cyber-security threat.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our clinical investigators, contractors and consultants, could be subject to power shortages, telecommunications failures, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates on a patient by patient basis. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. In particular, certain third-party manufacturers may be unable to comply with their contractual obligations to us due to disruptions caused by COVID-19, including reduced operations or headcount reductions, or otherwise, and in certain cases we may have limited recourse if the non-compliance is due to factors outside of the manufacturers control.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalties law, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health and Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information and their covered subcontractors, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Childrens Health Insurance Program (with certain exceptions) to report annually to the HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as require certain manufacturers and group purchasing organizations to report annually ownership and investment interests held by such physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by or are in conflict with HIPAA, including the European Union General Data Protection Regulation, or the GDPR, which became effective on May 25, 2018, and which imposes privacy and security obligations on any entity that collects and/or processes health data from individuals located in the European Union. Under the GDPR, fines of up to 20 million euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance. As well as complicating our compliance efforts, non-compliance with these laws could result in penalties or significant legal liability. The GDPR includes more stringent operational requirements for processors and controllers of personal data and creates additional rights for data subjects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to state and foreign equivalents of each of the U.S. healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the U.S. will also subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. We may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. For example, in May 2019, we were added as an additional defendant in an ongoing civil tort lawsuit in federal court in Los Angeles, California. The complaint alleges claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability-failure to warn, breach of express warranty and products liability design or manufacturing defect. Claims could also be asserted under state consumer protection acts. We have filed a demurrer and motion to strike the fourth amended complaint, which is not currently set for hearing but will be rescheduled pursuant to a further order from the court. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, federal or state liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of managements time and our resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to clinical trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any product candidate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our share price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop, alone or with corporate collaborators. We currently carry product liability insurance covering our clinical trials, with other coverage limits as appropriate for certain foreign jurisdictions. Although we maintain such insurance, our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had aggregate U.S. net operating loss carryforwards of approximately $478.0 million, and aggregate U.S. federal and Texas state research and development credits of approximately $13.0 million and $5.1 million, respectively. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. U.S. federal net operating loss carryforwards generated in taxable years beginning before </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2018, may be carried forward only 20 years to offset future taxable income, if any. Under current U.S. federal income tax law, U.S. federal net operating loss carryforwards generated in taxable years beginning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 31, 2017, can be carried forward indefinitely, but the deductibility of such </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating loss carryforwards in taxable years beginning after December 31, 2020, is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to federal law.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an ownership change (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporations ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We may have experienced one or more ownership changes in the past, including with respect to our August 2019 public offering, and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a BLA to the FDA, or similar approval filings to other foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidates safety, purity and potency for each desired indication. It must also include significant information regarding the chemistry, manufacturing and controls for the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, FDAs Office of Tissues and Advanced Therapies, or OTAT, has limited experience with combination products that include a small molecule component. Approval of our GoCAR-T product candidates, will likely require this FDA office to consult with other divisions of the FDA, which may result in further challenges in obtaining regulatory approval, including in developing final product labeling. The regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of financial resources to commence and complete our planned clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting suitable patients to participate in a clinical trial; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having patients complete a clinical trial or return for post-treatment follow-up; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites deviating from clinical trial protocol, failing to follow GCPs, or dropping out of a clinical trial; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials. </span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such clinical trials are being conducted, or recommended for termination by the Data Monitoring Committee for such clinical trial, or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, in December 2020 we announced that the FDA had placed a clinical hold on our BPX-601 trial in pancreatic cancer due to the death of a patient in the trial. Although the FDA released the hold in January 2021, there can be no assurance that future patients deaths in this or any of our clinical trials will not trigger additional clinical holds. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the EU or U.S., including additional preclinical studies or clinical trials. Studies and clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the EU and U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties and/or withdrawal of product approval if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of manufacturing at one or more manufacturing facilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDAs and other regulatory authorities policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign legislative changes may also affect our ability to commercialize our product candidates. Effective as of May 25, 2018, the GDPR imposes privacy and security obligations on any entity that collects and/or processes personal information from individuals located in the European Union. Under the GDPR, fines of up to 20 million euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as potential cancer treatments is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Many factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which our product candidates are approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and quality of the clinical evidence supporting the efficacy and safety of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of our product candidates as well as competitive products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our product candidates and the availability of adequate reimbursement by third-party payors and government authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness and ability of patients to pay out-of-pocket in the absence of coverage by third-party payors, including government authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">confusion or lack of understanding regarding the effects of rimiducid and the timing and size of dosing of rimiducid after immune cell therapy; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we are not utilizing embryonic stem cells or replication competent vectors, adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such clinical trials to demonstrate that these therapies are safe and effective may limit market acceptance our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend in large part on global reimbursement policies and may be affected by future healthcare reform measures, both in the United States and other key international markets. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Therefore, successful commercialization of our products will depend in part on the availability of governmental and third-party payor reimbursement for the cost of our product candidates and/or payment to the physician for administering our product candidates. In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. One third-party payors decision to cover a particular medical product or service does not assure that other payors will also provide coverage for the medical product or service, or to provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that adequate coverage and reimbursement will be obtained. Further, a third-party payors decision to provide coverage for a medical product or service does not imply that an adequate reimbursement rate will be approved. The market for our product candidates will depend significantly on access to third-party payors formularies or lists of treatments for which third-party payors provide coverage and reimbursement. Third party payors may also have difficulty in determining the appropriate coverage of our product candidates, if approved, due to the fact that they are combination products that include a small molecule drug, rimiducid.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors establish coverage and reimbursement policies for new products, including our product candidates. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for treatments based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. In the United States, the EEA and other significant or potentially significant markets for our product candidate, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in Canada and the EEA will put additional pressure on product pricing, coverage, reimbursement and utilization, which may adversely affect our product sales and results of operations. These pressures can arise from policies&nbsp;and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, coverage and reimbursement policies and pricing in general. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the PPACA, became law in the United States. PPACA substantially changed the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. Among the provisions of the PPACA of greatest importance to the pharmaceutical industry are the following: (i)&nbsp;an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; (ii)&nbsp;an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; (iii)&nbsp;a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers outpatient drugs to be covered under Medicare Part&nbsp;D; (iv)&nbsp;extension of manufacturers Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (v)&nbsp;expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers Medicaid rebate liability; (vi)&nbsp;expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; (vii)&nbsp;expansion of health care fraud and abuse laws, including the federal civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; and (viii)&nbsp;a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been executive judicial and Congressional challenges to other aspects of the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the PPACA have been signed into law. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the individual mandate. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA-mandated Cadillac tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the individual mandate was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Further, although the U.S. Supreme Court has not yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA and our business.</span></div><div style="text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, following passage of the Bipartisan Budget Act of 2018, will remain in effect through 2031 with the exception of a temporary suspension from May 1, 2020 through December 31, 2022 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drugs average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, recently there has been heightened governmental scrutiny in the United States over the manner in which drug manufacturers set prices for their marketed products, in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administrations proposals. As a result, the FDA released a final rule and guidance on September 24, 2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administrations Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinded the MFN model interim final rule. In July 2021, the Biden administration released an executive order, Promoting Competition in the American Economy, with multiple provisions aimed at prescription drugs. In response to Bidens executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal and state healthcare reform measures will be adopted in the future, any of which could result in reduced demand for our products or other adverse effects on our business. For example, it is possible that additional governmental action is taken to address the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional federal and state healthcare reform measures, such as further amendments and changes to the PPACA will be adopted in the future, any of which could result in reduced demand for our products or other adverse effects on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries have a very difficult reimbursement environment and we may not obtain reimbursement or pricing approval, if required, in all countries where we expect to market a product, or we may obtain reimbursement approval at a level that would make marketing a product in certain countries not viable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any products that we may develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the small size of our target patient populations, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our target patient populations for our potential product candidates are relatively small, as a result, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial and manufacturing infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates, for example, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement for administration of our product candidates to patients, is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations governing data privacy and the protection of personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. There are foreign and state law versions of these laws and regulations to which we are currently and/or may in the future, be subject. For example, the collection and use of personal health data in the European Union is governed by the GDPR. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large monetary penalties for noncompliance. The GDPR requirements apply not only to third-party transactions, but also to transfers of information within our company, including employee information. The GDPR and similar data privacy laws of other jurisdictions place significant responsibilities on us and create potential liability in relation to personal data that we or our third-party service providers process, including in clinical trials conducted in the United States and European Union. In addition, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, California recently enacted legislation that has been dubbed the first GDPR-like law in the United States.&nbsp;Known as the California Consumer Privacy Act, or the CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.&nbsp;As of January 1, 2020, the CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As currently written, the CCPA will likely impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws.&nbsp; We can face serious consequences for violations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. &nbsp;Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. &nbsp;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.&nbsp;We engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We also expect our non-U.S. activities to increase in time. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.&nbsp; Compliance with these legal standards could impair our ability to compete in domestic and international markets.&nbsp; We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Departments Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C.  201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&nbsp; Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&nbsp; We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&nbsp; We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.&nbsp; We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. &nbsp;Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the&nbsp;FDA, the SEC&nbsp;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the&nbsp;FDA&nbsp;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the&nbsp;FDA&nbsp;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the&nbsp;FDA and the SEC, have had to furlough critical&nbsp;FDA, SEC and other government&nbsp;employees and stop critical activities. If repeated or prolonged&nbsp;government&nbsp;shutdowns&nbsp;occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We license from Baylor College of Medicine, or Baylor, certain intellectual property related to methods for activating antigen presenting cells, to certain genetic constructs and to certain methods for inducing apoptosis. Baylor may terminate or modify our licenses in the event of a material breach by us that remains uncured following the date that is 90 days after written notice of such breach or upon certain insolvency events that remain uncured following the date that is 30 days following written notice of such insolvency event. In addition, we have funded certain of our clinical development activities and may fund certain of our future clinical development with funds from the State of Texas. The State of Texas may have rights to commercialize the results of those clinical trials if it determines that we have failed, after notice and an opportunity to cure, to use diligent and commercially reasonable efforts to commercialize or otherwise bring to practical application the results of the funded clinical trials. We are also dependent on our license agreements with Agensys, Inc. (a subsidiary of Astellas Pharma, Inc.) with respect to PSCA-targeted CARs, and BioVec Pharma Inc. with respect to making retrovirus for all of our programs.  The termination of any of these licenses could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination of these agreements, or other agreements to which we are a party could result in the loss of significant rights and could harm our ability to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors and other partners regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Certain intellectual property which is covered by our in-license agreements has been developed at academic institutions which have retained non-commercial rights to such intellectual property.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several pending U.S. and foreign patent applications in our portfolio, and we anticipate additional patent applications will be filed both in the U.S. and in other countries, as appropriate. However, we cannot predict:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if and when patents will issue; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property. We cannot be certain that the claims in our pending patent applications directed to compositions of matter for our product candidates will be considered patentable by the U.S. Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid by courts in the U.S. or foreign countries. Method of use patents have claims directed to the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the U.S. or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, it is possible that patent applications in our portfolio may not be the first filed patent applications related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March&nbsp;16, 2013, there is a greater level of uncertainty in the patent law with the passage of the America Invents Act (2012)&nbsp;which brings into effect significant changes to the U.S. patent laws that are yet untried and untested, and which introduces new procedures for challenging pending patent applications and issued patents. A primary change under this reform is creating a first to file system in the U.S. This will require us to be cognizant going forward of the time from invention to filing of a patent application.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. We require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements; however, it is possible that our trade secrets and other confidential proprietary information could be disclosed or that competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Recently, under U.S. patent reform, new procedures including inter parties review and post grant review have been implemented. As stated above, this reform is untried and untested and will bring uncertainty to the possibility of challenge to our patents in the future. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware or have not sufficiently analyzed with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, methods of use, including combination therapy or patient selection methods or any final product itself, the holders of any such patents may be able to block our ability to develop and commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. It is possible that any such license would not be available at all or on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are aware of a third-party patent having claims directed to chimeric DNA comprising DNA segments encoding (1)&nbsp;a single chain antibody domain and (2)&nbsp;transmembrane and cytoplasmic domains of an endogenous protein. Even though we have reason to believe that our product candidates are not covered by claims of this patent, an owner or licensee of the patent still might bring a patent infringement suit against us. If the patent is asserted against us, we may not prevail in defending against claims of infringement and/or challenging the validity of claims in the patent. We may not successfully develop alternative technologies or enter into an agreement by which we obtain rights to the patent. These rights, if necessary, may not be available on terms acceptable to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of third-party patents having claims that may be considered as being directed to single-chain antibody fragments that bind to PSCA and these patents may be considered relevant to BPX-601 and related technologies we are developing. We currently are evaluating whether or not we need to obtain rights to these patents under a license, and if it is determined that we need to obtain such rights, whether these rights can be obtained. We are also aware of third-party patent applications having claims that may be considered as being directed to cellular therapy constructs utilizing a heterodimer domain for activation of caspase 9.  We are monitoring these applications and if they are granted with the claims as drafted, they may be relevant to our potential dual-switch product candidates containing such a heterodimer activation domain.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, while we are aware there are other third-party patents having claims that may be considered relevant to technologies for which we are seeking, or plan to seek, regulatory approval, we believe those patents have a patent term that may expire prior to the time we expect to obtain regulatory approval for these technologies. The estimated expiration dates for those patents were determined according to information on the face pages of the patents, and certain factors that could influence patent term, such as patent term adjustment and patent term extension, for example, were not factored into these estimates. Accordingly, the estimated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expiration dates of those patents may not be accurate and one or more of those patents may not expire before we obtain regulatory approval for an applicable technology. Owners or licensees of one or more of those patents may bring a patent infringement suit against us. If one or more of those patents are asserted against us, we may be able to assert a defense for a safe harbor to patent infringement under 35 U.S.C. 271(e)(1) if certain requirements are met. It is possible that (1)&nbsp;certain of these requirements may not be met, and/or (2)&nbsp;one or more of the third-party patents might expire after one or more of our technologies obtain regulatory approval, and consequently we may not successfully assert such a defense to patent infringement. If we are unsuccessful in asserting a defense under 35 U.S.C. 271(e)(1), it is possible we may not prevail in defending against claims of infringement and/or challenging the validity of claims in those patents. We may not successfully develop alternative technologies or enter into agreements by which we obtain rights to applicable patents. These rights, if necessary, may not be available on terms acceptable to us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully complete negotiations and ultimately acquire the rights to the intellectual property that we may seek to acquire in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. It also is possible that a competitor we sue for patent infringement could countersue us for allegedly infringing one or more of their own patents or one or more patents they licensed from another entity. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. It also is possible that third parties could institute a patent office post-grant proceeding against one or more of our patents, or one or more patents licensed to us, such as a post grant review proceeding, inter parties review proceeding or reexamination proceeding at the USPTO, or an opposition proceeding in a jurisdiction outside the U.S. An unfavorable outcome in a post-grant proceeding could result in a loss of our patent rights. Litigation, interference proceedings or patent office post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We also may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent position could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1)&nbsp;non-U.S. patents and patent applications owned by us, and (2)&nbsp;patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions, for example, opposition proceedings.  Any such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art and that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patents directed to our product candidates. A loss of patent rights could have a material adverse impact on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S.&nbsp;patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S.&nbsp;Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the recent case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to satisfy applicable listing standards, our common stock may be delisted from the Nasdaq Capital Market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. On May 5, 2021, we were notified by The Nasdaq Stock Market LLC (Nasdaq), that we were in breach of Listing Rule 5450(b)(2)(A), for continued listing on The Nasdaq Capital Market because the market value of our listed securities for 30 consecutive business days had been less than $35 million. On December 10, 2021, we were notified by Nasdaq that we had regained compliance with Listing Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million for continued listing of our common stock. Accordingly, we regained compliance with the continued listing requirements of The Nasdaq Capital Market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we were able to regain compliance with the continued listing requirements of The Nasdaq Capital Market, we cannot assure you that we will be able to do so in the future. If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our common stock is delisted by Nasdaq, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. Further, if we are delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our shareholders to sell our common stock in the secondary market.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock is volatile and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including market conditions in general and a limited trading volume for our shares. In addition to the factors discussed in this Risk Factors section and elsewhere in our Annual Report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authoritys review of such filings, including without limitation the FDAs issuance of a refusal to file letter or a request for additional information; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays in our ongoing or future clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our CID technology platform and our small molecule drug rimiducid; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our contract manufacturers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to maintain successful collaborations or to establish new collaborations if needed; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to commercialize our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of our initial target markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully treat additional types of diseases and cancers or at different stages; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a companys securities. This type of litigation, if instituted, could result in substantial costs and a diversion of managements attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of 5% or more of our capital stock and their respective affiliates beneficially own a significant portion of our voting stock, including shares subject to outstanding options. As a result, if these shareholders were to choose to act together, they would have the ability to significantly influence all matters requiring stockholder approval. For example, these stockholders may be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in accounting rules, assumptions and/or judgments could materially and adversely affect us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting rules and interpretations for certain aspects of our operations are highly complex and involve significant assumptions and judgment. These complexities could lead to a delay in the preparation and dissemination of our financial statements. Furthermore, changes in accounting rules and interpretations or in our accounting assumptions and/or judgments, such as asset impairments, could significantly impact our financial statements. In some cases, we could be required to apply a new or revised standard retroactively, resulting in restating prior period financial statements. Any of these circumstances could have a material adverse effect on our business, prospects, liquidity, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our consolidated financial statements, including our liabilities and statements of operations are subject to quarterly changes in our accounting of our outstanding Series 1 Preferred Stock and related warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with&nbsp;ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Instruments and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities-Distinguishing from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, convertible preferred shares are accounted for as temporary equity and warrants are&nbsp;accounted&nbsp;for as liabilities at their fair value during periods where they can be net cash settled in case of a change in control transaction. The&nbsp;warrants&nbsp;are&nbsp;accounted&nbsp;for as a liability at their fair value at each reporting period. The value of the derivative warrant liability is re-measured at each reporting period with changes in fair value recorded in earnings. To derive an estimate of the fair value of these warrants, the binomial model is utilized, adjusted for the effect of dilution, which embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to determine the fair value of these instruments. This process requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. As a result, our consolidated financial statements and results of operations may fluctuate quarterly, based on factors, such as the trading value of our common stock and certain assumptions, which are outside of our control. Consequently, our liabilities and consolidated statements of operations may vary quarterly, based on factors other than our revenues and expenses. The liabilities and accounting line items associated with our derivative securities on our balance sheet and statement of operations are non-cash items, and the inclusion of such items in our financial statements may materially affect the outcome of our quarterly and annual results, even though such items are non-cash and do not affect the cash we have available for operations. Investors should take such derivative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting matters and other non-cash items into account when comparing our quarter-to-quarter and year-to-year operating results and financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain holders of our outstanding shares of common stock, are entitled to rights with respect to the registration of their shares under the Securities Act of 1933, as amended, or the Securities Act. Any sales of these shares by such stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We register on Form S-8 all shares of common stock that are issuable under our 2019 Equity Incentive Plan, as amended, or the EIP. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our EIP and shelf registration statement, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations, including conducting clinical trials, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, including pursuant to our shelf registration statement on Form S-3 that we filed with the SEC. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. For example, in December 2021 we completed a private placement pursuant to which we issued pre-funded warrants to purchase an aggregate of 20,559,210 shares of our common stock and accompanying warrants to purchase an aggregate of 2,055,920 shares of common stock, and our outstanding shares of common stock as of March&nbsp;21, 2022 was 8,552,207. This transaction resulted, and any similar future transactions may also result, in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the existing holders of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We completed a public offering of our Series 1 preferred stock on August 21, 2019, and if we are required to redeem shares of preferred stock, our cash position will be negatively impacted. In addition, we may not have sufficient funds to redeem such shares of preferred stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued 575,000 shares of Series 1 preferred stock in connection with our August 2019 public offering. Subject to the terms of our certificate of incorporation, at any time on or after August 21, 2024, some or all of our outstanding shares of preferred stock will be redeemable at the option of the holder at a redemption price of $100.00 per share of Series 1, upon delivery of an irrevocable written notice to us. If a holder of preferred stock requests redemption we will be required to redeem such shares of preferred stock. However, we may be unable to redeem such preferred stock if restrictions under applicable law or contractual obligations prohibit such redemption. For example, Delaware law provides that a redemption on capital stock may only be paid from surplus or, if there is no surplus, from a corporations net profits for the then-current or the preceding fiscal year. Unless we operate profitably, our ability to redeem the preferred stock would require the availability of adequate surplus, which is defined as the excess, if any, of our net assets (total assets less total liabilities) over our capital. To date, we have operated at a loss. Accordingly, if we do not have sufficient surplus under Delaware law, we would be unable to effect such redemption. If we do have sufficient surplus to effect such redemption, our available cash will be negatively impacted and our ability to use the net proceeds from this offering could be substantially limited. In addition, such reduction in our available cash could decrease the trading price of our common stock, and, accordingly, the preferred stock and our warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain investors in the 2019 private placement will have the ability to control or significantly influence certain business decisions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2019 securities purchase agreement for the private placement transaction, certain investors in the private placement transaction have consent rights over certain significant matters of the Companys business. These include decisions to authorize or issue equity securities that are senior or pari passu to the Series 3 preferred stock with respect to liquidation preference, the incurrence of indebtedness in excess of $1,000,000, the sale or license of the Companys iMC switch </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology and the payment of dividends. As a result, these stockholders, acting together, will have significant influence over certain matters affecting our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.*</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholders ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts that cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_22"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&nbsp;&nbsp;Unresolved Staff Comments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_25"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&nbsp;&nbsp;Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company exited its Houston and South San Francisco office facilities and the leases were terminated. As of December 31, 2021, the Company had no physical properties.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_28"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&nbsp;&nbsp;Legal Proceedings </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the Litigation subheading in Note 8 - Commitments and Contingencies of Notes to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&nbsp;&nbsp;Mine Safety Disclosures </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_34"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&nbsp;II </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_37"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&nbsp;&nbsp;Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on The Nasdaq Capital Market under the symbol "BLCM".</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;21, 2022, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 stockholders of record of our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Certain shares are held in street name and thus the actual number of beneficial owners of such shares is not known or included in the foregoing number. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item&nbsp;12 of Part III of this Annual Report. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_40"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&nbsp;[Reserved]</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_43"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&nbsp;&nbsp;Managements Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the financial statements and related notes included in "Item 8 - Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption Item 1A. Risk Factors. </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On February 5, 2020, we filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to (i) effect a reverse stock split of all issued and outstanding shares of our common stock at a ratio of&nbsp;1-for-10 and (ii) reduce the number of authorized shares of our common stock from 200,000,000 to 40,000,000.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On February 5, 2020, we effected a reverse stock split of all issued and outstanding shares of our common stock at a ratio of 1-for-10, and reduced the number of authorized shares of our common stock from 200,000,000 to 40,000,000. Share related amounts have been retroactively adjusted in this Annual Report on Form 10-K to reflect this reverse stock-split for all periods presented.  </span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_46"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. We are advancing CAR-T cell therapies, which are an innovative approach in which a patients or donors T cells are genetically modified to carry chimeric antigen receptors, or CARs. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better efficacy and safety outcomes than are seen with current cellular immunotherapies. For additional information about our business, and candidate development programs, see the discussions contained within Item 1. Business in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_49"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the periods indicated:</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supply agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,578&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,052&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,010&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,531&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,588&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,583&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,995)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Gain on dispositions, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,656&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,869)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,692)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,826&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant and private placement option liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,130&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,161&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,970&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,809)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,705)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,722)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:justify"><span><br></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenues for the year ended December 31, 2021, compared to last year, was due to agreements executed with external parties during the year. In the first quarter of 2021, we entered into a multi-year supply agreement with Takeda Development Center Americas, Inc. (Takeda) for the supply of rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The supply was fulfilled in the second quarter of 2021 generating revenue of $0.7 million. In the third quarter of 2021, we entered into an option and license agreement with The University of Texas M. D. Anderson Cancer Center (MD Anderson) for certain option and license rights to CaspaCIDe and related technologies. An upfront fee under the agreement of $5.0 million was recognized as revenue, together with $0.5 million of annual license fee under a previous license agreement with MD Anderson. For the year ended December 31, 2020, the only source of revenue was the annual license fee of $0.5 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (R&amp;D)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&amp;D expenses for the year ended December 31, 2021, compared to the year ended December 31, 2020, was primarily due to reduced expenses related to rivo-cel related activities, the sale of the manufacturing facility, and the reduction in force that was implemented in the fourth quarter of 2020, partially offset by an increase in expenses related to our GoCAR-T programs. This resulted in $12.3 million reduction in salaries, benefits, travel, and share based compensation related charges and a $3.2 million reduction in general R&amp;D supplies, technical operations and pharmaceutical development expenses and facility charges primarily due to lower clinical trial activities. Additionally, depreciation expense decreased $0.1 million due to the manufacturing facility and related laboratories disposed of in April 2020 and additional laboratory assets and equipment sold in March 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (G&amp;A)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in G&amp;A expenses for the year ended December 31, 2021, compared to the year ended December 31, 2020, was primarily due the aforementioned reduction in force that reduced employee-related charges by $6.8 million as well as the reduction in rivo-cel related commercialization activities that reduced charges by $1.7 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="text-align:justify"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Companys restructuring plan, the management elected to seek an exit to its leased R&amp;D facility in Houston, Texas during the fourth quarter of 2020. As a result, we reclassified the assets and liabilities associated with the leased facility as held for sale, which included a right-of-use asset of $0.5 million, and property plant and equipment of $2.3 million. Based on the cost to exit the lease and the net realizable value of the related assets, we recognized an impairment charge of $1.3 million for the year ended December 31, 2020. The sale of the assets and equipment was completed in the first quarter of 2021, and there was no additional impairment recognized for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on dispositions, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in gain of dispositions, net for the year ended December 31, 2021, compared to last year, was primarily due to the disposal of the clinical supply manufacturing facility to MD Anderson in the second quarter of 2020 which resulted a gain of $3.7 million in 2020. In addition, there was a loss on termination of the South San Francisco office space of $0.5 million during the first quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income or expense primarily consists of interest income, interest expense, and changes in fair values of our warrant liability and the private placement option, which are remeasured at each reporting period. Due to the nature of the inputs in the model used to assess the fair value of the warrant liability and private placement option, we may experience significant fluctuations at each reporting period. These fluctuations may be due to a variety of factors, including changes in our stock price and changes in stock price volatility over the remaining term of the warrants and options.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income for the year ended December 31, 2021, was primarily due to a decreased gain of $15.1 million from the change in fair value of our warrant and private placement option liabilities, compared to a gain from change in fair value of $46.1 million for the year ended December 31, 2020. The bigger change in fair value over 2020 was primarily driven by a more significant decrease in our stock price compared to 2021. Meanwhile, there is a decrease of $3.0 million in interest expense for the year ended December 31, 2021 compared to last year, as a result of the early retirement of the Oxford Loan in 2020.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, we had cash, cash equivalents, and restricted cash of $47.7 million and net cash used in operations of approximately $23.1 million for the year ended December 31, 2021. Notably, in December 2021, we completed a private placement equity financing transaction for gross proceeds of approximately $35.0&nbsp;million before deducting placement agent commissions and offering expenses.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis that there is no substantial doubt about our ability to continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. Our cash resources are primarily consumed by operating activities and we expect negative cash flows from operations to continue for at least the next 12 months. We do not have any material contractual obligations or commitments as of December 31, 2021. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses, and general overhead costs. Based on our current research and development plans and our timing expectations related to the progress of our programs, we believe that our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through at least mid-2023.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We plan to continue attempting to obtain future financing and/or engage in strategic transactions, but we cannot predict, with certainty, the outcome of our actions to generate liquidity, including the availability of additional equity or debt financing, or whether such actions would generate the expected liquidity as currently planned. To continue as a going concern, we may postpone or eliminate some of our research and development programs and reduce our administrative costs. We may also intend to seek additional funding including, but not limited to, any or all of the following potential sources:</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an effective shelf registration statement on Form S-3 for the offer and sale of up to $400.0 million of our securities, of which approximately $317.5&nbsp;million remains available for future offerings. We may pursue additional funding through the sale of our securities in one or more offerings under this registration statement; however, we cannot assure you that we will be able to do so on favorable terms. Our ability to offer and sell our securities in a primary offering on our Form S-3 is currently limited by Instruction I.B.6 of Form S-3, commonly referred to as the baby shelf limitation. If we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that could adversely affect the rights of our existing stockholders. If we raise additional capital through the issuance of debt securities, we could incur fixed payment obligations and become subject to certain restrictive covenants, including limitations on </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ability to incur additional debt and acquire or license intellectual property rights, and other operating restrictions that could restrict our ability to conduct our business.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may receive additional capital through the exercise of outstanding warrants to purchase our stock if our stock price sufficiently increases. As of December 31, 2021, warrants to purchase 5,750,000 shares of our Series 1 preferred stock at an exercise price of $130.00 per share (equivalent to $13.00 per share of common stock), warrants to purchase 4,149,378 shares of our common stock at an exercise price of $6.50 per share and warrants to purchase 2,055,920 shares of our common stock at an exercise price of $1.69 per share were outstanding. The preferred stock warrants expire on August 21, 2026 and the common warrants expire on November 3, 2025 and December 7, 2028, respectively.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. Moreover, if we do not obtain such additional funds, there could be substantial doubt about our ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to our stockholders and other security holders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash&nbsp;used in operating activities during the year ended December 31, 2021, was $23.1 million compared to $56.7 million for the year ended December 31, 2020. The primary operating activities during 2021 were (1) $9.7 million of net losses, (2) a $15.1 million non-cash gain from change in fair market value of warrant derivative and private placement option liabilities, (3) a $2.4 million decrease from operating assets and liabilities, and (4) a $0.5 million of loss on dispositions, net. These activities were partially offset by share-based compensation charges of $3.4 million and other smaller non-cash items.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the year ended December 31, 2021, was $0.9 million compared to $14.1 million for the year ended December 31, 2020. The net cash provided by investing activities during the year ended December 31, 2021,&nbsp;was primarily due to $0.9 million of net proceeds received from the sale of property and equipment. The $14.1 million of net cash provided by investing activities during 2020 was also related to proceeds from the sale of property and equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the year ended December 31, 2021, was $32.9 million compared to net cash used of $14.2 million for the year ended December 31, 2020. The net cash provided by financing activities during the year ended December 31, 2021&nbsp;was generated from the issuance of pre-funded warrants during the private placement closed in December 2021, net of offering expenses. The net cash used in financing activities for the year ended December 31, 2020 was primarily due to the principal payments and the subsequent early retirement of debt totaling $37.1 million partially offset by proceeds from the issuance of common stock and pre-funded warrants, net in the amount of $22.9 million.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we do not have any short-term or long-term lease liabilities, debt obligations or other material capital commitments. The expected capital expenditures for the next 12 months are minimal.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements (as defined by applicable regulations of the SEC) that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose.</span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Estimates </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be reasonable under the circumstances. In many instances, we could have reasonably used different accounting estimates, and in other instances changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from managements estimates under different assumptions or conditions. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. While our significant accounting policies are described in the notes to our financial statements, we believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies related to the more significant areas involving managements judgments and estimates. Our management has discussed the development and selection of these critical accounting estimates with the audit committee of our board of directors and the audit committee has reviewed the companys disclosure relating to it in this MD&amp;A.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Derivatives</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding public warrants exercisable for multiple underlying instruments are classified as liabilities. The Company accounts for these warrants in accordance with ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities From Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 480) and ASC Topic 815,&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Instruments and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;(ASC 815).  The Company estimates the fair value of these liabilities using the binomial option model. The option pricing model of our warrant derivative liabilities are estimates and are sensitive to changes to certain inputs used in the pricing model. See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of how the Company accounts for its warrant derivatives.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding pre-funded warrants and accompanying warrants exercisable for multiple underlying instruments are classified as equity. The Company accounts for these warrants in accordance with ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities From Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 480) and ASC Topic 815,&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Instruments and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;(ASC 815). Upon the issuance of pre-funded warrants or the exercise of its accompanying common warrants, the Company receives proceeds from its investors which are recognized as equity.  Furthermore, because pre-funded warrants and accompanying warrants do not participate in dividends with common stockholders, they are not considered a participating security in its current form and, therefore, they will be considered in the Companys basic and diluted EPS calculations (if in net income position). See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of how the Company accounts for its pre-funded warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Option</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company previously entered into a  2019 securities purchase agreement that contained a call option on preferred shares that are puttable outside the control of the Company. The Company accounted for the option in accordance with ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities From Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 480) and ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting for Derivative Instruments and Hedging Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ASC 815). The Company estimated the fair value of the liability using a binomial lattice model, which is sensitive to changes to certain inputs. See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of how the Company accounted for its private placement option derivative. The private placement option was terminated on December 4, 2021, in connection with the 2021 securities purchase agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses. We accrue for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of how the Company accounts for research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Companys share-based awards include stock option grants and restricted stock awards. The estimated fair value for stock options, which determines the Companys calculation of compensation expense, is based on the Black-Scholes pricing model, which requires a number of estimates, including the expected lives of awards, interest rates, stock volatility and other assumptions. Additionally, we apply a forfeiture rate to estimate the number of grants that will ultimately vest, as applicable, and adjust the expense as these awards vest.&nbsp;See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of how the Company accounts for share-based compensation.</span></div><div style="text-align:justify"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies for discussion regarding recent accounting pronouncements.</span></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_58"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a smaller reporting company, we are not required to provide information typically disclosed under this item.</span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&nbsp;&nbsp;Financial Statements and Supplementary Data</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Bellicum Pharmaceuticals, Inc. listed below are set forth in Item&nbsp;8 of this Annual Report for the year ended December 31, 2021: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_64" tabindex="18">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:AuditorFirmId" id="fact-identifier-39" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl82MS9mcmFnOmUxNTExMTM1ODA0YzQxYjk4MmI5NTExMTQ2ZDBlYWQ0L3RhYmxlOjU4YTE3ZDI2OGIxMTRlZDdiNjIzZDQwNDI0M2MzNDJhL3RhYmxlcmFuZ2U6NThhMTdkMjY4YjExNGVkN2I2MjNkNDA0MjQzYzM0MmFfMS0wLTEtMS0yNDE4MC90ZXh0cmVnaW9uOjYxMGY3OTdlOGRlODRiMjhiYmNjMmIxNWRlMzliOWU1XzIxOTkwMjMyNTU2MzY_ba4ed8bb-637b-4f0a-ac79-1f37871f91e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonnumeric></span>)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_64" tabindex="18">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_70" tabindex="18">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_70" tabindex="18">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_73" tabindex="18">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_73" tabindex="18">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_76" tabindex="18">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_76" tabindex="18"> (Deficit) Equity </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_76" tabindex="18">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_82" tabindex="18">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_82" tabindex="18">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_85" tabindex="18">Notes to the Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_85" tabindex="18">69</a></span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_64"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span><br></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Bellicum Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Bellicum Pharmaceuticals, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders (deficit) equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Companys management. Our responsibility is to express an opinion on the Companys financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Companys internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrant liability valuation of Bellicum Pharmaceuticals</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Companys warrant derivative liability is remeasured at fair value on each balance sheet date and is valued at $2.8 million as of December 31, 2021. As explained in Note 1 to the consolidated financial statements, the Company holds freestanding warrants that are exercisable for multiple underlying instruments that are potentially redeemable. </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing managements calculation of estimated fair value remeasurement of the warrant derivative liability was complex and judgmental due to the use of a complex valuation model and the level of uncertainty involved in managements assumptions used in the measurement process. In particular, management was required to estimate a volatility assumption at December 31, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantive audit procedures included, among others, evaluating the methodology and testing the significant assumption stated above and the accuracy and completeness of the underlying data used in managements warrant derivative liability valuation assessment. To test the volatility, we compared the assumption to historical information and performed a sensitivity analysis to evaluate the impact of changes in the fair value estimate that would result from changes in the underlying assumption. We also involved our valuation specialists to assist in the evaluation of the complex valuation model and the volatility assumption in the fair value estimate.</span></div></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:AuditorName" id="fact-identifier-40" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl82NC9mcmFnOjYxZTliYTNlODg1OTRiZDdhNmNiMjM5MGEyNmQyYTVmL3RleHRyZWdpb246NjFlOWJhM2U4ODU5NGJkN2E2Y2IyMzkwYTI2ZDJhNWZfMjE5OTAyMzI3NDk0NA_88c39afe-164e-42c2-8107-86d2fead8e78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ernst &amp; Young LLP</ix:nonnumeric></span></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Companys auditor since 2014.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="dei:AuditorLocation" id="fact-identifier-41" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl82NC9mcmFnOjYxZTliYTNlODg1OTRiZDdhNmNiMjM5MGEyNmQyYTVmL3RleHRyZWdpb246NjFlOWJhM2U4ODU5NGJkN2E2Y2IyMzkwYTI2ZDJhNWZfMjE5OTAyMzI3NDk0Ng_9610f8b9-bdf1-4a42-9f21-5f1a3443f254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Houston, Texas</ix:nonnumeric></span></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 24, 2022</span></div><div><span><br></span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_67"></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_70"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bellicum Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value and share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.874%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-42" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNC0yLTEtMS0xNjY4NA_39ca7227-e8b9-47f4-8773-2dd19e08f181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-43" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNC00LTEtMS0xNjY4NA_5b54fb76-0ccf-461f-ac8c-e321ee804d5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,495</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-44" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNS0yLTEtMS0xNjY4NA_fb3645c6-3582-4aa7-889e-3f1d55617e86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,501</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-45" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNS00LTEtMS0xNjY4NA_5808a841-fdf7-4040-a5ec-5b59c45853e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,501</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, interest and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="fact-identifier-46" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNi0yLTEtMS0xNjY4NA_7cf933b3-a5b4-4463-b74b-3254c19e7cd8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">205</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="fact-identifier-47" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNi00LTEtMS0xNjY4NA_3e5810cd-6a4d-457b-baf6-9064c5d70287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-48" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNy0yLTEtMS0xNjY4NA_236aaa17-2e34-4fcb-8d34-9a3c528bc165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,269</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="fact-identifier-49" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfNy00LTEtMS0xNjY4NA_bea7be8c-f8c8-44f8-9a2c-e22d45363404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">802</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-50" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfOC0yLTEtMS0xNjY4NA_927a45f7-8090-4f5f-8ebb-f5f8f0a6c9f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-51" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfOC00LTEtMS0xNjY4NA_64b439c1-3549-47a6-b5a6-502d78e2c269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,643</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-52" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfOS0yLTEtMS0xNjY4NA_7b943d4d-2ef4-4835-b105-06db33fdd9d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,131</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-53" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfOS00LTEtMS0xNjY4NA_1b812225-fb51-4db6-b82d-994fee4b03b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,443</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="fact-identifier-54" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTAtMi0xLTEtMTY2ODQ_661c915a-e8b2-4098-9faa-934bb5c9e020" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-55" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTAtNC0xLTEtMTY2ODQ_e143e594-dfa4-4aba-b117-f4b80bd69c47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">645</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-56" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTEtMi0xLTEtMTY2ODQ_13855369-26bd-42d2-bf28-dab7c22d3d99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-57" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTEtNC0xLTEtMTY2ODQ_454cd25c-a6cf-4259-bbec-0538d51b20c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">189</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-58" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTMtMi0xLTEtMTY2ODQ_8ac0c210-f50d-48cd-863b-2bd1bd65b055" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="fact-identifier-59" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTMtNC0xLTEtMTY2ODQ_b086d600-7e5e-45dc-81e9-b88f770500c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">307</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-60" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTQtMi0xLTEtMTY2ODQ_f8861faf-cbaa-474c-a548-b50d09617257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,143</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-61" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTQtNC0xLTEtMTY2ODQ_ffb5575b-51de-4b11-ad2a-acb87d1c2bd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,584</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-62" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTctMi0xLTEtMTY2ODQ_e9428ded-74f3-4615-9710-d888f93fa071" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-63" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTctNC0xLTEtMTY2ODQ_c291bb3c-65e3-4441-9252-5c4926d18df7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">891</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-64" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTgtMi0xLTEtMTY2ODQ_497ebf4d-d518-411e-81a3-1935486902db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,849</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-65" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTgtNC0xLTEtMTY2ODQ_b943f7fb-de33-47d9-b5cf-b0cc5cd5231c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,165</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-66" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTktMi0xLTEtMTY2ODQ_8f587a08-7b42-489e-8eb2-435ba9258a43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-67" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMTktNC0xLTEtMTY2ODQ_7cfc752e-67c2-4e9b-97e9-63ec159c615c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-68" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjAtMi0xLTEtMTY2ODQ_772d3cc2-5636-4771-baa4-35ecfba8cf97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-69" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjAtNC0xLTEtMTY2ODQ_867225f3-069c-4c9d-b138-4b575dd704f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,803</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:LeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-70" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjItMi0xLTEtMTY2ODQ_b3ba6eea-2b99-459e-b07c-1eba0613d093" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:LeaseLiabilityCurrent" scale="3" id="fact-identifier-71" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjItNC0xLTEtMTY2ODQ_05ac1e2b-df4c-4ee3-932e-3c8405d182cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">825</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-72" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjMtMi0xLTEtMTY2ODQ_24381140-9ea6-4f77-abeb-ace46601d21a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="fact-identifier-73" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjMtNC0xLTEtMTY2ODQ_d4b664c8-f84a-4624-8db7-515211ae100e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">672</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-74" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjQtMi0xLTEtMTY2ODQ_979bbdc3-3aa7-4738-b93f-d22b9d9f1f9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,712</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-75" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjQtNC0xLTEtMTY2ODQ_23b0ec2d-be48-4285-b35a-e5a34527a92f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,701</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:LeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-76" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjYtMi0xLTEtMTY2ODQ_d5d0739c-d742-4cc1-a701-90ac6235fcdd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:LeaseLiabilityNoncurrent" scale="3" id="fact-identifier-77" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjYtNC0xLTEtMTY2ODQ_27db0917-0c9f-4a80-8594-5e685f6f3429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">344</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-78" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjctMi0xLTEtMTY2ODQ_ca7007d1-c1b3-4fa9-85d4-aef8f9419cc0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,712</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-79" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjctNC0xLTEtMTY2ODQ_8558d00c-42e8-4c19-9bbf-ea53e1d221d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,045</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-80" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjgtMi0xLTEtMTY2ODQ_035632a5-38c5-47b3-bb6b-853676eaba43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-81" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjgtNC0xLTEtMTY2ODQ_744711d3-718c-4949-a794-170cd780a198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable Preferred stock: $<span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="fact-identifier-82" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjktMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpjYWMyNDRkZjA4MDc0NTYwOTg3ZDEwZGJhMWIzNmMyNV8yMQ_5594f0dc-180a-4a34-bb74-213cca6a181d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="fact-identifier-83" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjktMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpjYWMyNDRkZjA4MDc0NTYwOTg3ZDEwZGJhMWIzNmMyNV8yMQ_fb47f5f3-0841-4a9a-a1eb-e6459d98ab81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></ix:nonfraction></span> par value; <span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-84" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjktMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpjYWMyNDRkZjA4MDc0NTYwOTg3ZDEwZGJhMWIzNmMyNV8zNQ_601fb25f-77f5-4eae-90a8-8793963f7235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-85" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMjktMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpjYWMyNDRkZjA4MDc0NTYwOTg3ZDEwZGJhMWIzNmMyNV8zNQ_a164512a-68d2-4dd7-a83a-b2d675b6dc64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series 1 redeemable convertible preferred stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i4a78daf18e4d4444a873de7ad4b3dff5_I20211231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="fact-identifier-86" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV81Mw_96f4679a-e453-4d67-8481-87bf952f2e1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i6f2df821c7c74542bdf0f02561b57bfc_I20201231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="fact-identifier-87" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV81Mw_d98b7b58-be9e-4e53-9892-a1a48761c259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></ix:nonfraction></span> par value, <span><ix:nonfraction unitref="shares" contextref="i4a78daf18e4d4444a873de7ad4b3dff5_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-88" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV82Nw_3407fcdd-2598-40dd-a215-17ea2b725c72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i6f2df821c7c74542bdf0f02561b57bfc_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-89" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV82Nw_a5804d2b-0bc6-4ac0-9f4b-0f5129bac88f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,517,500</ix:nonfraction></span></ix:nonfraction></span> shares authorized at December 31, 2021 and December 31, 2020, <span><ix:nonfraction unitref="shares" contextref="i4a78daf18e4d4444a873de7ad4b3dff5_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-90" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV8xMDI_01993606-1d8c-49eb-aa82-4cae526d9826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i6f2df821c7c74542bdf0f02561b57bfc_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-91" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV8xMDI_1efd58ea-f87c-441f-b9ed-1315c26b7b32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i4a78daf18e4d4444a873de7ad4b3dff5_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-92" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV8xMDI_6b2d8acc-37be-473c-96a5-2d4f6b059912" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i6f2df821c7c74542bdf0f02561b57bfc_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-93" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjozMmI0ODgzNTc5MjM0Mzk5ODg3MGNmODVlZTg4NmVlYV8xMDI_6f4e7d43-a38f-44a6-8c76-ce823ac4b97a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,000</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding at December 31, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-94" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtMi0xLTEtMTY2ODQ_6f91eab1-13ee-41d7-99c6-ac3f90589b9d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,036</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-95" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzAtNC0xLTEtMTY2ODQ_6dd71bca-1962-4d9b-92fd-2fc9a6064d5f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,036</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-96" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18xOA_07a21d97-9330-4b94-869f-12b274e095f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-97" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18xOA_ee04f229-8068-47ff-8615-801ec0949bc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></ix:nonfraction></span> par value; <span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-98" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18zMg_a2ebf4d3-ba80-4c7f-89e7-63fb9bc912f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-99" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18zMg_d191dc87-5ca3-41dd-a909-b4ffa853b89f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized at December 31, 2021 and December 31, 2020, respectively; <span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-100" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM184MQ_093a7a62-b528-4de7-b729-8b673707bfc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,497,025</ix:nonfraction></span> shares issued and <span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-101" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18xMDI_f4dc0a70-f3d0-4221-b791-ed924428088b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,429,279</ix:nonfraction></span> shares outstanding at December 31, 2021; <span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-102" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18xMzE_715fba5e-144c-41d1-9238-80ecdee5b421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,385,650</ix:nonfraction></span> shares issued and <span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-103" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo5ZDQxYTMxNmQ2ZTE0MTk3YWUwYzBkM2M4YTc3ZDJlM18xNTI_2a50f50b-41f3-495e-939a-c370c0b31911" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,317,904</ix:nonfraction></span> shares outstanding at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-104" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItMi0xLTEtMTY2ODQ_29ceeb03-df92-4fd8-ac47-55af79818c24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-105" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzItNC0xLTEtMTY2ODQ_0b8218ee-b015-4123-8e29-13be710fea45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock: <span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-106" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzMtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkYzljN2Q0YzkyOWY0MmQzOWI1OTc2ZjJmYzc1ODMyZl8yMA_1911c374-b7b8-45fc-9166-a044ea4b0e77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-107" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzMtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkYzljN2Q0YzkyOWY0MmQzOWI1OTc2ZjJmYzc1ODMyZl8yMA_7f043a95-d3e1-46d6-9d48-3642aa140ae1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,746</ix:nonfraction></span></ix:nonfraction></span> shares held at December 31, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-108" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzMtMi0xLTEtMTY2ODQ_975f7c9e-87be-42ca-badd-092e4f55c23f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,056</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-109" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzMtNC0xLTEtMTY2ODQ_b11add88-7eb1-4244-a066-38a16d309904" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,056</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-110" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzQtMi0xLTEtMTY2ODQ_e5b7ed57-3d53-4ede-95bc-64f6480a127e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">580,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-111" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzQtNC0xLTEtMTY2ODQ_81104936-595c-4395-9df2-94b67ab27c9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">543,561</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="fact-identifier-112" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzUtMi0xLTEtMTY2ODQ_521e4f09-7dbc-49d9-b2fa-1d075216d691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">338</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="fact-identifier-113" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzUtNC0xLTEtMTY2ODQ_f78025c8-45bf-4517-a854-182d6686e459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">339</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-114" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzYtMi0xLTEtMTY2ODQ_eab4b69b-dd95-43cf-9e80-702491af7053" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">550,452</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-115" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzYtNC0xLTEtMTY2ODQ_197e8438-26b1-4ad7-a0ed-f684d2a09623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">540,747</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-116" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzctMi0xLTEtMTY2ODQ_3cf8d33d-ea47-48f1-87b0-783bd0284360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,395</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-117" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzctNC0xLTEtMTY2ODQ_148e1406-8b82-486f-9ed4-916ff2de84ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,497</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, redeemable preferred stock and stockholders equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-118" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzgtMi0xLTEtMTY2ODQ_bdf85923-4978-4fea-bb6b-90ce231415d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,143</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83MC9mcmFnOmZjNjdhY2U4NjM3MDRiZGQ5YmJlNDZmOTJmMmZjYTUzL3RhYmxlOmY2YTU1Y2Y2M2I4MzRkMmVhMjY3NDZiMWY2Mjk0MjA1L3RhYmxlcmFuZ2U6ZjZhNTVjZjYzYjgzNGQyZWEyNjc0NmIxZjYyOTQyMDVfMzgtNC0xLTEtMTY2ODQ_23fdda7f-ed3a-4857-a996-961e64a576e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,584</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_73"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bellicum Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><span><br></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.035%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supply agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8197c47b53244633b86290ed0d8a0a9f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMy0yLTEtMS0xNjY4NA_4242f452-75b0-43d5-b787-c224f9a0d7f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i14fbc315d00d4cfb8bcf75d8905f7337_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMy00LTEtMS0xNjY4NA_3ab61491-2ee9-4850-9bf3-13806a5cb873" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i49e41a9785be4a358abf336c5012c31d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNC0yLTEtMS0xNjY4NA_945750f7-db75-4265-9ee9-d8f53ddf88ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d6f31c6fa964fcab52a7a4bf2b34862_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNC00LTEtMS0xNjY4NA_d971e24f-24c2-49b7-b086-a34af597edc8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if1e39ffd71a84496a0777d73585f2ad6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNS0yLTEtMS0xNjY4NA_f0eec725-5cd7-4268-949b-0a91f8c99fa1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,200</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic52559a7a1de41bdb34aac1e042e3fd3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNS00LTEtMS0xNjY4NA_0ab7871e-f8f9-4c9c-b73b-83053dd15bfd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNy0yLTEtMS0xNjY4NA_a29d1eb0-38a3-4c43-93fd-22b8aca35e6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,578</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfNy00LTEtMS0xNjY4NA_10f1af76-2884-413e-b5c2-8abc4dabcf6c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,052</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfOC0yLTEtMS0xNjY4NA_ec0e6d60-5016-4ae4-8385-230324e4b4ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,010</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-129" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfOC00LTEtMS0xNjY4NA_070a3758-46b9-4d67-9eb5-57c29c22ab19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,531</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-130" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfOS0yLTEtMS0xNjY4NA_518f1cec-ef26-4f6d-8d58-c4e5752f019c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,588</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-131" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfOS00LTEtMS0xNjY4NA_43fc583c-ef39-403b-ba65-9370a77e8688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,583</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="fact-identifier-132" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTEtMi0xLTEtMTY2ODQ_efb3a2a3-df24-4431-b0da-5242c4a119f5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-133" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTEtNC0xLTEtMTY2ODQ_7980fa7c-25f0-4ae5-81fa-7dd66e6ce9a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,265</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Gain on dispositions, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="fact-identifier-134" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTItMi0xLTEtMTY2ODQ_c638d70a-b93a-45a2-bbcb-3e084b0ffb89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">478</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-135" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTItNC0xLTEtMTY2ODQ_c3e6cbb8-1672-4390-b118-07b5464470bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,656</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other operating income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="fact-identifier-136" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTMtMi0xLTEtMTY2ODQ_cf15ec83-7ee8-41df-b660-8df2c9541386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">478</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-137" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTMtNC0xLTEtMTY2ODQ_77b64615-48b2-4764-9dff-0b22403e5526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,391</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-138" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTQtMi0xLTEtMTY2ODQ_8a678e8f-7b4c-44f0-93b7-6babb33aa9f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,866</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-139" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTQtNC0xLTEtMTY2ODQ_1fafb8f6-07b5-4b10-9c88-31e7f945a295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,692</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeDomesticDeposits" scale="3" id="fact-identifier-140" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTYtMi0xLTEtMTY2ODQ_793b5414-c224-40df-8a7b-9c3767eec114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeDomesticDeposits" scale="3" id="fact-identifier-141" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTYtNC0xLTEtMTY2ODQ_36e8eef0-4135-4de9-a5ba-f27193a825ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">387</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-142" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTctMi0xLTEtMTY2ODQ_0c97aa04-7a28-4612-8d0a-2ac1b18311cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-143" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTctNC0xLTEtMTY2ODQ_877de655-a463-47f7-b8ae-1c18a260b668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,659</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant and private placement option liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-144" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTgtMi0xLTEtMTY2ODQ_6cf70559-f8b6-4b41-8ca3-8815dd3433f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,126</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-145" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTgtNC0xLTEtMTY2ODQ_6b245d90-19ae-4262-9a99-5515889e04b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,130</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-146" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTktMi0xLTEtMTY2ODQ_1c1b40d7-b862-487c-8193-d944d2d076c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-147" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMTktNC0xLTEtMTY2ODQ_ff4f7e83-9b40-4ad0-ae2a-d2b4dbb2fec6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="fact-identifier-148" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjAtMi0xLTEtMTY2ODQ_1d570f5c-9ed6-4c5c-8566-6d7271d125da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="fact-identifier-149" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjAtNC0xLTEtMTY2ODQ_f956f061-d4a3-445a-ba4c-488b67d313b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-150" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjEtMi0xLTEtMTY2ODQ_c81a72c3-8908-470d-ac1d-7aec7231bfc4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,161</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-151" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjEtNC0xLTEtMTY2ODQ_5ff3a0a9-0094-4463-8d8c-18c35b285b02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,970</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-152" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjItMi0xLTEtMTY2ODQ_e16cb9e4-75c8-4018-9981-0dc726f4a3bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,705</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-153" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjItNC0xLTEtMTY2ODQ_c014edf1-5b78-4c73-8bb5-bb7998bd6faf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,722</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share attributable to common shareholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-154" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjQtMi0xLTEtMTY2ODQ_06890b05-2227-4c79-90ac-3b40e2123011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-155" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjQtMi0xLTEtMTY2ODQ_ff24f1e5-635f-4278-be6d-1eb1f97247a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.84</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-156" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjQtNC0xLTEtMTY2ODQ_4daf7d98-5833-4bba-b669-ee3ca76c6274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-157" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjQtNC0xLTEtMTY2ODQ_eedfa34e-2185-4d68-81ed-58423763701b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.34</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding-basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-158" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjUtMi0xLTEtMTY2ODQ_ac0c8599-5e5a-42b8-9d98-ba61a6b4b5f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-159" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjUtMi0xLTEtMTY2ODQ_fb2e0bf5-c5f7-4459-b53a-11f3d5f8c86b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,504,294</ix:nonfraction></span></ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-160" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjUtNC0xLTEtMTY2ODQ_2cba1171-a7b3-48d7-b9b8-6347afc8a143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-161" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjUtNC0xLTEtMTY2ODQ_fb2053bd-73ea-42e9-9e7e-73f988df676b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,760,159</ix:nonfraction></span></ix:nonfraction></span></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-162" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjctMi0xLTEtMTY2ODQ_c6b30507-7c11-43eb-90b7-a80336dadaea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,705</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-163" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMjctNC0xLTEtMTY2ODQ_de0b67ec-188e-4784-b53c-3edc3327bd45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,722</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-164" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMzAtMi0xLTEtMTY2ODQ_08df1440-8d6f-4dfb-b7e6-eb622c081054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-165" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMzAtNC0xLTEtMTY2ODQ_9f0a6ed5-907f-4bb7-95e9-51ac4bd50032" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-166" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMzEtMi0xLTEtMTY2ODQ_54d73f1a-3253-427b-917d-72634ea54d4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,704</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-167" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83My9mcmFnOjkwYTVhZTY4ZDQ0OTRjYjZhOGYyN2NkZjdhODZlNjFkL3RhYmxlOjMxZTJhMzg3ZjliNTRiZjdhYmY5YzhmOWE3NmM0YjBiL3RhYmxlcmFuZ2U6MzFlMmEzODdmOWI1NGJmN2FiZjljOGY5YTc2YzRiMGJfMzEtNC0xLTEtMTY2ODQ_fdfccf87-92e4-4f81-b5e8-da657521b072" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,734</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br></span></div><div><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_76"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bellicum Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders (Deficit) Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(amounts in thousands, except share data) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.348%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series 1 Preferred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Stockholders     (Deficit) Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia6005e4e2600496eacd7133e6cbbc6b7_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-168" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0yLTEtMS0xNjY4NA_a8ab57d0-4141-49f7-b74b-61b824b82ff8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">538,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia6005e4e2600496eacd7133e6cbbc6b7_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-169" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi00LTEtMS0xNjY4NA_9ff506ef-e3ad-48eb-b97c-4af3b2df0e71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,468</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i270ba8e9980b47baa9945d3afc7b23ce_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-170" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi02LTEtMS0xNjY4NA_09f3fcc9-8e68-40cb-b1d5-d3c33cf4d8ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,076,593</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i270ba8e9980b47baa9945d3afc7b23ce_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-171" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi04LTEtMS0xNjY4NA_61a63781-3ede-47fa-932f-ad0a86922f93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">507</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="ibda9d2641e7847b792e2baa55f098195_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-172" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0xMC0xLTEtMTY2ODQ_f4aead8e-e991-432c-bdd6-d5c886317ff5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,746</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ibda9d2641e7847b792e2baa55f098195_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-173" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0xMi0xLTEtMTY2ODQ_656a9059-9a7b-4bf3-a523-eca8b32349ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,056</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i08f4fd14058040819142b3a3682c7815_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-174" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0xNC0xLTEtMTY2ODQ_92902827-f300-49f5-9f5e-e47967b11117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">511,684</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i6bdf7ac618464cdc87976bf10e6ba688_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-175" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0xNi0xLTEtMTY2ODQ_0b00f92b-93b7-4f78-a0a7-f96ed4d2ddf2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">533,025</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3390ec76a6b040df98b7edab94eaaec0_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-176" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0xOC0xLTEtMTY2ODQ_842b3131-6e30-4254-ab4e-cef873b6a773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">327</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ieae66221f10e47949897a952036d7680_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-177" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMi0yMC0xLTEtMTY2ODQ_6ac727dd-6ba8-4b61-9a19-11d46ac43a2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,217</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-178" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMy0xNC0xLTEtMTY2ODQ_779be0b9-49fb-412b-b3c8-3fe3b310cc2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,031</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-179" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMy0yMC0xLTEtMTY2ODQ_9b259dec-c8b7-4833-8317-74401c106bc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,031</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-for-10 Reverse Stock Split</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="fact-identifier-180" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNC04LTEtMS0xNjY4NA_601bfc78-50b5-4fa4-b82a-c0d34262dd87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">457</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="fact-identifier-181" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNC0xNC0xLTEtMTY2ODQ_3f2a73b5-b52c-49b6-a11d-8d093ecc5e03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">457</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" format="ixt:fixed-zero" scale="3" id="fact-identifier-182" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNC0yMC0xLTEtMTY2ODQ_48b932d8-344f-451d-b323-191b1309802e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock - Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-183" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNS02LTEtMS0xNjY4NA_cba6d880-c101-4fc9-8e74-5722d8bd4f2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,975</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-184" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNS0xNC0xLTEtMTY2ODQ_eb482fcb-5d4d-49f7-a29c-630a6a2622b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-185" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNS0yMC0xLTEtMTY2ODQ_f5eb1b0d-ea86-40e7-8f51-81687fa56c90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-186" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfNi02LTEtMS0xNjY4NA_ea602b79-c203-40f4-9305-177690f55c64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,406</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock and pre-funded warrants exercise, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="INF" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-187" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOC02LTEtMS0xNjY4NA_d2efa16e-415c-40e3-8e38-eb968f7763b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,432,676</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="-3" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue" scale="3" id="fact-identifier-188" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOC04LTEtMS0xNjY4NA_a8f06bc9-c77f-4289-a9b6-0979ab57c692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231" decimals="-3" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-189" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOC0xNC0xLTEtMTY2ODQ_e2dd7ca1-a605-4051-85bc-799f5e5bf493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">22,888</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-190" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOC0yMC0xLTEtMTY2ODQ_413cb56f-1b47-43f3-b1f8-f48c91686bb0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">22,913</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of redeemable convertible preferred stock into common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="ifc4aff4354f7407693da8140420899ad_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-191" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS0yLTEtMS0xNjY4NA_76417623-306e-492b-9236-68cb64c5c515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">86,000</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ifc4aff4354f7407693da8140420899ad_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-192" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS00LTEtMS0xNjY4NA_31f39684-1306-4c27-909f-fd263b017f89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,432</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-193" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS02LTEtMS0xNjY4NA_80eb30de-3d37-440a-8866-e70ebc7359c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">860,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iab5298264bba49d687b45d538a946669_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="fact-identifier-194" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS04LTEtMS0xNjY4NA_c5ea36fc-c259-406d-afe3-03b52dea99b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia4ed8243a6754f5b8fe0d92bbd54c585_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-195" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS0xNC0xLTEtMTY2ODQ_764ece33-c33e-405f-ab23-d8075e624d2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,423</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-196" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfOS0yMC0xLTEtMTY2ODQ_b72ee528-5762-4935-b7c9-281f7e44fa1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,432</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i06446714655e44b0bbcc02310f59a608_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-197" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTAtMTYtMS0xLTE2Njg0_ef6c3b92-94eb-45fc-8fb3-a484e19d109d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,722</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i36dcd997b73b408e8f6d2cd5f014ef7b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-198" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTAtMTgtMS0xLTE2Njg0_00f4e35d-f9f0-41ad-9f1d-33f98cc49597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-199" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTAtMjAtMS0xLTE2Njg0_6d04c2a8-1289-4693-a6e6-625fd94933b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,734</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib607e68aa1b24b61906b8997c1b81421_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-200" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMi0xLTEtMTY2ODQ_7c723b1c-8b07-44e6-8747-6a395e08bf8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib607e68aa1b24b61906b8997c1b81421_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-201" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtNC0xLTEtMTY2ODQ_34ad8b36-2fac-41e8-a532-a4a9d97c0cd0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,036</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia124e39a89294e649f6c2fcc64b9d47a_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-202" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtNi0xLTEtMTY2ODQ_ead7b321-8d42-4bd5-a6c6-951995755d56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,385,650</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia124e39a89294e649f6c2fcc64b9d47a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-203" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtOC0xLTEtMTY2ODQ_66b3ddfa-38fb-4195-a060-babdbd8258bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="ieba061572fbc45989dc245feefe6e544_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-204" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMTAtMS0xLTE2Njg0_c880595f-d0e6-4ac7-9526-e976b5ada2a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,746</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ieba061572fbc45989dc245feefe6e544_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-205" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMTItMS0xLTE2Njg0_2624b819-3988-40c3-b6a3-273fb8ae57cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,056</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i44415b809fe84311823510ac1a664238_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-206" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMTQtMS0xLTE2Njg0_ab6fbd0c-c559-4b2b-8c38-a282c895956c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">543,561</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i43455d9c6bc2493caf9ac4680bf8aecb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-207" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMTYtMS0xLTE2Njg0_95c6bf27-7d17-47a3-857d-374fc363c9a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">540,747</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ifc165ec32d85465d96eaf628fdb7c81e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-208" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMTgtMS0xLTE2Njg0_3fa2f4be-b371-4a22-911a-4d9bf285ec49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">339</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-209" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTEtMjAtMS0xLTE2Njg0_85f37003-ef7f-461f-8e66-aad0c7032ab7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,497</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3bb5f34373434fef8ec9f96f55451803_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-210" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTItMTQtMS0xLTE2Njg0_18077f08-ba67-4e2e-9019-1537e7a74955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,439</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-211" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTItMjAtMS0xLTE2Njg0_b88a9a81-b9a9-41a3-a571-6e25196da0c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,439</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i564e615d88a24980a0e4df003a5382ec_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-212" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTMtNi0xLTEtMTY2ODQ_b5fc6e41-088d-4dd3-a229-b9fc8ebe7704" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,375</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i564e615d88a24980a0e4df003a5382ec_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="fact-identifier-213" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTMtOC0xLTEtMTY2ODQ_fb2f7f4c-be15-4c92-95c9-d329c9364e2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3bb5f34373434fef8ec9f96f55451803_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="fact-identifier-214" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTMtMTQtMS0xLTE2Njg0_9d23d090-0582-4a59-a322-b43e67552b96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="fact-identifier-215" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTMtMjAtMS0xLTE2Njg0_485b0772-5eca-418a-827c-8ef70f2f5f1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3bb5f34373434fef8ec9f96f55451803_D20210101-20211231" decimals="-3" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-216" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTctMTQtMS0xLTE2Njg0_6ec78a0e-93f0-4f1d-a8b3-de37466d4837" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">32,908</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="blcm:StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-217" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTctMjAtMS0xLTE2Njg0_b149db74-3a8a-46df-b029-92f3ebdd560f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">32,908</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extinguishment of private option liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3bb5f34373434fef8ec9f96f55451803_D20210101-20211231" decimals="-3" name="blcm:ExtinguishmentOfPrivateOptionLiability" scale="3" id="fact-identifier-218" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTQtMTQtMS0xLTIyNDY0_5f37fdfd-6ee8-489f-8340-3306b8780047" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">249</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="blcm:ExtinguishmentOfPrivateOptionLiability" scale="3" id="fact-identifier-219" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMTQtMjAtMS0xLTIyNDY0_d6c4e87f-0208-438d-9466-aeb833be3341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">249</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="if0bf8488c873418a99609b6fd35b3885_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-220" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjAtMTYtMS0xLTE2Njg0_d7f0adb8-2c83-462a-9df9-caeb5f45fb6d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,705</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if1b42b25f0734d2490e534472aa95f9c_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-221" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjAtMTgtMS0xLTE2Njg0_a9fe092d-b588-4406-ad2d-4d9937e5f2b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-222" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjAtMjAtMS0xLTE2Njg0_27432bd8-f2e0-4101-9ae2-6c363a9c4379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,704</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ie7642c00ae4f4ec583c78dbcc8782679_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-223" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMi0xLTEtMTY2ODQ_1907dc51-59e2-46f1-8851-a8f9cd0a1c8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7642c00ae4f4ec583c78dbcc8782679_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-224" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtNC0xLTEtMTY2ODQ_9fc31e02-1fef-4eb3-98fb-b92f6874274c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,036</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i50315a911ef84b559894ae80afb809f6_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-225" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtNi0xLTEtMTY2ODQ_cc46dd13-ab81-4056-b75b-afbb16f381ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,497,025</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i50315a911ef84b559894ae80afb809f6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-226" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtOC0xLTEtMTY2ODQ_aa5b298e-85e2-4b49-99bc-c03a973c64dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i27b41e8f7657434289c92793a055c713_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-227" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMTAtMS0xLTE2Njg0_8b2b3626-84ce-4196-ad77-5cb70d719de4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,746</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i27b41e8f7657434289c92793a055c713_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-228" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMTItMS0xLTE2Njg0_054d3227-8e10-4c54-ad54-bd7785e7a96d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,056</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3e05e74e201143acb0c1666360398d67_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-229" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMTQtMS0xLTE2Njg0_09e6b1b1-560d-4d7a-be5a-45e4117ec4f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">580,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9c9289f5e30d4f61870d1098c203861e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-230" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMTYtMS0xLTE2Njg0_e5580865-09ff-4d9b-81c3-b691b82c46bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">550,452</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ia8f897c7d761462aabf05ee0c0b28959_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-231" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMTgtMS0xLTE2Njg0_55b120c4-8d7a-42bf-b278-289a22a53602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">338</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-232" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl83Ni9mcmFnOmNmY2UyZjk4MzNiMzQ4MDNhYTk2ZjNlZmUyNDQ1OTdhL3RhYmxlOjhlY2Q4Y2E0NzA3OTQ1ZWVhY2VhNWYxN2MyY2U0YjEwL3RhYmxlcmFuZ2U6OGVjZDhjYTQ3MDc5NDVlZWFjZWE1ZjE3YzJjZTRiMTBfMjEtMjAtMS0xLTE2Njg0_28f24de3-64e1-4ca6-9cdb-6aa940824db3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,395</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_82"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bellicum Pharmaceuticals Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.985%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-233" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMy0yLTEtMS0xNjY4NA_d23d3980-5379-47ca-9048-d47a0cb3a99c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,705</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-234" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMy00LTEtMS0xNjY4NA_978d59a5-0f5f-48d1-8afe-f7fa7df139e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,722</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-235" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNS0yLTEtMS0xNjY4NA_80d0116d-3f4a-419a-983f-b56d97e9313f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,439</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-236" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNS00LTEtMS0xNjY4NA_8c0659a8-8516-444f-bd20-d668f7b4018c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,031</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="fact-identifier-237" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNi0yLTEtMS0xNjY4NA_d4881577-dbbc-448a-8086-c1db1c91c4e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-238" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNi00LTEtMS0xNjY4NA_7325bfa6-41cd-463c-b12f-953b4e54930c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,472</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant and private placement derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-239" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNy0yLTEtMS0xNjY4NA_63369987-08fa-4d87-bf5b-065e1bbcd336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,126</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-240" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNy00LTEtMS0xNjY4NA_e996e6b7-b956-4454-aea1-8c7ad84cf668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,130</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on dispositions, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="fact-identifier-241" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTAtMi0xLTEtMTY2ODQ_0a0b69c9-2b7b-459c-a855-60556cb12018" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">478</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-242" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTAtNC0xLTEtMTY2ODQ_b853f6fc-666f-4799-be3e-cb156addaf4b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,656</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="fact-identifier-243" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTEtMi0xLTEtMTY2ODQ_70954674-0ce1-4e44-a8ab-2f9f7721da8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="fact-identifier-244" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTEtNC0xLTEtMTY2ODQ_c84daf2b-d8a6-4c58-98fc-45826a4e29bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">402</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="blcm:AmortizationofLeaseLiability" scale="3" id="fact-identifier-245" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTItMi0xLTEtMTY2ODQ_5dee23fa-bbf4-4442-9bc7-4761a04fe840" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">23</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="blcm:AmortizationofLeaseLiability" scale="3" id="fact-identifier-246" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTItNC0xLTEtMTY2ODQ_ed3471d0-1188-4a77-9b2c-f6403bfe2d7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">414</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="fact-identifier-247" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTMtMi0xLTEtMTY2ODQ_980a2f3a-83e7-4233-8cdc-2e0f4fd7bf1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-248" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTMtNC0xLTEtMTY2ODQ_797fcf26-c2d8-4c69-819e-dbfb14c05f8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,265</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="fact-identifier-249" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTQtMi0xLTEtMTY2ODQ_1fe8e65c-4985-4baf-839f-8da74d37667d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="fact-identifier-250" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTQtNC0xLTEtMTY2ODQ_8aec443b-91e1-447a-80e3-f643bcf8c401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">550</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-251" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTUtMi0xLTEtMTY2ODQ_e31cca97-6363-49d0-9c72-ac9ca984c666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-252" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTUtNC0xLTEtMTY2ODQ_353c8670-80df-4291-8046-dacb9bcd3a14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, interest and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="fact-identifier-253" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTgtMi0xLTEtMTY2ODQ_f4bf9dbb-105f-4f6b-ba39-250247fb1e9a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">170</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="fact-identifier-254" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTgtNC0xLTEtMTY2ODQ_0e1a10c3-b63c-44b6-b5d9-deb03291a2ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-255" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTktMi0xLTEtMTY2ODQ_965ca4a7-5523-4894-967b-91de86bd5171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">462</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-256" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMTktNC0xLTEtMTY2ODQ_e5d44326-c4e5-4008-ac33-be3562f9ec88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">563</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="fact-identifier-257" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjAtMi0xLTEtMTY2ODQ_0b2637e4-0db5-4f52-b137-4de4e9f7a7e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">801</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-258" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjAtNC0xLTEtMTY2ODQ_6b7a58cd-da8a-420c-a57f-6cc3b4aff7a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,917</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-259" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjEtMi0xLTEtMTY2ODQ_2252d3e3-01c1-44fb-8d71-03e5b0ac8ba7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,260</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-260" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjEtNC0xLTEtMTY2ODQ_b533b8ee-b541-4c8e-9ff5-82b232b1954c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,111</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-261" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjMtMi0xLTEtMTY2ODQ_00b4d8af-e42c-4cf7-8442-905f8fab3905" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,106</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-262" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjMtNC0xLTEtMTY2ODQ_522b8875-44c4-4c21-a783-058ec86ec3e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,650</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="fact-identifier-263" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjYtMi0xLTEtMTY2ODQ_31aec3ca-1e20-45a6-a77d-5c507791456a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-264" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjYtNC0xLTEtMTY2ODQ_854f4437-4058-45ec-94db-f3eb0ed43a0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,705</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-265" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjctMi0xLTEtMTY2ODQ_fee9d32d-f64a-4e30-9f87-ac466fd79ff4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-266" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjctNC0xLTEtMTY2ODQ_3119049c-34e5-486a-b522-06d2e771f4a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">625</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-267" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjgtMi0xLTEtMTY2ODQ_e9c3522b-783a-4a87-aa3e-d128dfdbb48e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">893</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-268" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMjgtNC0xLTEtMTY2ODQ_91a297c5-21bb-496c-9723-a90520ade9ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,080</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment on debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-269" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzAtMi0xLTEtMTY2ODQ_503d55d7-ca52-42ee-b11b-a1ad19fa0744" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-270" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzAtNC0xLTEtMTY2ODQ_54f1fcbb-ec2a-4bb7-b01b-d8d51376cab7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,155</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="fact-identifier-271" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzUtMi0xLTEtMTY2ODQ_8bfac2be-f61d-4050-8bd1-9d20151a1254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-272" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzUtNC0xLTEtMTY2ODQ_b6ee8e11-da74-40d7-b4b0-63c505982d6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of stock from employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="fact-identifier-273" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzYtMi0xLTEtMTY2ODQ_3de167e0-8955-41c9-82b3-1eb61b4bc990" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="fact-identifier-274" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzYtNC0xLTEtMTY2ODQ_9e18d01b-211a-4972-9bbb-4eb293e2cca9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of pre-funded warrants, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-275" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzctMi0xLTEtMTY2ODQ_7d814261-e389-47c5-b797-3698f117c58e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,908</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-276" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzctNC0xLTEtMTY2ODQ_139c48aa-c3ce-4a37-aaf4-d7b441fd0715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,901</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment on financing lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="fact-identifier-277" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzgtMi0xLTEtMTY2ODQ_bc282ea7-82f3-4f6d-bf25-a42ad484bde9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="fact-identifier-278" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzgtNC0xLTEtMTY2ODQ_e6f69aa7-ab27-480e-a9f8-dafe6b70256a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-279" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzktMi0xLTEtMTY2ODQ_bdb8e7c5-ea47-4a08-8166-3ef43b8c3a3a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,873</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-280" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfMzktNC0xLTEtMTY2ODQ_afc314fd-4b2c-4438-b1bf-1edbcbc7c54e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,238</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-281" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDAtMi0xLTEtMTY2ODQ_37d57002-a9cd-464f-b93e-227de61a74c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-282" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDAtNC0xLTEtMTY2ODQ_a86bcaeb-8782-4700-ab84-66ff8ea8036e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-283" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDEtMi0xLTEtMTY2ODQ_b43a45a8-e729-44b1-a75b-9b70f16e38f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,661</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-284" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDEtNC0xLTEtMTY2ODQ_370094fa-9fc2-4228-a51b-6cab6d5e9c46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,820</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-285" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDItMi0xLTEtMTY2ODQ_63354153-8a5f-4413-a448-88d10fccac96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,996</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieae66221f10e47949897a952036d7680_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-286" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDItNC0xLTEtMTY2ODQ_6b3c85fd-323f-4124-a604-5dcbabb2cf6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,816</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-287" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDMtMi0xLTEtMTY2ODQ_ae1c6fc0-321c-44af-882b-ac5ec9285b32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47,657</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-288" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDMtNC0xLTEtMTY2ODQ_3197f17f-6a00-43e3-8ebf-5f7639196e32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,996</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-289" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDUtMi0xLTEtMTY2ODQ_19d3c3bb-49c8-452a-b96b-ec6e0bf5aa94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-290" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDUtNC0xLTEtMTY2ODQ_053db3bb-f5bb-4d2e-87d6-c361f6c87c69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,340</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of redeemable preferred stock into common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="fact-identifier-291" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDktMi0xLTEtMTY2ODQ_efde9249-8de9-4aeb-a368-f05bd5eaa602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-292" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNDktNC0xLTEtMTY2ODQ_b2950345-41a5-4505-be6e-4edb1ce6d6c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,432</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of property and equipment, net to assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="blcm:TransferOfPropertyAndEquipmentToHeldForSale" format="ixt:fixed-zero" scale="3" id="fact-identifier-293" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNTAtMi0xLTEtMTY2ODQ_9ed5db80-fc93-4702-bc6f-90fd8d7a9539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="blcm:TransferOfPropertyAndEquipmentToHeldForSale" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-294" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNTAtNC0xLTEtMTY2ODQ_e2ba005b-9ee2-430d-ae82-09781b10d8c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements paid by landlord</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="blcm:OtherSignificantNoncashTransactionConsiderationPaidByThirdParty" format="ixt:fixed-zero" scale="3" id="fact-identifier-295" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNTItMi0xLTEtMTY2ODQ_cc34da6d-39ec-4291-be64-9f1f93946284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="blcm:OtherSignificantNoncashTransactionConsiderationPaidByThirdParty" scale="3" id="fact-identifier-296" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84Mi9mcmFnOmI2MGQ0MGM3YzE0NjQyMDk5ZGNhZGNiMTZkNTU3NTQxL3RhYmxlOjZlY2JkMjU4ODJlNzQ1YTQ4OTVlNGExN2ZhNGY0MjcxL3RhYmxlcmFuZ2U6NmVjYmQyNTg4MmU3NDVhNDg5NWU0YTE3ZmE0ZjQyNzFfNTItNC0xLTEtMTY2ODQ_c8d9afb0-c18e-4e7c-b2b8-d454c428d1b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">113</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_85"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bellicum Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="fact-identifier-297" continuedat="i713b9de149664c53897297087932abaa" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mzk_cb6b1048-9460-4c63-b564-c6026afd2513" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonnumeric></span></span></div><div><span><br></span></div><span><ix:continuation id="i713b9de149664c53897297087932abaa" continuedat="ia10384af37dd44cd917aba914f097079" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer. Bellicum is devoting substantially all of its present efforts to developing next-generation CAR-T product candidates in cellular immunotherapy.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bellicum has <span><ix:nonfraction unitref="subsidiary" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="blcm:NumberOfWhollyOwnedSubsidiariesFormed" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-299" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc4MDA0Mg_b1681502-d2fe-4576-8de0-a66a54a16a78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">two</ix:nonfraction></span> wholly-owned subsidiaries, Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom, and Bellicum Pharma GmbH, a private limited liability company organized under German law. Both were formed for the purpose of developing product candidates in Europe. Bellicum, Bellicum Pharma Limited and Bellicum Pharma GmbH are collectively referred to herein as the Company. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it has <span><ix:nonfraction unitref="segment" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-300" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTI4OQ_4b9fe5e6-8dc3-4e47-9889-89cb4b0a1425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="segment" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-301" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTI4OQ_844425ae-6c17-4b96-9c97-a1a2e00ac240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span></ix:nonfraction></span> operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Companys chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><div><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2020, the Company filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to (i) effect a reverse stock split of all issued and outstanding shares of the Companys common stock at a ratio of&nbsp;1-for-10 and (ii) reduce the number of authorized shares of the Companys common stock from <span><ix:nonfraction unitref="shares" contextref="i47fea5ad8abd4bbf9f75e99524a4d163_I20200204" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-302" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMjA2Mg_b2dd0921-babe-4fcb-bda5-33d0587d4460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span> to <span><ix:nonfraction unitref="shares" contextref="ia17a5142cdcc4ce8a220db71d648fa86_I20200205" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-303" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMjA2OA_235103f2-b615-472e-a44a-7d40d4810dd8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000,000</ix:nonfraction></span>. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, the Company filed with the Secretary of State of the State of Delaware a Second Certificate of Amendment to the Companys Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Companys common stock from <span><ix:nonfraction unitref="shares" contextref="i81cf2b55430f4019b410337d7717d334_I20200614" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-304" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMjUyMw_cd29eb78-bd48-43e9-b73e-f6a5beec0923" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000,000</ix:nonfraction></span> shares to <span><ix:nonfraction unitref="shares" contextref="i733849ef74504c28964019582a43ef48_I20200615" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-305" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMjUzNg_f37d2b76-4548-49ab-a318-3a2ae2076330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,000,000</ix:nonfraction></span> shares.</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="fact-identifier-306" continuedat="i803eb1b95f30494e8a8fec0d02ed900a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NTA_9cce3508-8625-47b7-975b-fb1ec36a6ee1" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Basis of Presentation</ix:nonnumeric></span></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i803eb1b95f30494e8a8fec0d02ed900a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The accompanying financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (GAAP).</ix:continuation></span> </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements&nbsp;have been prepared&nbsp;on a basis that&nbsp;assumes that&nbsp;the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Companys assets and the satisfaction of the Companys liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has experienced net losses since its inception and if the Company does not successfully obtain regulatory approval and commercialize any of its product candidates, the Company will not be able to achieve profitability.&nbsp;As of December 31, 2021, the Company has an accumulated deficit of $<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-308" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzY3Mw_1aa6931e-fca2-4d52-ac62-71fe9179c8b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">550.5</ix:nonfraction></span> million.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its current capital resources, which consist of cash and cash equivalents, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of additional equity, incurrence of debt, the entry into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to </span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="ia10384af37dd44cd917aba914f097079" continuedat="i4f570a4af67b428b86c1c8894f0c9c7c" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:UseOfEstimates" id="fact-identifier-310" continuedat="ibb3907d4348e435eb8afaf80051544e5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NjM_a15a1c47-be65-400b-8d17-79736d532498" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Use of Estimates </ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ibb3907d4348e435eb8afaf80051544e5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The preparation of the financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenue recognition, and expenses. Actual results could differ materially from those estimates.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="fact-identifier-312" continuedat="i847f7bf637bc447c8492ee6634080d3d" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NjQ_0f424b7d-1285-469e-8f31-b6221b601470" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Companys sources of revenue in 2021 were from its supply agreement with Takeda Development Center Americas, Inc. ("Takeda") and from its licensing agreements with The University of Texas MD Anderson Cancer Center (MD Anderson). The Company has generated revenue from its licensing agreements since 2019. Prior to 2019, the Company's only source of revenue was from grants. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply of Product</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised product in the supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company entered a multi-year supply agreement with Takeda. The Company will supply Takeda with rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The Company generated revenue of $<span><ix:nonfraction unitref="usd" contextref="i3bf9fa5695b941d99db8c96d059ea1fb_D20210401-20210630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-313" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc3ODE5NQ_108ed055-a327-4d7b-975b-39c2694dbb10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.7</ix:nonfraction></span>&nbsp;million in the second quarter of 2021, with the possibility of additional revenue from future sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Companys intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2019, the Company entered into a licensing and commercialization agreement with MD Anderson (the 2019 MD Anderson License Agreement). Under the 2019 MD Anderson License Agreement, the Company granted MD Anderson non-exclusive rights in certain Caspase-9 and related technologies and use of a small molecule known as rimiducid in a certain cell therapy program. During the fourth quarter of 2019, and under the terms of the 2019 MD Anderson License Agreement, MD Anderson exercised an option to grant a non-exclusive sublicense of the rights licensed by the Company to MD Anderson. MD Anderson, as a result of this exercise, granted a sublicense that entitled the Company to receive as consideration an upfront license fee as well as additional future annual maintenance fees, milestone payments related to the achievement of pre-specified development, regulatory, and commercialization events, and royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 31, 2021, the Company entered into a second licensing and commercialization agreement with MD Anderson (the 2021 MD Anderson Option and License Agreement). Under the 2021 MD Anderson Option and License Agreement, MD Anderson has certain rights to the use of CaspaCIDe and rimiducid in product candidates nominated under the agreement, and receives options to non-exclusive licenses to the technology in these candidates. These options were evaluated and were not determined to be material rights. Upon sublicense of the product candidates nominated under the agreement, or upon exercise of an option and sublicense of a product candidate to a third party, the Company is entitled to a sublicense execution fee, a percentage of certain consideration received by MD Anderson for the sublicense, an annual maintenance fee, and a percentage royalty on net sales of licensed products. During the third quarter of 2021, the Company received an upfront payment of $<span><ix:nonfraction unitref="usd" contextref="iecb1e483333a485ab9ecce6be458637d_D20210701-20210930" decimals="-5" name="blcm:UpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-314" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDgxMTQyOA_57c2a888-6fec-4712-8b59-124f98d83426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.0</ix:nonfraction></span> million, which was recognized as revenue upon execution of the agreement, and granted licenses for two nominated programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within the Company's control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations when such obligations have been fulfilled.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i4f570a4af67b428b86c1c8894f0c9c7c" continuedat="i0c2eadb58cdf41fc9cf9c485e7b0ea14" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i847f7bf637bc447c8492ee6634080d3d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="fact-identifier-317" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3MzU_e91af85e-fea9-452a-9170-bc57707e31c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all short-term, highly liquid investments with a maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="fact-identifier-318" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3MzE_30959076-1c84-4ebe-ab3c-5aa781c859fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="fact-identifier-319" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NTE_c5d04268-b10c-43fb-98b5-18f0582c1bb8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:6.6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:66.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-320" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfMS0yLTEtMS0xNjY4NA_dc19e180-bc1d-4e51-bfc0-a6cd0a1e6e6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-321" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfMS00LTEtMS0xNjY4NA_bdd8dfca-d473-4215-98a9-2bdc8537a46d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,495</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-322" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfMi0yLTEtMS0xNjY4NA_07f7769c-7467-4477-a1cb-c2d71d3878e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,501</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-323" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfMi00LTEtMS0xNjY4NA_03e6d7a2-416f-4510-907e-5a65faff4582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,501</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-324" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfNC0yLTEtMS0xNjY4NA_c368714c-2450-4eb6-8f93-3cf8cc09f25c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47,657</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-325" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI2Mjg2NzU2MzdiZjRmMWU5MjZjYzcyNDRkNzFkMmI5L3RhYmxlcmFuZ2U6YjYyODY3NTYzN2JmNGYxZTkyNmNjNzI0NGQ3MWQyYjlfNC00LTEtMS0xNjY4NA_950c1341-5030-4398-8c3e-beead43b3a53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,996</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:nonnumeric></span><div style="text-align:center"><span><br></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the Asset Purchase Agreement with M.D. Anderson on April 14, 2020, $<span><ix:nonfraction unitref="usd" contextref="i6d15b7b6d1e94bde9ac536c88a06851f_D20200414-20200414" decimals="-5" name="us-gaap:EscrowDepositsRelatedToPropertySales" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-326" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTM2MjM_d57ad490-78a0-459c-8c18-7f22259d1f81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million of the cash proceeds received are subject to certain escrow provisions and recorded as restricted cash. The funds are required to be held until any claims against the escrow are resolved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disposition of Assets and Liabilities Held for Sale and Held for Use</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, in connection with the Companys restructuring plan, Management elected to seek an exit to its leased manufacturing facility in Houston, Texas. As a result of this decision, the Company reclassified the assets and liabilities associated with the leased facility as held for sale. The reclassified assets and liabilities included a right-of-use asset of $<span><ix:nonfraction unitref="usd" contextref="i4f20fc086b374ccdb6df517498fff915_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-327" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDMzNg_0ed10319-6411-43e1-b04b-7b9f358aedb8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million, property and equipment of $<span><ix:nonfraction unitref="usd" contextref="i4f20fc086b374ccdb6df517498fff915_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-328" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDM1MA_370cf768-d636-4572-99d4-8922b072c94a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;million and the related lease liability of $<span><ix:nonfraction unitref="usd" contextref="i4f20fc086b374ccdb6df517498fff915_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-329" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDM2NA_97ae9e4e-682e-46b0-9755-0c460384d13a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.7</ix:nonfraction></span>&nbsp;million. Based on the cost to exit the lease and the net realizable value of the related assets, the Company recognized an impairment charge of $<span><ix:nonfraction unitref="usd" contextref="i3cdbd9b9b188403f93314e3343a81afa_D20201001-20201231" decimals="-5" name="us-gaap:ImpairmentChargeOnReclassifiedAssets" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-330" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDM3OA_baade013-e749-458d-8887-2ab7fd397a29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span>&nbsp;million in the fourth quarter of 2020.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposal of the assets and liabilities associated with the Houston facility was completed on February 26, 2021. Under the terms of the agreement, a third party assumed the lease for the facility. In addition, the third party paid $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-331" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDM5Mg_60c7a760-25f8-4353-9d62-95afbb90ed48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span>&nbsp;million to the Company for substantially all of the property and equipment associated with the location. The consideration included $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="blcm:DisposalGroupIncludingDiscontinuedOperationConsiderationCash" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-332" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQwNg_08613abe-84c4-444f-95f2-c455985ea864" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span>&nbsp;million in cash and an unsecured promissory note for $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="blcm:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-333" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQyMA_9c3c4393-f2cf-4cc7-8398-0b25d4b20b60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span>&nbsp;million.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2021, the Company entered an agreement to terminate its sub-lease of the South San Francisco office space contingent upon consent of the prime lessor. Under the terms of the agreement, the company agreed to pay a lease termination fee of $<span><ix:nonfraction unitref="usd" contextref="idceb87b2e4bc48a592ea6f325e3399eb_D20210315-20210315" decimals="-5" name="blcm:LesseeOperatingSubleaseTerminationFee" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-334" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQ0OA_9b8ff2a0-5e47-46a7-9a82-a3ad9dcc0824" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span>&nbsp;million while the security deposit of $<span><ix:nonfraction unitref="usd" contextref="i807426abce39417e85c2b2d54aace245_D20210601-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInSecurityDeposits" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-335" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQzNA_135b65e3-c7d5-4961-bd11-e852f2985038" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;million was returned to the Company in June 2021. The decision to exit this lease reflects the ability of the Company to carry on its administrative function remotely. On March 26, 2021, the Company met all of the conditions of the agreement and disposed of substantially all of the assets and liabilities associated with the lease including the right-of-use asset of $<span><ix:nonfraction unitref="usd" contextref="i6991c90827564c2aabd5fe8e3909b9c2_I20210326" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-336" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQ2Mg_a5b9b6a2-784e-4956-93ae-f8a07f0a6de2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>&nbsp;million, leased equipment with a net book value less than $<span><ix:nonfraction unitref="usd" contextref="i066342492db944de806136139abade48_I20210326" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-337" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfOTM0NTg0ODkzMjI4MA_3092ee2a-bfc3-4ce9-abd3-d89eef0cc234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>&nbsp;million, and the related lease liability of $<span><ix:nonfraction unitref="usd" contextref="i6991c90827564c2aabd5fe8e3909b9c2_I20210326" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-338" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQ5Mg_6a9759d6-4f7c-46a3-bee3-73a9c7d96bd4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million. The Company recognized a loss on termination of $<span><ix:nonfraction unitref="usd" contextref="i88d68d2cea79442d8f597ee73ada01a4_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-339" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc2MDQ3Ng_e7c8086f-e98b-40fb-9c77-eb76eef4558e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million during the first quarter of 2021.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="fact-identifier-340" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDE_878a8a41-1068-4a2c-8cdd-ffd267135e0d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from <span><ix:nonnumeric contextref="ib3f40d22d071427d81353598d6cac168_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-341" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTg0MjI_d82b8f5b-421e-47d6-819a-5031cbdebd4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span> to <span><ix:nonnumeric contextref="i88aa024e2d884c569e5cf292f8f5372e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-342" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTg0Mjg_58e214b8-c3e8-42da-ab50-1990849e5ff3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span> years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</span></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="fact-identifier-343" continuedat="i56560a4f10344db2826fd352b2ab4d66" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3MzI_e06e9e7d-73b1-4f22-aa1c-b86be75d3d3f" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Property and equipment consisted of the following:</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i0c2eadb58cdf41fc9cf9c485e7b0ea14" continuedat="i22bdb53044cb41c09030a497dafe00c7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:11pt"><span><ix:continuation id="i56560a4f10344db2826fd352b2ab4d66" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except useful lives)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated&nbsp;Useful&nbsp;Lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4e2a121b78854d30be8796f794388932_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-346" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMS00LTEtMS0xNjY4NA_31c9324b-d50c-4598-a3ca-8ba2c6324f4f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i59ae1df39ae145e0863c07163a179c3a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="fact-identifier-347" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMS03LTEtMS0xNjY4NA_806d49f6-744b-48ba-befe-fd2637355fef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7450386338cb40fa9c82c4a56156dea0_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-348" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMS05LTEtMS0xNjY4NA_e71cd1b5-3280-4a4b-b789-fcd00c446a26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">167</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i8ca56416361c44eabf0c13b56e7d74c8_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-349" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMi00LTEtMS0xNjY4NA_7cc4ea21-8d2c-458a-8b86-d578ac7e6c84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9acce5a3a0534092b158ed744a273675_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-350" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMi03LTEtMS0xNjY4NA_0a58379d-e6fe-4794-a499-ad5c0fb17517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">530</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i12ac7473376540ce8ca91a46bf14add5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-351" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMi05LTEtMS0xNjY4NA_2cf8930d-d0aa-4910-8762-7bfca052f152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">530</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4c6615dadd0c4d8fb3e5dc94cfcbaa51_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-352" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNC00LTEtMS0xNjY4NA_a9ff8f7d-dd24-4823-8f61-980408163113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4cb9807f5ef549269fe62572a5c7f78d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-353" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNC03LTEtMS0xNjY4NA_1b7be514-fee7-41b3-b2d7-5617a9ad7b59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idcf4b7646dbf4d5aa825c03ca6c9affa_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-354" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNC05LTEtMS0xNjY4NA_42cfe4bb-d875-4589-b972-e37bd56a3fdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i28527a1ff1aa4559a4d40897a6dc1a39_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-355" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNS0yLTEtMS0xNjY4NA_112ce9f7-eb5e-442a-aa13-606ac479bc74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i80cefc192e1149ccb3c4ebf1a7e7274a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-356" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNS00LTEtMS0xNjY4NA_77e84d29-2d9d-4844-b681-db30387b4b32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i850ab4078f234749b4e9b46d0b852d74_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-357" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNS03LTEtMS0xNjY4NA_321d1fc8-3cad-44dd-af73-762d38c66e11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">841</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i741e89e6497945fdb9b592b0c23595fa_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-358" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNS05LTEtMS0xNjY4NA_cd40b159-b01b-4b7a-88c0-5126f52d0065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">834</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ibcdea42408f740b8894840014d5aaa60_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="fact-identifier-359" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNy00LTEtMS0xNjY4NA_8a5c88ce-7098-4caa-84b4-1934589c8e9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iabb2e91846094a18b7b7195eeef64f56_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-360" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNy03LTEtMS0xNjY4NA_3fb591eb-660a-427e-86c5-4de3c57a4970" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ife363db7ddbd448c8b52d37166de46e8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-361" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfNy05LTEtMS0xNjY4NA_438e15d7-7094-4d4f-a8b7-8c33155f3d66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-362" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfOC03LTEtMS0xNjY4NA_c5ec1eeb-f43d-4dc3-911a-2cc3e768783a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,603</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-363" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfOC05LTEtMS0xNjY4NA_27a66471-010c-4d06-9bee-ab7eca438ffc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,763</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-364" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfOS03LTEtMS0xNjY4NA_9ba3ba84-9b4c-4fba-a473-91a4e6268aaa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,591</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-365" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfOS05LTEtMS0xNjY4NA_794bd705-be68-443c-a105-45a2ecae02ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,574</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-366" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMTAtNy0xLTEtMTY2ODQ_b3195e1d-4fe5-4bf6-af0c-f06e9faa949a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-367" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOjlhZmEzNjViODdlNzQzZGFiZjg4MTg5OGYzZWM2NzAyL3RhYmxlcmFuZ2U6OWFmYTM2NWI4N2U3NDNkYWJmODgxODk4ZjNlYzY3MDJfMTAtOS0xLTEtMTY2ODQ_6b07500a-4b6b-4691-8f98-948776d86943" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">189</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div><span><br></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-368" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTg2NTQ_2ed0989a-d94a-4c80-8c44-93445f1a9a53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-369" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMTg2NjE_a9ee6e60-ecbd-4695-83cd-95a47f66a035" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span> million of depreciation expense, respectively.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="fact-identifier-370" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NTI_549ee091-3b0d-4dbb-9980-c4971c0a9c85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</span></div></ix:nonnumeric></span><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="fact-identifier-371" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NTM_43e610a3-7bf4-4524-8bd8-13722b64557a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="fact-identifier-372" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMS0yLTEtMS0xNjY4NA_3e903e14-434e-4545-9318-191cfd889066" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">320</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-373" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMS00LTEtMS0xNjY4NA_7efeb863-472f-4ae1-8b15-081ed6aeaa19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,071</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued patient treatment costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:PatientTreatmentCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-374" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMi0yLTEtMS0xNjY4NA_bd37fe2a-924a-4184-a50c-12b15946ff73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,086</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:PatientTreatmentCosts" scale="3" id="fact-identifier-375" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMi00LTEtMS0xNjY4NA_cc59ba7a-74b4-4313-bab3-c9d5d0b2a30f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">899</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical research costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:AccruedClinicalResearchCostsCurrent" scale="3" id="fact-identifier-376" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMy0yLTEtMS0xNjg4NQ_4c22f305-5b4f-4b8a-8cba-2ba33932f68d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">479</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:AccruedClinicalResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-377" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMy00LTEtMS0xNjg5Mg_7ec68b1d-fe82-4332-8733-1195f72f1ac1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,562</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:AccruedManufacturingCostsCurrent" scale="3" id="fact-identifier-378" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMy0yLTEtMS0xNjY4NA_1d9e4648-0360-494b-8eed-43be091c2ea5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">328</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:AccruedManufacturingCostsCurrent" scale="3" id="fact-identifier-379" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfMy00LTEtMS0xNjY4NA_7a02e1cc-277e-43de-9d46-6f68759d9124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">41</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="3" id="fact-identifier-380" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfNC0yLTEtMS0xNjY4NA_906eaf84-93e0-4597-8c2d-3b152a1ec231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">305</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="3" id="fact-identifier-381" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfNC00LTEtMS0xNjY4NA_d2747b3f-6941-4cec-b058-d9d522abf252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">279</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-382" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfNy0yLTEtMS0xNjY4NA_c355ed13-df09-4ee8-95b5-473dae27b77c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">331</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-383" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfNy00LTEtMS0xNjY4NA_cb53c699-1969-429b-befd-fcbe21891ccf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-384" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfOC0yLTEtMS0xNjY4NA_0b0132a2-5eb6-4a37-81e8-b22cde2ef220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,849</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-385" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmM4YjI0OTk0Mjk1MjRhNWVhNWMyY2I5MjFjOTEwOWIxL3RhYmxlcmFuZ2U6YzhiMjQ5OTQyOTUyNGE1ZWE1YzJjYjkyMWM5MTA5YjFfOC00LTEtMS0xNjY4NA_500736dc-0b82-4d35-9433-82147d4ea591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,165</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the 2021 presentation. Expenses related to clinical studies totaling $<span><ix:nonfraction unitref="usd" contextref="i550c48074d4a4c6e9f46c274eca07adf_I20201231" decimals="-5" name="blcm:AccruedClinicalResearchCostsCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-386" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc4MDA2Nw_532bfe47-990c-4cb6-b3da-0d4e32f48416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span>&nbsp;million were reclassified from Accrued Other to Accrued Clinical Research Costs. Another $<span><ix:nonfraction unitref="usd" contextref="i550c48074d4a4c6e9f46c274eca07adf_I20201231" decimals="-5" name="blcm:AccruedManufacturingCostsAndAccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-387" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfMzg0ODI5MDc4MDA1Mg_75a727a5-3755-4933-b41c-2e87e29d4ff6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>&nbsp;million for expenses related to drug manufacture and professional consulting services were reclassified from Accrued Other to Accrued Manufacturing Costs and Accrued Professional Services.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="fact-identifier-388" continuedat="i0ecfb3e915834c32beaa44b76ab911c2" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NjA_77f2c02d-32e7-4b61-ab10-b1fdc7436014" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Derivatives</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an underwritten public offering (the 2019 Offering), the Company issued Series&nbsp;1 Redeemable Convertible&nbsp;Non-Voting&nbsp;Preferred Stock (the Series&nbsp;1 Preferred Stock) and warrants (the 2019 Public Warrants) to purchase its common stock. These 2019 Public Warrants are classified as liabilities in the accompanying consolidated balance sheets, because the public warrants embody a conditional or unconditional obligation to repurchase the Companys shares. The Company accounted for these warrants at fair value on the date of issuance and they are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying consolidated statements of operations and comprehensive loss. The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit. See Note 5 - Public Offering and Private Placement for discussions of the 2019 Public Warrants.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i22bdb53044cb41c09030a497dafe00c7" continuedat="i07f9ad5f951d4f0da9788e741f9de656" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i0ecfb3e915834c32beaa44b76ab911c2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In November 2020 and December 2021, the Company issued prefunded warrants and accompanying warrants (the 2020 Pre-funded Warrants and 2020 Common Warrants, the 2021 Pre-funded Warrants and 2021 Common Warrants, respectively). These pre-funded warrants and common warrants are classified as equity. The pre-funded warrants and common warrants neither embody a conditional or unconditional obligation, nor are they indexed to an obligation, to repurchase the Companys shares by transferring assets. Furthermore, the monetary value of the pre-funded warrants and accompanying warrants, at inception, is not solely or predominately based on (a) a fixed monetary amount, (b) variations in something other than the fair value of the Companys shares, or (c) variations inversely related to the fair value of the Companys own shares. Therefore, the pre-funded warrants and common warrants do not meet the criteria requiring liability classification. See</ix:continuation></span> Note 5 - Public Offering and Private Placement for discussions of the 2020 Pre-funded and Common Warrants and 2021 Pre-funded and Common Warrants.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:PrivatePlacementOptionPolicyPolicyTextBlock" id="fact-identifier-391" continuedat="i0d7eeb4b4a174d36b3d0529de2386051" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mjc_806c8457-3ea3-4074-915c-1802417e1e35" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Option</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Besides the 2019 Offering, the Company completed a private placement and entered into the 2019 Securities Purchase Agreement that contained a call option on preferred shares that are puttable outside the control of the Company. Prior to the fourth quarter of 2021, the Company recorded the option as a liability and measured the option at fair value. The Company re-measured the option to fair value at each balance sheet date and recorded changes in fair value in other income (expense) in the accompanying consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of these liabilities using a binomial lattice model, which utilized assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.</span></div></ix:nonnumeric></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><span><ix:continuation id="i0d7eeb4b4a174d36b3d0529de2386051" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In 2021, the Company entered into the 2021 Securities Purchase Agreement, pursuant to which certain of the purchasers irrevocably waived the right to cause the Company to conduct the First Closing and Second Closing under the private placement option contained in the 2019 Securities Purchase Agreement (each term as defined in the 2019 Securities Purchase Agreement), which releases the Company of potential obligations.</ix:continuation></span> The Company has therefore derecognized the option liability at its balance sheet date ended on December 31, 2021.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:TemporaryEquityPolicyTextBlock" id="fact-identifier-393" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mjg_c0276f15-ef46-4a2b-bcdb-340633e988d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Companys control) are classified within mezzanine equity in the accompanying consolidated balance sheets. At all other times, preferred shares are classified within stockholders deficit.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="fact-identifier-394" continuedat="i754e00e09edc47b087a0970f0bd1d7d9" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NTU_141fd504-df21-4a6c-a05b-5973a4e3f8d3" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Companys obligation to make lease payments arising from the lease, and a corresponding right-of-use (ROU) asset which represents the Companys right to use an underlying asset during the lease term. </span></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i754e00e09edc47b087a0970f0bd1d7d9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet at the commencement date based on the present value of the future minimum lease payments over the lease term calculated using the Companys incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.</ix:continuation></span> </span></div><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="fact-identifier-396" continuedat="i268b9698293442c5a1ffc5e2f6495e2e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDc_d9711316-d6c4-4dd3-a0dd-11f20e32246d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a fair value hierarchy has been established that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inputs are classified into the following hierarchy:</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i07f9ad5f951d4f0da9788e741f9de656" continuedat="i3658652d7cb3460bb4d60725c7a155aa" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i268b9698293442c5a1ffc5e2f6495e2e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:5pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Level 3 Inputs - unobservable inputs for the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, accrued liabilities, and debt approximate their fair values due to the short-term nature of these instruments.</span></div></ix:continuation></span><div style="text-align:justify"><span><br></span></div><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="fact-identifier-399" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDM_1ff2b05d-02be-469f-966d-124950ef2399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsIssuancesPolicy" id="fact-identifier-400" continuedat="ib4b7541d412f425a9eace97303432ad1" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mzc_7e5c4938-2412-4acc-888e-196de1a4ae3e" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Equity Issuance Costs </ix:nonnumeric></span></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ib4b7541d412f425a9eace97303432ad1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Equity issuance costs represent costs paid to third parties in order to obtain equity financing. These costs have been netted against the proceeds of the equity issuances.</ix:continuation></span> </span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:LicensesPatentsAndResearchAndDevelopmentExpensePolicyPolicyTextBlock" id="fact-identifier-402" continuedat="i1e04c63e29e34821812fc4665ca6706e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NjE_d5bbc045-2143-421a-8722-1f4151cb8885" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Licenses and Patents </ix:nonnumeric></span></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i1e04c63e29e34821812fc4665ca6706e" continuedat="i7063bedd05eb4c758c0b03e2f61041fd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Licenses and patent costs for technologies that are utilized in research and development and have no alternative future use are expensed as incurred. Costs related to the license of patents from third parties and internally developed patents are classified as research and development expenses.</ix:continuation></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="fact-identifier-404" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDg_cd56211a-d70b-476e-8392-3bc06e760463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Legal costs related to patent applications and maintenance are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</ix:nonnumeric></span></span></div><div style="text-align:justify"><span><br></span></div><span><ix:continuation id="i7063bedd05eb4c758c0b03e2f61041fd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known.</span></div></ix:continuation></span><div style="text-align:justify"><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:CollaborationAgreementsPolicyTextBlock" id="fact-identifier-406" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NjI_e66ed28e-eb53-4f5f-b9f4-fc014d6b1937" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities. The Company may&nbsp;share the costs of research and development activities with a collaborator, or the Company may be reimbursed for all or a significant portion of the costs of the Company</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s research and development activities. The Company records its internal and third-party development costs associated with these collaborations as research and development expenses.  When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as a deduction to the research and development expenses. If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, the Company also recognizes, as research and development expenses in the period when its collaborator incurs development expenses, the portion of the collaborator's development expenses that the Company is obligated to reimburse.</span></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:ContractManufacturingServicesPolicyTextBlock" id="fact-identifier-407" continuedat="i6562ad9992054433966b4c98481eba79" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDI_fa65c03b-6955-41d8-8960-9943a31eee8b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Contract Manufacturing Services </ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i6562ad9992054433966b4c98481eba79" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Contract manufacturing services are expensed as incurred. Prepaid expenses are capitalized and amortized as services are performed.</ix:continuation></span> </span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i3658652d7cb3460bb4d60725c7a155aa" continuedat="icd9eab3187a147edae0bec8c21558653" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="fact-identifier-410" continuedat="i8c400535da4b41e488cd4276f04b928f" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDQ_8d86eb39-da01-4dc3-95ef-68ca6d415fa4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation based on the measurement and recognition of compensation expense for all share-based payment awards made to employees, directors and consultants to be recognized in the financial statements, based on their fair value. </span></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i8c400535da4b41e488cd4276f04b928f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company calculates the fair value of stock options on the date of grant using the Black-Scholes pricing model, which requires a number of estimates, including the expected life of awards, interest rates, stock volatility and other assumptions. Restricted stock is measured based on the fair market value of the underlying stock on the date of grant. If the awards are classified as liability awards, the fair value is remeasured at each reporting date and the compensation expense is adjusted accordingly. Additionally, the Company applies a forfeiture rate to estimate the number of grants that will ultimately vest, as applicable, and adjusts the expense as these awards vest. All of the Companys current equity awards are service based awards and the share-based compensation cost is being recognized over the requisite service period of the awards on a straight-line basis.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="fact-identifier-412" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mzg_2e835d2a-3ecc-495b-b40d-472ce42c6882" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss and tax credit carry forwards, to the extent that realization of such benefits is more likely than not. A valuation allowance is recorded when the realization of future tax benefits is uncertain. The Company records a valuation allowance for the full amount of deferred tax assets, which would otherwise be recorded for tax benefits relating to the operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had recorded a full valuation allowance on its net U.S. and foreign deferred tax assets because the Company expects that it is more likely than not that its deferred tax assets will not be realized in the foreseeable future. Should the actual amounts differ from our estimates, the amount of the valuation allowance could be materially impacted.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of the Accounting Standards Codification (ASC) 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2021 and 2020, the Company had no uncertain tax positions and no interest or penalties have been charged for the years ended December 31, 2021 and 2020. The Company is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The tax years 2005 through 2021 remain open to examination by the U.S. Internal Revenue Service.</span></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="fact-identifier-413" continuedat="i9d3fd811edad4bb38a37d0548354ff37" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3NDk_d97e3c61-9b13-4961-9924-f03af4a0fbf5" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Comprehensive Loss</ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i9d3fd811edad4bb38a37d0548354ff37" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Comprehensive loss is defined as the change in equity of a business enterprise during a period, from transactions, and other events and circumstances from non-owner sources. Components of other comprehensive loss includes, among other items, unrealized gains and losses on the changes in fair value of investments and unrealized gains and losses on the change in foreign currency exchange rates. These components are added, net of their related tax effect, to the reported net loss to arrive at comprehensive loss.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="fact-identifier-415" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3Mjk_a9ba7880-7a3a-4b53-a90a-2cc0ad5bda46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted earnings per share is based on the more dilutive method between the two-class method and the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the conversion of preferred stock to common stock, exercise of warrants to purchase common stock, exercise of stock options, and vesting of restricted stock units. For periods of net loss, diluted net loss per share is calculated similarly to basic net loss per share.</span></div></ix:nonnumeric></span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="fact-identifier-416" continuedat="i321fc1bc59e541e3b1932e6ba5a05168" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3MzQ_8c20f950-fdc2-4527-a871-15c5fc863ad4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following outstanding shares of common stock equivalents were excluded from the computations of diluted earnings per share (if in a net income position) of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive. </ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="icd9eab3187a147edae0bec8c21558653" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:center"><span><ix:continuation id="i321fc1bc59e541e3b1932e6ba5a05168" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible series 1 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if42cd2bebc534723abfd2794b121dd10_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-419" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfMi0yLTEtMS0xNjY4NA_6b984c7a-c203-4b77-996a-b060f742fbae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,520,000</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3fd3938d544841399a920cc75b84c1f6_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-420" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfMi00LTEtMS0xNjY4NA_c9732723-80a8-4219-8c43-acfecf4b0b40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,520,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i6fd0f81e5de6497ab96125c754b1a270_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-421" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfMy0yLTEtMS0xNjY4NA_bc6d9362-713a-46d4-a10f-be1d2375ffc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,750,000</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="idcc9d1f406f1468bab9d96585ee49ac6_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-422" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfMy00LTEtMS0xNjY4NA_aed74066-b9f2-43ab-90a3-25f09be784ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,616,080</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i85c43e0099974f2c96d8d65176b416cd_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="fact-identifier-423" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNC0yLTEtMS0xNjY4NA_0d90d9ce-68cf-4d18-a06d-92738a892102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i80c09730973e494d9604a078ae0789c8_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-424" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNC00LTEtMS0xNjY4NA_3fe55320-725e-4ec3-acff-4ceb00e8a61c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,675,000</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7291d40f8b8d4a35bb5a7844a02d6d84_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-425" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNS0yLTEtMS0xNjY4NA_c49d0c17-b20b-4c3e-904d-035a7c16da15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,140,618</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i51e2c4cb965f49568b7ddf3cf4034629_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-426" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNS00LTEtMS0xNjY4NA_4922ac17-8e65-4e3a-8049-33a55ec6cd60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,510,968</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7554edb959f2477ca9152b14a5ea59a9_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-427" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNi0yLTEtMS0xNjY4NA_8dec7865-29b9-49a8-8c63-a2d7fe74cdfa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,504</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i820931bfd608449387c86d23ddb78592_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-428" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNi00LTEtMS0xNjY4NA_8680c905-7ded-450e-8aa2-6ce8cc56bc5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129,861</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total anti-dilutive common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-429" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNy0yLTEtMS0xNjY4NA_a8e4ada8-220a-4ac9-883f-e3f42432eb65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,548,122</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-430" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RhYmxlOmI4NDM3MjViMzcyYTQ5YTU4MDE5MWVlZjIyZmZlOGZiL3RhYmxlcmFuZ2U6Yjg0MzcyNWIzNzJhNDlhNTgwMTkxZWVmMjJmZmU4ZmJfNy00LTEtMS0xNjY4NA_d69bc66b-e49e-4180-b4d1-d396d5c798e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,451,909</ix:nonfraction></span></span></td></tr></tbody></table></ix:continuation></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="fact-identifier-431" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl84OC9mcmFnOjIxZWFiZDRmMjc1YjRmYWZhMTdiNzVlNzk3NjBlMTRlL3RleHRyZWdpb246MjFlYWJkNGYyNzViNGZhZmExN2I3NWU3OTc2MGUxNGVfNDA3MzA_00e3a04f-a696-419b-8e0e-7ee26c89ea04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Requirements and Disclosures </span></div><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments  Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&nbsp;No. 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&nbsp;Financial Instruments  Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial InstrumentsCredit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standards Update No. 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> InvestmentsEquity Securities (Topic 321), InvestmentsEquity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt  Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging  Contracts in Entitys Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which reduces the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, the update amends the guidance for the derivatives scope exception for contracts in an entitys own equity to reduce form-over-substance-based accounting conclusions. Furthermore, this update improves the related EPS guidance. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_94"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="fact-identifier-432" continuedat="i3c8970b4a0904401a6eb2d0002cbf57a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RleHRyZWdpb246NTE5YzFjZmZjNDMxNDc3ZTg5NWNjMjBiNDMxZjExOTJfMjM0OA_97503e5b-791b-47c9-a5bf-891d8cd02abf" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES</ix:nonnumeric></span></span></div><div><span><br></span></div><span><ix:continuation id="i3c8970b4a0904401a6eb2d0002cbf57a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="fact-identifier-434" continuedat="if5c28ad5f17e4c5583aaee5b24d4cb56" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RleHRyZWdpb246NTE5YzFjZmZjNDMxNDc3ZTg5NWNjMjBiNDMxZjExOTJfMjM1MA_191c5e94-d732-4eb2-b579-7e812bee1faa" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Companys investment securities (including those classified on the Companys balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of December 31, 2021 and 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and treasury bills</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaadf80ff2fb843c8b7b5ad1b8d24a7bd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-435" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy0xLTEtMS0xNjY4NA_51e43cc5-bdcd-47a3-8107-5aed0449f669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,487</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1be28a1b69b140a4a0d42e31e606cdc8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-436" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy0zLTEtMS0xNjY4NA_ceaffed9-fb5b-4d68-a625-d9c126cfb546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7b2bea2442214cd58a87bd1dd9e0eb5a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-437" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy01LTEtMS0xNjY4NA_c0b59a05-0fd2-4fa3-937b-5117d7e9fa78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9fd1576642634498a3ae399ffb58e423_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-438" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy03LTEtMS0xNjY4NA_1f044ded-13c8-4658-9abb-11d6fb767808" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,463</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie416e19ccd7e4d1180a83271076fdd2f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-439" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy05LTEtMS0xNjY4NA_2fd400c3-c838-4cae-8c12-fb71c7f7d29c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i38bb9b6283364f49a44f66c8336eb323_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-440" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfMy0xMS0xLTEtMTY2ODQ_17c6dcb3-31f3-44bc-a3ab-cc604c927aba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib520ab89d65b43428caf3691f4a0223d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-441" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC0xLTEtMS0xNjY4NA_08a93316-66fa-4792-9f00-a7ec15ef2bf4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,487</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if59a539aa3a84094875ebf2288f7f698_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-442" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC0zLTEtMS0xNjY4NA_005ba123-8928-4fb1-869f-aecd2c30759f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2591ba79d8b44645880b208c04c4dfd1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-443" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC01LTEtMS0xNjY4NA_b7284f9f-771f-418f-bc12-5ab29b9651e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieb6c6baf87684479a4f330127176a713_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-444" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC03LTEtMS0xNjY4NA_e4ff8102-85f2-44bc-b9c7-e31cdbac81cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,463</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74d4ab66f78a4b0189a572ce60b43ef4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-445" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC05LTEtMS0xNjY4NA_9e90d706-15e2-4dee-bd45-10f8a0e68730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5ff90f34369747d99cc5527c2de360e8_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-446" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjIyYzU5NDk3NTU0NjRlM2U5ZjliYWM3N2Q0OWQ5OGI5L3RhYmxlcmFuZ2U6MjJjNTk0OTc1NTQ2NGUzZTlmOWJhYzc3ZDQ5ZDk4YjlfNC0xMS0xLTEtMTY2ODQ_e529a9ae-26b5-4145-9aa6-b8beda832db5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:5pt"><span><br></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the $<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-447" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RleHRyZWdpb246NTE5YzFjZmZjNDMxNDc3ZTg5NWNjMjBiNDMxZjExOTJfMzM5_39a8fe3f-2624-4a22-a661-8defaa9d68b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million of restricted cash on the Company's balance sheet is held in a money market fund as of December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and U.S. Treasury bills are valued based on various observable inputs such as benchmark yields, reported trades, broker/dealer quotes, benchmark securities and bids.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Warrant Derivative Liability and Private Placement Option Liability</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Companys financial liabilities recorded at fair value on a recurring basis include the fair values of the warrant derivative liability and the private placement option liability prior to its derecognition in December 2021. Inputs used to determine estimated fair value (Level 3) of the warrants include the fair value of the underlying stock relative to the warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the warrants, and risk-free interest rates.</span></div><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values of the warrant derivative liability and the private placement option liability, prior to its derecognition in December 2021, are classified as current liabilities in the accompanying consolidated balance sheets. These liabilities will be shown as current liabilities on the balance sheet when it is deemed more probable than not by management to be exercised within one year. On December 4, 2021, the Company entered into the 2021 Securities Purchase Agreement, pursuant to which certain of the investors irrevocably waived the right to cause the Company to conduct the First Closing and Second Closing under the private placement option contained in the 2019 Securities Purchase Agreement (each term as defined in the 2019 Securities Purchase Agreement). The Company derecognized the private placement option liability and recorded a gain on change in the fair value for the year ended December 31, 2021 of $<span><ix:nonfraction unitref="usd" contextref="i152d7bd2d2244bbb8e164ea87a6cb427_D20210101-20211231" decimals="-5" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-448" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RleHRyZWdpb246NTE5YzFjZmZjNDMxNDc3ZTg5NWNjMjBiNDMxZjExOTJfMzg0ODI5MDcwNjgwMw_00bdaf9d-8788-478c-9372-5360cc5e68d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.8</ix:nonfraction></span>&nbsp;million in the accompanying statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="fact-identifier-449" continuedat="ie275432f8db64efcb32498bb37320e1d" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RleHRyZWdpb246NTE5YzFjZmZjNDMxNDc3ZTg5NWNjMjBiNDMxZjExOTJfMjM2MQ_d38235b9-777d-49cb-b860-0704008d2553" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i152d7bd2d2244bbb8e164ea87a6cb427_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-450" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMS0yLTEtMS0xNjY4NA_cdb46b75-79da-4c35-86a3-e478cf9d3ebc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i0346bc06dc7b4c1197eed20af6fc7913_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-451" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMS00LTEtMS0xNjY4NA_4c510c0c-5e79-449a-9b57-b1b3b907d7d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.46</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i152d7bd2d2244bbb8e164ea87a6cb427_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-452" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMi0yLTEtMS0xNjY4NA_a3220f4d-e69e-4080-8778-2a0531280eb7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i0346bc06dc7b4c1197eed20af6fc7913_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-453" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMi00LTEtMS0xNjY4NA_c7ff2583-b7a7-4677-bf42-77a8cbdd20d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i152d7bd2d2244bbb8e164ea87a6cb427_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-454" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMy0yLTEtMS0xNjY4NA_2abe381d-fbc0-4d6e-befd-5851c725d5bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.64</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i0346bc06dc7b4c1197eed20af6fc7913_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-455" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOjg4OGNiOGVjZDkzMjQwMDViZGQ1MjU3NjljMzM4ZTBmL3RhYmxlcmFuZ2U6ODg4Y2I4ZWNkOTMyNDAwNWJkZDUyNTc2OWMzMzhlMGZfMy00LTEtMS0xNjY4NA_fcc4e554-41ac-4156-95b3-33e3ad00c39e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.64</ix:nonnumeric></span></span></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><span><ix:continuation id="if5c28ad5f17e4c5583aaee5b24d4cb56" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the warrant derivative and private placement option liabilities reported at fair value and measured on a recurring basis:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:24.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib520ab89d65b43428caf3691f4a0223d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-457" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi0xLTEtMS0xNjY4NA_8126deb6-c8de-434f-a03b-5300868f76e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if59a539aa3a84094875ebf2288f7f698_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-458" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi0zLTEtMS0xNjY4NA_b35461f2-14f4-4ad3-823e-184d7fdb5b79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2591ba79d8b44645880b208c04c4dfd1_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-459" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi01LTEtMS0xNjY4NA_7a9342de-99d8-4172-a1f4-3be9e18b9792" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieb6c6baf87684479a4f330127176a713_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-460" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi03LTEtMS0xNjY4NA_ed3c06c9-3a9e-410e-a49c-de59564c92e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74d4ab66f78a4b0189a572ce60b43ef4_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-461" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi05LTEtMS0xNjY4NA_33fa1a28-c519-467c-afb4-42afff95f566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5ff90f34369747d99cc5527c2de360e8_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-462" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMi0xMS0xLTEtMTY2ODQ_1f5438d0-bb6f-4afc-be9f-e826646e7626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib520ab89d65b43428caf3691f4a0223d_I20211231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-463" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy0xLTEtMS0xNjY4NA_9cfbfe5d-a291-494b-ac71-267e8ed5271a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if59a539aa3a84094875ebf2288f7f698_I20211231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-464" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy0zLTEtMS0xNjY4NA_7619963d-3df1-4403-8cf2-07f7df2f243a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2591ba79d8b44645880b208c04c4dfd1_I20211231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-465" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy01LTEtMS0xNjY4NA_635661b1-dbff-46eb-b497-2436c77114e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieb6c6baf87684479a4f330127176a713_I20201231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-466" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy03LTEtMS0xNjY4NA_6d9ff034-8416-407f-b05d-9c4e2d436f6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74d4ab66f78a4b0189a572ce60b43ef4_I20201231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:fixed-zero" scale="3" id="fact-identifier-467" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy05LTEtMS0xNjY4NA_b26b8369-737a-45ac-8172-b4170050e2bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5ff90f34369747d99cc5527c2de360e8_I20201231" decimals="-3" name="blcm:DerivativeLiabilityPrivatePlacementOption" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-468" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfMy0xMS0xLTEtMTY2ODQ_2f42e4d4-696b-423f-9e55-06348c2e029e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,803</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib520ab89d65b43428caf3691f4a0223d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-469" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC0xLTEtMS0xNjY4NA_f3159263-4f71-47f5-a8ac-c7dee500be2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if59a539aa3a84094875ebf2288f7f698_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-470" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC0zLTEtMS0xNjY4NA_0af63386-a1d5-4217-8da5-bd84246888c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2591ba79d8b44645880b208c04c4dfd1_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-471" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC01LTEtMS0xNjY4NA_ea569de0-cc18-4be3-835c-567ad4996cc0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieb6c6baf87684479a4f330127176a713_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-472" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC03LTEtMS0xNjY4NA_e7121f5d-4bf3-495d-a791-3823e9421d4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74d4ab66f78a4b0189a572ce60b43ef4_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-473" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC05LTEtMS0xNjY4NA_3bd8e36c-13fe-4561-bbf6-230c08d9297a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5ff90f34369747d99cc5527c2de360e8_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-474" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85NC9mcmFnOjUxOWMxY2ZmYzQzMTQ3N2U4OTVjYzIwYjQzMWYxMTkyL3RhYmxlOmVmYWRlZGU5MTE1ZTQzZTRhNWEzZmM0MGZjODVjZmEwL3RhYmxlcmFuZ2U6ZWZhZGVkZTkxMTVlNDNlNGE1YTNmYzQwZmM4NWNmYTBfNC0xMS0xLTEtMTY2ODQ_6e4e956c-35a6-417a-a0b3-cab642b803ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,148</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ending balance of the Level 3 financial instruments presented above represents the Companys best estimate of valuation and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_97"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE 3 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="fact-identifier-475" continuedat="ie554e5d2d30b4b0199dca390ef2d8ace" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTcxMA_b315a1e5-eb79-4924-abb5-6d0c802d1fe7" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="fact-identifier-476" continuedat="i7f5b325b0e62490fb02d6dc790e7c9a2" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTcxNA_47ae0421-f3b7-4a5a-af7b-41d28cd8b4d9" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">LEASES</ix:nonnumeric></span></ix:nonnumeric></span></span></div><div style="text-align:justify"><span><br></span></div><span><ix:continuation id="ie554e5d2d30b4b0199dca390ef2d8ace" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i7f5b325b0e62490fb02d6dc790e7c9a2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a lease agreement for office and laboratory space in Houston, Texas commencing in July 2020 and expiring in 2023. The Company recorded ROU assets of $<span><ix:nonfraction unitref="usd" contextref="i42ed175dd0fa4ee5a08aa7cf7f205e52_I20200731" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-479" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfNTg2_a3592213-2d5f-41df-b59f-04032ae432bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span> million and a corresponding lease liability of $<span><ix:nonfraction unitref="usd" contextref="i42ed175dd0fa4ee5a08aa7cf7f205e52_I20200731" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-480" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfNjI4_7c67020d-230c-4ff5-b815-43acd90358dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span> million upon lease commencement. In October 2020, in connection with the Companys restructuring plan, Management elected to seek an exit to its leased office and laboratory space in Houston, Texas. As a result of this decision, the Company reclassified the assets and liabilities associated with the leased facility as held for sale. The reclassified assets included a right-of-use asset of $<span><ix:nonfraction unitref="usd" contextref="i1367724e706543e0ac1a58c9c3c5444c_I20201031" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-481" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTAxNg_f08e0a14-c2e7-40d3-adbf-8a5143770712" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million, property and equipment of $<span><ix:nonfraction unitref="usd" contextref="i1367724e706543e0ac1a58c9c3c5444c_I20201031" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-482" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTA0Ng_e03c3768-09ac-4c9a-8eeb-5189ef8d2fbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;million, and related lease liability of $<span><ix:nonfraction unitref="usd" contextref="i1367724e706543e0ac1a58c9c3c5444c_I20201031" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-483" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTA4MQ_0a441abc-7791-4fb1-a2b7-eae7fb247651" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.7</ix:nonfraction></span>&nbsp;million.  Based on the cost to exit the lease and the net realizable value of the related assets, the Company recognized an impairment charge of $<span><ix:nonfraction unitref="usd" contextref="i2928d70a4c294b5cbb91813850f56d81_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentChargeOnReclassifiedAssets" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-484" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTIyMA_aa3ce4da-9a0a-406d-9343-52f0f365dabe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span>&nbsp;million in 2020. The disposal of the assets and liabilities associated with the facility was completed on February 26, 2021. Under the terms of the agreement a third party assumed the lease for the facility. In addition, the third party paid $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-485" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMDgwMw_5d849c90-3ce7-4630-bea2-df10eff0f51a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span>&nbsp;million to the Company for substantially all of the property, and equipment associated with the location. The consideration included $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="blcm:DisposalGroupIncludingDiscontinuedOperationConsiderationCash" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-486" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMDgzMQ_531a83d5-2d65-4f36-babb-a5f59959dd18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span>&nbsp;million in cash and an unsecured promissory note for $<span><ix:nonfraction unitref="usd" contextref="idd31d8ebabc345d9b65c42fcd3e1d869_I20210226" decimals="-5" name="blcm:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-487" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMDgxNw_7d2d0de6-b053-4322-aaf1-c852a92e8e5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span>&nbsp;million.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2021, the Company entered an agreement to terminate its sub-lease of the South San Francisco office space contingent upon consent of the prime lessor. Under the terms of the agreement, the company agreed to pay a lease termination fee of $<span><ix:nonfraction unitref="usd" contextref="idceb87b2e4bc48a592ea6f325e3399eb_D20210315-20210315" decimals="-5" name="blcm:LesseeOperatingSubleaseTerminationFee" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-488" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfOTM0NTg0ODg0MzYyMQ_c24b2568-4433-4a10-b9af-6df3c0569b95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span>&nbsp;million while the security deposit of $<span><ix:nonfraction unitref="usd" contextref="idceb87b2e4bc48a592ea6f325e3399eb_D20210315-20210315" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInSecurityDeposits" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-489" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMTcyOQ_672d8e17-5c21-4c2c-8505-4e8ee1321885" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;million was returned to the Company. On March 26, 2021, the Company met all of the conditions of the agreement and disposed of substantially all of the assets and liabilities associated with the lease including the right-of-use asset of $<span><ix:nonfraction unitref="usd" contextref="i6991c90827564c2aabd5fe8e3909b9c2_I20210326" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-490" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMTg1Nw_5b01c529-793c-4dee-9ed3-c6728c6aec15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>&nbsp;million, leased equipment with net book value less than $<span><ix:nonfraction unitref="usd" contextref="i066342492db944de806136139abade48_I20210326" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-491" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMTg3MQ_0c107bd1-4aac-443f-9af4-4d5936ffefb3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>&nbsp;million, and the related lease liability of $<span><ix:nonfraction unitref="usd" contextref="i6991c90827564c2aabd5fe8e3909b9c2_I20210326" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-492" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMTg4Nw_55d181f3-6f59-4f16-87a6-23ef6eb8d6a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million. The Company recognized a loss on termination of $<span><ix:nonfraction unitref="usd" contextref="iba0c172ad2c64a8c8f5d8eea1dd744f9_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-493" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMzg0ODI5MDcwMTkwMQ_027ef037-874e-43b5-89cd-34cae5e9553a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million during the year ended December 31, 2021. </span></div><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="fact-identifier-494" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RleHRyZWdpb246MzdhMzBiODgxOGQyNDQzNzlmOTVjODQ3NjBmZDM3NzlfMTcxMQ_8163855e-017e-40e9-916b-67aac52d478f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:49.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="fact-identifier-495" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMi0xLTEtMS0xNjY4NA_6059b0a1-5314-4e06-b346-a31e19f4adda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="fact-identifier-496" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMi0zLTEtMS0xNjY4NA_a5b5a696-2640-49d7-8753-1bc71b17f6c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="fact-identifier-497" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMy0xLTEtMS0xNjY4NA_69bfb32c-2da0-4fdd-a350-0c26e35b9de5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="fact-identifier-498" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMy0zLTEtMS0xNjY4NA_7b41d956-c5e5-471c-8ed3-c1815aa15b6f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-499" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNC0xLTEtMS0xNjY4NA_1c591585-d2ea-44cb-9f8e-c9a2341cb5ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-500" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNC0zLTEtMS0xNjY4NA_71e91921-3265-4672-a63b-053511ebe3f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">814</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-501" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNS0xLTEtMS0xNjY4NA_502412e8-d91d-4c98-acfe-ac9f5864ac23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-502" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNS0zLTEtMS0xNjY4NA_315f3ce2-266e-425b-b7a3-96dbca6a7b7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">582</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="fact-identifier-503" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNi0xLTEtMS0xNjY4NA_a8c74ea6-a6f6-49ab-9615-49afc76346a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">130</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-504" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfNi0zLTEtMS0xNjY4NA_5a3202a5-c468-4a0f-b494-650bd57d51b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,491</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-505" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfOS0xLTEtMS0xNjY4NA_be4a932d-55f9-470e-af11-8023c32dabfe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonnumeric></span> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i236c04c5165044769887aa3cb89df57a_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-506" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfOS0zLTEtMS0xNjY4NA_b9ae365b-06d5-42ba-b960-8805071a0ace" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.7</ix:nonnumeric></span> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-507" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTAtMS0xLTEtMTY2ODQ_baec7590-eb69-4e7a-8ce8-df14d94951d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonnumeric></span> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i236c04c5165044769887aa3cb89df57a_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-508" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTAtMy0xLTEtMTY2ODQ_4175bcd2-3ec5-4145-82c4-8c715c3b5485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonnumeric></span> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:fixed-zero" scale="-2" id="fact-identifier-509" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTItMS0xLTEtMTY2ODQ_c16aa3ba-19f2-4b30-bbef-06f52646e851" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-510" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTItMy0xLTEtMTY2ODQ_907dcfb8-8d8f-457a-9afe-3c3ffdb0257b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.47</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" format="ixt:fixed-zero" scale="-2" id="fact-identifier-511" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTMtMS0xLTEtMTY2ODQ_6b3d49f1-ec2a-44b2-8e28-76c8222d08b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-512" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmExNjRiOTc1YjJkMjRjZDlhYWQ3OGFmNWFiZWE1ZTNkL3RhYmxlcmFuZ2U6YTE2NGI5NzViMmQyNGNkOWFhZDc4YWY1YWJlYTVlM2RfMTMtMy0xLTEtMTY2ODQ_6ba360dc-f063-43b9-9c10-7145d7a4addf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.05</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Supplemental cash flow information and non-cash activity related to the Companys operating and finance leases are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:49.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-513" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfMi0xLTEtMS0xNjY4NA_77b530de-ff21-422a-911c-08e412df1be9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-514" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfMi0zLTEtMS0xNjY4NA_cae1879a-13bd-4631-afca-fd6865bc13b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">950</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="fact-identifier-515" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfMy0xLTEtMS0xNjY4NA_52b5b8cd-2d6a-4fdd-9197-dee03c565673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="fact-identifier-516" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfMy0zLTEtMS0xNjY4NA_6caca15d-55f8-4303-aebd-076639880947" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="fact-identifier-517" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfNC0xLTEtMS0xNjY4NA_0bf343ea-5e92-4d4c-8362-b7c2596353fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="fact-identifier-518" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl85Ny9mcmFnOjM3YTMwYjg4MThkMjQ0Mzc5Zjk1Yzg0NzYwZmQzNzc5L3RhYmxlOmFjOTcyNjcxYmUxMTRiYmI5ZGNjYzIzMGFlMzAwMGFmL3RhYmxlcmFuZ2U6YWM5NzI2NzFiZTExNGJiYjlkY2NjMjMwYWUzMDAwYWZfNC0zLTEtMS0xNjY4NA_df817b28-6775-440a-83a6-1a5ce8063f04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span></ix:continuation></span><div style="margin-bottom:13pt;margin-top:7pt;text-align:justify"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_103"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="fact-identifier-519" continuedat="i0d06ae8c0aae463dab8fecdbc871fbb3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzQyMzI_6e84195c-7593-4f20-a697-16d5ff1ef6f5" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">DEBT</ix:nonnumeric></span></span></div><span><ix:continuation id="i0d06ae8c0aae463dab8fecdbc871fbb3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Oxford Loan</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;21, 2017 (the Oxford Closing Date), the Company entered into a loan and security agreement (the Oxford Loan Agreement) with Oxford Finance LLC, pursuant to which the Company borrowed $<span><ix:nonfraction unitref="usd" contextref="i0e2813a3ee0e4e2f99d15c8285718655_I20171221" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-521" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzM4NDgyOTA3MDQyMjM_003024c7-4a6e-4545-831d-470e7238127a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35.0</ix:nonfraction></span>&nbsp;million in a single term loan (the Oxford Loan). On the Oxford Closing Date, the Company used approximately $<span><ix:nonfraction unitref="usd" contextref="if64d051bd51d4728a00d89379ea857ac_D20171221-20171221" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-522" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzM4NDgyOTA3MDQyNTI_ce1f85ee-9873-4fe4-b200-d2554499fdb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32.9</ix:nonfraction></span>&nbsp;million of the proceeds from the Oxford Loan to repay its indebtedness to a previous lender.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid expenses related to the Oxford Loan Agreement of $<span><ix:nonfraction unitref="usd" contextref="i46fd340b112349708dde16636df6e630_D20171221-20171221" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-523" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzMzNjU_bdf8f35b-0f56-42e2-b91b-432bfcc4b877" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million, which, along with the final facility charge of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i46fd340b112349708dde16636df6e630_D20171221-20171221" decimals="-5" name="blcm:DebtInstrumentFinalFacilityChargePayment" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-524" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzM0MTY_db3b4783-dd60-49b9-af59-5f8f5635ee8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span> million, were recorded as deferred issuance costs, which offset long-term debt on the Companys consolidated balance sheet. The deferred issuance costs were being amortized over the term of the loan as interest expense using the effective interest method. During the year ended December 31, 2020, interest expense&nbsp;included  $<span><ix:nonfraction unitref="usd" contextref="i779b010644c2422ab46cb955249d0ba0_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-525" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzM3NzE_f4f67abd-7ac2-4f2e-b6b0-a49fa101ecb2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span> million of amortized deferred issuance costs.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2020, the Company entered into an agreement for the early settlement of all debt obligations under the Oxford Loan Agreement. During the same month, the Company remitted payment of $<span><ix:nonfraction unitref="usd" contextref="id1f2c6a642de4c239e41f6c1faaee71f_D20201101-20201130" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-526" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzM5ODc_1758ea46-1f73-4bfc-863e-ebb4d387a49c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.4</ix:nonfraction></span>&nbsp;million, which included full repayment of the outstanding principal balance, the Oxford Final Payment Fee, and accrued interest. As of December 31, 2020, the Company recorded a gain on extinguishment of $<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-527" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDMvZnJhZzo0NWI4MjcwYjJiM2E0ZGZhYThjMTkyYTQyMjZlYjQxZS90ZXh0cmVnaW9uOjQ1YjgyNzBiMmIzYTRkZmFhOGMxOTJhNDIyNmViNDFlXzQxNjA_d2a8eb03-3363-45bc-b3c8-03bf09b8e783" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>&nbsp;million in the accompanying statements of operations and comprehensive loss.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_106"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE 5 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="fact-identifier-528" continuedat="ia27f4089dc8647de9c785d41a699e861" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzU1MjY_634233a0-6404-41b6-be30-ebba407c0328" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">PUBLIC OFFERING AND PRIVATE PLACEMENT</ix:nonnumeric></span></span></div><span><ix:continuation id="ia27f4089dc8647de9c785d41a699e861" continuedat="i3410566234df49b798577e6fc291e326" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2021 Private Placement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2021, the Company entered into a Securities Purchase Agreement (the 2021 Securities Purchase Agreement) with certain institutional investors (the Purchasers), pursuant to which the Company agreed to issue to the Purchasers 2021 pre-funded warrants to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="i1933ec3b38aa4fccacd6f69a9fa72567_I20211204" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-530" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTE4NzE_189bc658-408f-4560-88e8-b24e4e72c0dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,559,210</ix:nonfraction></span> shares of its common stock and accompanying 2021 common warrants to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="ice8621cd26cf4fdc9966ac003cf1f721_D20211204-20211204" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-531" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTE4ODM_bd86a7ad-c555-4d1c-83df-af40ca8f33ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,055,920</ix:nonfraction></span> shares of common stock. Each pre-funded warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i4670d1c5aa28403ca34a064c8e31781d_D20211204-20211204" decimals="INF" name="blcm:ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-532" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzkzNDU4NDg4NTc5MzQ_6e8e99ba-fb52-4421-8942-8fd52d8b7075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of common stock will be sold together with a warrant to purchase one-tenth of one share of common stock at a combined unit price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i1933ec3b38aa4fccacd6f69a9fa72567_I20211204" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-533" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTMwMDk_90c7fef6-cabb-49fb-9382-146c15ccba45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.7024</ix:nonfraction></span>. The pre-funded warrants will be immediately exercisable at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i1933ec3b38aa4fccacd6f69a9fa72567_I20211204" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-534" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTI5OTM_25fe12ff-0cf6-4978-b607-59cee67c1e57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span> per share of common stock. The accompanying common warrants will be immediately exercisable at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i1933ec3b38aa4fccacd6f69a9fa72567_I20211204" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-535" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTMwMDI_d0836dd0-6c3e-4b08-9f6a-9b5243188c8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.69</ix:nonfraction></span> per share of common stock and will expire <span><ix:nonnumeric contextref="ice8621cd26cf4fdc9966ac003cf1f721_D20211204-20211204" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-536" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTM2NjM_a119852c-1d75-4f25-a663-2a5979a1fd57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">seven years</ix:nonnumeric></span> from the date of issuance.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds to the Company from the private placement were approximately $<span><ix:nonfraction unitref="usd" contextref="ice8621cd26cf4fdc9966ac003cf1f721_D20211204-20211204" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-537" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NDgyOTA3MTM2ODA_bb5df52c-1a71-4aa6-b849-eb7a02e4d92b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35.0</ix:nonfraction></span>&nbsp;million before deducting placement agent commissions and offering expenses payable by the Company, excluding any proceeds that may be received upon exercise of the accompanying warrants.</span></div><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, pursuant to the 2021 Securities Purchase Agreement, certain of the Purchasers irrevocably waived the right to cause the Company to conduct the First Closing and Second Closing under the 2019 Securities Purchase Agreement (each term as defined in the 2019 Securities Purchase Agreement), which releases the Company of potential cash or equity obligations. The representations, warranties and covenants contained in the 2021 Securities Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">November 2020 Underwritten Offering</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2020, the Company closed an underwritten offering of <span><ix:nonfraction unitref="shares" contextref="i9082828cad6b4405a8d40811842239b4_I20201102" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-538" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE1Mw_8019efde-f4c3-45d6-8dcb-faf81584abe3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,040,000</ix:nonfraction></span> shares of its common stock, 2020 pre-funded warrants to purchase <span><ix:nonfraction unitref="shares" contextref="i9082828cad6b4405a8d40811842239b4_I20201102" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-539" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzIxNg_b814c3a1-ef97-4e7e-b1c5-9a183cad8c23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,109,378</ix:nonfraction></span> shares of its common stock, and accompanying 2020 common warrants to purchase up to an aggregate of <span><ix:nonfraction unitref="shares" contextref="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-540" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzMxNA_b8e66178-67ec-4290-9318-7ca44ce72ca0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,149,378</ix:nonfraction></span> shares of its common stock. Each share of common stock and pre-funded warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102" decimals="INF" name="blcm:ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-541" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzkzNDU4NDg4NTc5Njk_6728dce0-181f-47c1-9472-b8df53e6cde0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of common stock was sold together with a common warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102" decimals="INF" name="blcm:ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-542" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzkzNDU4NDg4NTc5Nzc_2b8146d9-d522-4450-acfc-dc0bed67db1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of common stock. The public offering price of each share of common stock and accompanying common warrant was $<span><ix:nonfraction unitref="usdPerShare" contextref="i98ea0b692bea4b2aad6645d7dc7fe076_D20201102-20201102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="fact-identifier-543" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzYwNA_6bc5e6b0-fff3-4250-8dda-7bfb4f9f21f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.025</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usdPerShare" contextref="ie6aef2c2186c4f2da748dd183f26a8eb_D20201102-20201102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="fact-identifier-544" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzYxMQ_784694fd-1826-4f1d-a794-e8b7343d7e74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.024</ix:nonfraction></span> for each pre-funded warrant. The pre-funded warrants were immediately exercisable at a price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9082828cad6b4405a8d40811842239b4_I20201102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-545" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzcxMA_f8544bfd-0310-4be6-b5b6-0ac0febb5a31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share of common stock. The common warrants were immediately exercisable at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9082828cad6b4405a8d40811842239b4_I20201102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-546" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzgxMw_f8f75eb9-5b6c-4067-985a-8c163da3feda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.50</ix:nonfraction></span> per share of common stock and will expire <span><ix:nonnumeric contextref="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-547" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzg1OA_2d27369b-bd4e-4bc7-931f-c6c1dc5c495d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five years</ix:nonnumeric></span> from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company were approximately $<span><ix:nonfraction unitref="usd" contextref="i47d397f06bb94c218c0a8ac000faf9bb_D20201102-20201102" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-548" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzExMDA_4e406c98-0a72-4ba1-a8ca-431263436566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span>&nbsp;million before deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Public Offering</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;16, 2019, the Company entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the Underwriters), relating to an underwritten public offering (the 2019 Offering) of <span><ix:nonfraction unitref="shares" contextref="if9ba5bd43a4f4124b8dc1624a7ec8aa1_D20190816-20190816" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-549" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE1MTc_e142a867-44b8-47bb-a8ff-0bc6f2754a20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">575,000</ix:nonfraction></span> shares of the Series&nbsp;1 Redeemable Convertible&nbsp;Non-Voting&nbsp;Preferred Stock of the Company (the Series&nbsp;1 Preferred Stock) and warrants (the 2019 Public Warrants) to purchase up to <span><ix:nonfraction unitref="shares" contextref="i382a6ed5a2094a409a6c38ff25e8b573_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-550" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE2OTY_5e26f4b0-bb7b-4d16-8968-03f4d4e07c25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,750,000</ix:nonfraction></span> shares of its common stock. Each share of Series&nbsp;1 Preferred Stock was sold together with a warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i637e568e11f54af08fb024dea2b251ab_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="fact-identifier-551" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE4MTc_475862e5-2199-480f-9f3e-de30548737c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> shares of common stock at a combined price to the public of $<span><ix:nonfraction unitref="usdPerShare" contextref="i382a6ed5a2094a409a6c38ff25e8b573_I20190816" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-552" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE4ODA_b3bec043-9df5-4418-9a46-1536676cb9f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.00</ix:nonfraction></span>. Under certain circumstances, each warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i637e568e11f54af08fb024dea2b251ab_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="fact-identifier-553" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzE5Mzg_476d630b-c415-4b83-9905-f987ddb75b8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> shares of common stock will be exercisable, at the irrevocable election of the holder, for one share of Series 1 Preferred Stock. The offering closed on August&nbsp;21, 2019, and the net proceeds to the Company from the Offering was approximately $<span><ix:nonfraction unitref="usd" contextref="icdd5d8e93865417f8b7913f3e4f8a9de_D20190821-20190821" decimals="-5" name="blcm:ProceedsFromPublicOffering" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-554" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzIxODM_acce70ca-5599-43c2-a0b1-ab07f63620e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">53.8</ix:nonfraction></span> million, after deducting underwriting discounts and commissions and offering expenses payable by the Company, and excluding any proceeds that the Company may receive upon exercise of the Public Warrants.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the 2019 Public Warrants sold in the 2019 Offering have an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i637e568e11f54af08fb024dea2b251ab_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-555" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzI0NTc_732712cb-263d-4d3a-a2d7-57bd80506d64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.00</ix:nonfraction></span> per share of common stock or, in certain circumstances, for $<span><ix:nonfraction unitref="usdPerShare" contextref="ib147d3c88f894b2dbefc3315da0f987e_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-556" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzI1MjA_e38b63c4-cded-495b-8bab-902d720672ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">130.00</ix:nonfraction></span> per share of Series 1 Preferred Stock, subject to proportional adjustments in the event of stock splits or combinations or similar events. The 2019 Public Warrants were immediately exercisable upon issuance, provided that the holder is prohibited, subject to certain exceptions, from exercising a warrant for shares of common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than <span><ix:nonfraction unitref="number" contextref="i713c3cce74c84a89861e978700f74605_I20190816" decimals="4" name="blcm:ClassofWarrantsorRightsLimitationsonOwnershipAfterExercise" scale="-2" id="fact-identifier-557" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzMwMjM_19df355f-64c0-4832-83fc-f732a620f131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9.99</ix:nonfraction></span>% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holders election to a lower percentage at any time or to a higher percentage not to exceed <span><ix:nonfraction unitref="number" contextref="i919b66337c4e44b7a245422d8aec0b2d_I20190816" decimals="4" name="blcm:ClassofWarrantsorRightsLimitationsonOwnershipAfterExercise" scale="-2" id="fact-identifier-558" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzMyMzI_ad5c0cca-5985-4acf-946b-fc05e8680af5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">19.99</ix:nonfraction></span>% upon <span><ix:nonnumeric contextref="i637e568e11f54af08fb024dea2b251ab_I20190816" name="blcm:ClassOfWarrantOrRightNoticePeriodForPercentageChange" format="ixt-sec:durday" id="fact-identifier-559" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzkzNDU4NDg4NTc5NjI_9b7b6ac1-79e9-409f-b135-0b9319b2a335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">61</ix:nonnumeric></span> days notice to the Company. The Public Warrants will expire on August&nbsp;21, 2026, unless exercised prior to that date</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ie275432f8db64efcb32498bb37320e1d" continuedat="ic480994fa33b4621952bfd00c75e589f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The following table reflects the fair value roll forward reconciliation of the 2019 Public Warrants liabilities for the period ended December 31, 2021:</ix:continuation></span></span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="i3410566234df49b798577e6fc291e326" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><ix:continuation id="ic480994fa33b4621952bfd00c75e589f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.345%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Derivative Liability</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie0959896ecc7431e959b752d3863f8d6_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-563" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTo5MjdlMzk3ZWNjNzQ0MzE5OTg4ZTJlZmQ4ZGQwZWU0MC90YWJsZXJhbmdlOjkyN2UzOTdlY2M3NDQzMTk5ODhlMmVmZDhkZDBlZTQwXzEtMS0xLTEtMjE3MzQ_63522221-893f-48ab-8592-8ce3e5d50000" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i1c4eb1cd202340b4bc735a8b464e862b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-564" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTo5MjdlMzk3ZWNjNzQ0MzE5OTg4ZTJlZmQ4ZGQwZWU0MC90YWJsZXJhbmdlOjkyN2UzOTdlY2M3NDQzMTk5ODhlMmVmZDhkZDBlZTQwXzItMS0xLTEtMjE3MzQ_851406f5-fd77-4c24-82b5-3f237d073645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,572</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5e00fcfd10ee4a5b99fdd49917102609_I20211231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-565" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTo5MjdlMzk3ZWNjNzQ0MzE5OTg4ZTJlZmQ4ZGQwZWU0MC90YWJsZXJhbmdlOjkyN2UzOTdlY2M3NDQzMTk5ODhlMmVmZDhkZDBlZTQwXzMtMS0xLTEtMjE3MzQ_ea8d9f39-2e33-4ce1-8518-2fd95e91a879" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Placement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;16, 2019, the Company entered into a securities purchase agreement (the 2019 Securities Purchase Agreement) with certain institutional investors named therein (the Purchasers), pursuant to which the Company agreed to issue in a private placement (i)&nbsp;<span><ix:nonfraction unitref="shares" contextref="i0893334e832a4c4c952688a563749369_D20190816-20190816" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-566" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM2NDA_49bc52d2-f2e4-484a-a26e-e850b2cb99b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">350,000</ix:nonfraction></span> shares of its Series&nbsp;2 Redeemable Convertible&nbsp;Non-Voting&nbsp;Preferred Stock (the Series&nbsp;2 Preferred Stock), at a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i2d6bd600428941e3bba159d84401718f_I20190816" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-567" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM3NzM_e5d823d8-cab4-44e4-81a2-178fde86e03f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.00</ix:nonfraction></span> per share, and related warrants to purchase up to <span><ix:nonfraction unitref="shares" contextref="i2d6bd600428941e3bba159d84401718f_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-568" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM4NTE_506258f3-18e0-4f7c-81af-af0d4ae84f8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,800,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i2d6bd600428941e3bba159d84401718f_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-569" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM5MDE_6a01e22c-aa3b-44e9-a4a0-246889dbea16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span> per share, and (ii)&nbsp;<span><ix:nonfraction unitref="shares" contextref="i49d16349f5874275a7532fef1b358c0c_D20190816-20190816" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-570" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzM5MjQ_910e2fd2-b82e-4dfa-a7cd-cc83f2130b72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span> shares of its Series 3 Redeemable Convertible&nbsp;Non-Voting&nbsp;Preferred Stock (the Series 3 Preferred Stock and, together with the Series&nbsp;1 Preferred Stock and Series 2 Preferred Stock, the Preferred Stock), at a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i20dbd00730a8427da42a70ff8a5695bd_I20190816" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-571" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzQxNTc_322110a4-d1f5-4692-bd5e-d29a823b3dd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140.00</ix:nonfraction></span> per share, and related warrants to purchase up to <span><ix:nonfraction unitref="shares" contextref="i20dbd00730a8427da42a70ff8a5695bd_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-572" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzQyMzc_146ad80c-7be8-4d1c-ac3c-50015a8bde64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">875,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i20dbd00730a8427da42a70ff8a5695bd_I20190816" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-573" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzQyODc_0398e3d1-238a-44d0-843e-f2f8e4ab97d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.00</ix:nonfraction></span> per share. The right of the Purchasers to purchase such securities was waived, effective as of December 4, 2021, pursuant to the 2021 Purchase Agreement.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<span><ix:nonfraction unitref="usd" contextref="i5d8309509e674155b9d4f0c57e5668c3_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-574" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzUxMjQ_fa7633e3-9f98-4d21-b0ea-28574686bd1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span> million in net option fee proceeds, net of offering costs, upon the execution of the 2019 Securities Purchase Agreement. Pursuant to the 2021 Securities Purchase Agreement entered into on December 4, 2021, the Company derecognized the private placement option liability, and the Company is no longer obligated to issue the Series 2 Preferred Stock, Series 3 Preferred Stock, or any associated Private Warrants.</span></div><div style="text-align:justify"><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="fact-identifier-575" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90ZXh0cmVnaW9uOjMxYjc2MTZlOWYyZDQxN2RiZGZkNjBlZjE5MWY4ODNkXzkzNDU4NDg4NTc5Njg_b5f6e229-deb6-424d-b622-2d9d96aa6ff2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrants outstanding and exercisable as of December 31, 2021 is as follows:</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Issued</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(per share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-576" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzMtMS0xLTEtMjM0MzU_8ba6c994-018d-4ca4-8a14-3bad6d28c347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,750,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="fact-identifier-577" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzMtMi0xLTEtMjM0MzU_abcc5929-80d3-4cc5-bd89-85ded7e5b984" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.64</ix:nonnumeric></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="fact-identifier-578" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzMtMy0xLTEtMjM0MzU_20f81629-5f8e-4f79-85a2-e42cbfcd1bc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-579" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzMtNS0xLTEtMjM0MzU_08efb37b-bdc3-4757-aa9b-c6eeade0e0b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,750,000</ix:nonfraction></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i4d9f724d863843d88aaf40cda0dc6f8c_I20211231" decimals="2" name="blcm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" id="fact-identifier-580" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzMtNi0xLTEtMjM0MzU_ac49a758-1cbc-46e9-b47d-3ad198b8a122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i38e11c30f7584f0dbd95e510b96aef8a_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-581" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzQtMS0xLTEtMjM0MzU_fec52bd8-ad50-49f1-9c14-a1e810e433d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,149,378</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i38e11c30f7584f0dbd95e510b96aef8a_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="fact-identifier-582" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzQtMi0xLTEtMjM0MzU_49d2b719-af62-4125-bd36-23ccac490619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.84</ix:nonnumeric></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i38e11c30f7584f0dbd95e510b96aef8a_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="fact-identifier-583" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzQtMy0xLTEtMjM0MzU_f8c528a4-e019-4bd0-9c1b-690520ac77fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.50</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i38e11c30f7584f0dbd95e510b96aef8a_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-584" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzQtNS0xLTEtMjM0MzU_e8772d63-fd37-4f5d-a73b-ff0c0a79b93f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,149,378</ix:nonfraction></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i38e11c30f7584f0dbd95e510b96aef8a_I20211231" decimals="2" name="blcm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" id="fact-identifier-585" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzQtNi0xLTEtMjM0MzU_eab4cb1c-9ac4-4419-b3cb-05d10a13781c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.50</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i036f43da78cd4d5a9a447a47f85acaf6_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-586" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzUtMS0xLTEtMjM0MzU_dd4e6572-fec7-48eb-9d65-67462baf32c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,716,702</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i036f43da78cd4d5a9a447a47f85acaf6_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:fixed-zero" id="fact-identifier-587" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzUtMy0xLTEtMjM0MzU_865cfc6c-b84a-4d43-8554-e5c91f75a32f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i036f43da78cd4d5a9a447a47f85acaf6_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-588" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzUtNS0xLTEtMjM0MzU_d41ffba1-b254-49ce-b4f7-c058ecad4d1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,716,702</ix:nonfraction></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i036f43da78cd4d5a9a447a47f85acaf6_I20211231" decimals="2" name="blcm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" format="ixt:fixed-zero" id="fact-identifier-589" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzUtNi0xLTEtMjM0MzU_fba83636-14be-47f0-a308-b3eb8c551d77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-590" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzYtMS0xLTEtMjM0MzU_2cfa91f4-991d-4a23-ab9b-e668716c722d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,055,920</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="fact-identifier-591" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzYtMi0xLTEtMjM0MzU_811cb4f4-a3c8-4e56-bbbf-41ae4f172788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.94</ix:nonnumeric></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="fact-identifier-592" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzYtMy0xLTEtMjM0MzU_fe0adaed-e434-45a2-8926-f672c56df70c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.69</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-593" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzYtNS0xLTEtMjM0MzU_ae612cfb-fbce-44b3-83d6-cac719a87fed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,055,920</ix:nonfraction></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ia985f98d2ad24e7dbc516abdcfb640f8_I20211231" decimals="2" name="blcm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" id="fact-identifier-594" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzYtNi0xLTEtMjM0MzU_0c0f8715-173b-4456-bc8a-186c5404d9e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.69</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if0a2e56672544f4d9720011d110ec46e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-595" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzctMS0xLTEtMjM0MzU_7c070aa1-fc81-4ccf-8788-68bda955b4b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,559,210</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="if0a2e56672544f4d9720011d110ec46e_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:fixed-zero" id="fact-identifier-596" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzctMy0xLTEtMjM0MzU_854d3994-e772-4d12-b9ab-c2c8b0d23534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if0a2e56672544f4d9720011d110ec46e_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-597" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzctNS0xLTEtMjM0MzU_92026498-889b-4f90-b25b-3063a1afdf91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,559,210</ix:nonfraction></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="if0a2e56672544f4d9720011d110ec46e_I20211231" decimals="2" name="blcm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" format="ixt:fixed-zero" id="fact-identifier-598" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzctNi0xLTEtMjM0MzU_ba658735-cb9c-47b8-a132-37d59b6b62c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="fact-identifier-599" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzgtMS0xLTEtMjM0MzU_6d084de8-e5d0-4f8c-ac40-b2997f4bf756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,231,210</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="blcm:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" id="fact-identifier-600" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMDYvZnJhZzozMWI3NjE2ZTlmMmQ0MTdkYmRmZDYwZWYxOTFmODgzZC90YWJsZTpmZjM1ZThkNjk3ZTI0ZTRlODM4MDJiMWIyNTJlNDUxYi90YWJsZXJhbmdlOmZmMzVlOGQ2OTdlMjRlNGU4MzgwMmIxYjI1MmU0NTFiXzgtNS0xLTEtMjM0MzU_b5b547cc-1508-44b3-8763-d535e42ae065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">34,231,210</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE 6 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:ConvertibleRedeemablePreferredStockTextBlock" id="fact-identifier-601" continuedat="i78d1c037b4884cd4a9cfe9e22e9bd5c4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQ3Mzc_a786062b-86a6-4bb8-9902-ae0000616e63" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">REDEEMABLE CONVERTIBLE PREFERRED STOCK</ix:nonnumeric></span></span></div><span><ix:continuation id="i78d1c037b4884cd4a9cfe9e22e9bd5c4" continuedat="i6249f70a6a284cb6b036cac60fb9c1ba" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, the Company sold Series 1 Preferred Stock pursuant to the 2019 Offering. The Company has <span><ix:nonfraction unitref="shares" contextref="i9ccaf58778004b12a0b950fb7ac915bc_I20190831" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-603" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzE1Mw_498895e3-4202-4321-9544-d246512a2d61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span> authorized shares of preferred stock with a par value of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9ccaf58778004b12a0b950fb7ac915bc_I20190831" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-604" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzIxMw_2144e236-2871-4c01-8b96-b05b816fdfd1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span>, of which the Company has designated <span><ix:nonfraction unitref="shares" contextref="i31d0f94167d6416480140728dba0a23b_I20190831" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-605" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzI1Mw_faa2eb9c-76fb-4aad-99d3-2fd27db36184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,517,500</ix:nonfraction></span> shares as Series 1 redeemable convertible non-voting preferred stock, <span><ix:nonfraction unitref="shares" contextref="if439c35e57f84f8198941723e0bb891e_D20190801-20190831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-606" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzMyNg_9d25cd6d-8482-4939-8544-205af91f78a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">350,000</ix:nonfraction></span> shares as Series 2 redeemable convertible non-voting preferred stock and <span><ix:nonfraction unitref="shares" contextref="ifa898288c1094519b1b2a863aebd2629_D20190801-20190831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-607" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQwMg_c82dd9ad-9fc8-49cf-b63e-8bd754c73741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span> shares as Series 3 redeemable convertible non-voting preferred stock.  There were <span><ix:nonfraction unitref="shares" contextref="i162a4a2602074271bd15a1bff826ea96_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-608" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQ4Nw_9b2b5266-d010-4e28-b0bb-1993f9850554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i6ec2cb72cd6c4787a50a1c0b755892f9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-609" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQ4Nw_9c174810-55dd-4667-b70c-a4e38c5ea5a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i6ec2cb72cd6c4787a50a1c0b755892f9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-610" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQ4Nw_af996ea5-2478-4cc0-96ff-9e1355263d09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i162a4a2602074271bd15a1bff826ea96_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-611" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzQ4Nw_dae6b093-da31-4d69-83c6-ffe54cea0f1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,000</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> shares of Series 1 Preferred Stock issued and outstanding as of both December 31, 2021 and 2020. There were <span><ix:nonfraction unitref="shares" contextref="i1322c0bf879f4b78ab0cd5d18b363cb6_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-612" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0NjY_219ffa5d-fc9e-450e-bc4d-47b7eee03f43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i1322c0bf879f4b78ab0cd5d18b363cb6_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-613" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0NjY_69942d09-6fa5-4ed0-bcfd-176a6b1fa983" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i741ac74c96474994908a43a0dd00cbe5_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-614" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0NjY_e324e79d-dd55-4db6-a0c5-4f5f6421caae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i741ac74c96474994908a43a0dd00cbe5_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-615" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0NjY_f1c02916-56b6-4625-a4f1-dcb805ff54e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> shares of Series 2 or 3 Preferred Stock issued or outstanding as of December 31, 2020, and the Series 2 and 3 Preferred Stock were cancelled during 2021 pursuant to the 2021 Securities Purchase Agreement. The Series 1 Preferred Stock was issued together with warrants for a combined purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="icdf8f1df9f314548bbe07dc3661f75f8_I20190831" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-616" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzc4Mw_e7b0d432-5610-4eb7-8daa-e49cceed0c74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.00</ix:nonfraction></span> per share of Series 1 Preferred Stock and one warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i31d0f94167d6416480140728dba0a23b_I20190831" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="fact-identifier-617" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzg1Mg_553fe291-aaf0-4684-8c73-e75dbc5059b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> shares of common stock. There were <span><ix:nonfraction unitref="shares" contextref="i3fd3938d544841399a920cc75b84c1f6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-618" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkyNg_5a0f11cd-72c8-4c6e-b5d5-3de52de4bf37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">86,000</ix:nonfraction></span> shares of Series 1 Preferred Stock converted to common stock as of December 31, 2020, while <span><ix:nonfraction unitref="shares" contextref="if42cd2bebc534723abfd2794b121dd10_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="fact-identifier-619" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0NzQ_326b9326-dc8b-4381-9c3d-c079fd7500a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> shares were converted during 2021.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company classified the Series 1 preferred stock within mezzanine equity, as the Series 1 preferred stock is redeemable at the option of the holders upon passage of time, which is outside of the Companys control to prevent.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series 1 Preferred Stock is not currently redeemable and is only redeemable upon a fundamental change at a redemption price. The Company does not believe a fundamental change is considered probable until it occurs. Subsequent adjustment of the amount presented within mezzanine equity to its redemption amount is unnecessary if it is not probable that the instrument will become redeemable. As (i) the Series 1 Preferred Stock is only redeemable upon a fundamental change, the occurrence of which is not </span></div></ix:continuation></span><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The pre-funded warrants issued on November 2, 2020 do not have an expiration date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The pre-funded warrants issued on December 7, 2021 do not have an expiration date.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="i6249f70a6a284cb6b036cac60fb9c1ba" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable, and (ii) the occurrence of Transition Date (defined below) is probable, the Company did not accrete the Series 1 Preferred Stock to its redemption amount.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optional Conversion</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Preferred Stock is initially convertible into <span><ix:nonfraction unitref="shares" contextref="i162a4a2602074271bd15a1bff826ea96_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="fact-identifier-621" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzIwMTI_20a069fd-27ae-42b3-b569-a20b95d3f8da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> shares of Common Stock. The conversion price at which Preferred Stock may be converted into shares of common stock is subject to adjustment in connection with certain specified events.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the applicable Transition Date (defined below), at any time on or after the date that is the fifth (5th) anniversary of the initial issue date of the applicable series of preferred stock, all or any portion of the preferred stock is redeemable at the option of the holder at a redemption price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i162a4a2602074271bd15a1bff826ea96_I20211231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-622" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzI1MTc_47bc8023-39a3-4880-83d6-3a606004c5e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.00</ix:nonfraction></span> per share (for Series 1 Preferred Stock).&nbsp; The Transition Date means the first date following August 21, 2021, on which each of the Conditions (as defined below) is met.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Conditions mean: (1)&nbsp;the closing price of the Companys common stock has been equal to or exceeded $<span><ix:nonfraction unitref="usdPerShare" contextref="i162a4a2602074271bd15a1bff826ea96_I20211231" decimals="INF" name="blcm:CommonStockRedemptionRequirementClosingPriceMinimumPerShare" scale="0" id="fact-identifier-623" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzMzMTg_cd58f334-ea68-4621-9617-1bced28f38a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25.00</ix:nonfraction></span>&nbsp;per share for <span><ix:nonnumeric contextref="if42cd2bebc534723abfd2794b121dd10_D20210101-20211231" name="blcm:CommonStockRedemptionRequirementClosingPriceThresholdPeriod" format="ixt-sec:durday" id="fact-identifier-624" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM1MDI_9071811b-bcd8-484b-ba63-0557cd2a6ff1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonnumeric></span> calendar days (for determining if the Conditions are met for the Series 1 Preferred Stock) for <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:CommonStockRedemptionRequirementClosingPriceThresholdPeriod" format="ixt-sec:durday" id="fact-identifier-625" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0ODU_ebebb18d-a102-4d53-aa79-a300e550160c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonnumeric></span> calendar days; (2)&nbsp;the&nbsp;<span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="blcm:CommonStockRedemptionAverageTradingVolumePeriod" format="ixt-sec:durday" id="fact-identifier-626" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzkzNDU4NDg4NDM0OTQ_162c44b7-9f57-4294-a024-a7d40f42cf9a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonnumeric></span>-day&nbsp;average trading volume of the Companys common stock on the Nasdaq stock market is greater than <span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="blcm:CommonStockRedemption50DayAverageTradingVolumeShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-627" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTIvZnJhZzowN2U4ZjhlZmMzMDc0ODUyYjA0MTUxNmJlNjE2Mjg1YS90ZXh0cmVnaW9uOjA3ZThmOGVmYzMwNzQ4NTJiMDQxNTE2YmU2MTYyODVhXzM2NDU_9a329519-7b04-440e-8605-d6a99b015dda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000</ix:nonfraction></span> shares; and (3)&nbsp;a Phase 3 or Phase 2 pivotal clinical trial for one of the Companys CAR-T product candidates has been initiated, meaning that at least one clinical trial site has been activated.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Preferred Stock will be entitled to receive dividends equal to (on&nbsp;an&nbsp;as-if-converted-to-common&nbsp;stock&nbsp;basis), and in the same form and manner as, dividends actually paid on shares of common stock.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the applicable Transition Date, in the event of a liquidation, dissolution, winding up or deemed liquidation, holders of the Preferred Stock will receive a payment equal to the applicable per share purchase price of their Preferred Stock before any proceeds are distributed to the holders of Common Stock. The liquidation preferences, protective voting provisions and redemption rights of the Preferred Stock will terminate upon the occurrence of certain events.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Preferred Stock will generally have no voting rights, except to the extent expressly provided in the Companys certificate of incorporation or as otherwise required by law.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_115"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="fact-identifier-628" continuedat="i9e8c5e5eccb941a2af33461e2ce62419" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDM_a48882bc-407e-432a-8f34-83e4705f69f5" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SHARE-BASED COMPENSATION PLANS</ix:nonnumeric></span></span></div><div><span><br></span></div><span><ix:continuation id="i9e8c5e5eccb941a2af33461e2ce62419" continuedat="ie858147025a74334994f6ba3ac581d20" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has&nbsp;<span><ix:nonfraction unitref="plan" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="blcm:NumberofSharebasedCompensationPlans" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-630" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzEyOTQ_27700ecd-6736-4b3f-bd2f-566d058b3710" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">five</ix:nonfraction></span>&nbsp;share-based compensation plans, including the 2019 Equity Incentive Plan the (2019 Plan) which was adopted in June 2019.  Each plan authorizes the granting of shares of common stock and/or options to purchase common stock to employees and directors of the Company, as well as non-employee consultants, and allows the holder of the option to purchase common stock at a stated exercise price. The only plan under which the Company may currently grant equity awards is the 2019 Equity Incentive Plan although there remain outstanding awards under the other four plans. Options vest according to the terms of the grant, which may be immediately or based on the passage of time, generally over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzM4NDgyOTA3MDcwMTk_a17e1c62-af41-44b8-899c-87995b64e5c6"><span><ix:nonnumeric contextref="i1c15b69bc95943e99465b595082081eb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="fact-identifier-631" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzM4NDgyOTA3MDcwMTk_a17e1c62-af41-44b8-899c-87995b64e5c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">two</ix:nonnumeric></span></span> to&nbsp;<span><ix:nonnumeric contextref="i8015dbb7c1574fcba04a45a6e113ddd0_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="fact-identifier-632" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzE5ODU_6b8c6f3e-1a77-4c07-864c-1e326d901dcd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four years</ix:nonnumeric></span>, and have a term of up to&nbsp;<span><ix:nonnumeric contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="fact-identifier-633" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzIwMTQ_6a179c7b-fd1a-4990-8ae7-d59b4b723b8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonnumeric></span> years. Unexercised stock options terminate on the expiration date of the grant. The Company recognizes the share-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period.</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019 Equity Incentive Plan</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The 2019 Plan, is designed to secure and retain the services of the Companys employees and directors. The 2019 Plan is successor to and continuation of the 2014 Equity Incentive Plan, as amended, the (2014 Plan), and no additional awards may be issued from the 2014 Plan. Subject to adjustment for certain changes in the Companys capitalization, the aggregate number of shares of common stock that may be issued under the 2019 Plan (the "Share Reserve") will not exceed the sum of (i) <span><ix:nonfraction unitref="shares" contextref="i06813ca5a85147509b9b8c6443b909f4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-634" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzI3NzQ_857e1ffe-2e50-42e4-838e-f37d73990d47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span> new shares, plus (ii) an additional <span><ix:nonfraction unitref="shares" contextref="ib51fd5ec5af4430f978c4e71af75c33f_D20200101-20200131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-635" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzI4MTM_91fe7384-86e1-4a23-9e88-b464049d3f68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">600,000</ix:nonfraction></span> shares that were approved at the Companys Special Meeting of Stockholders in January 2020, plus (iii)&nbsp;an additional <span><ix:nonfraction unitref="shares" contextref="i7d02271004464836a18b9b40a78284ce_D20200601-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-636" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzI5Mzc_fab5b9c8-012b-40a3-87fd-37ad291f289f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span> shares that were approved at the Companys Annual meeting of Stockholders in June 2020, (iv) an additional <span><ix:nonfraction unitref="shares" contextref="i69a898e7a0584ba28886035348e44ad7_D20210601-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-637" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzM4NDgyOTA3MDcyNDc_4443ed07-1f7a-40aa-aaa7-afc188bf557f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span> shares that were approved at the Companys Annual Meeting of Stockholders in June 2021 and plus (v) the Prior Plans Returning Shares, as defined in the 2019 Plan documents, in an amount not to exceed <span><ix:nonfraction unitref="shares" contextref="ibd00764da8f34e98a98f83a0dab746dd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-638" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzMxNDM_3356f541-b60c-4ae0-8222-2c5f04adde38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">600,540</ix:nonfraction></span> shares, including any stock award granted under the 2014 Plan, 2011 Stock Option Plan, as amended, or 2006 Stock Option Plan, as amended, that were outstanding as of the date the 2019 Plan were approved by the Companys stockholders, as such shares become available from time to time.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following shares of common stock (the 2019 Plan Returning Shares) will also become available again for issuance under the 2019 Plan: (i)&nbsp;any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award is settled in cash; and (iii)&nbsp;any shares issued pursuant to a stock award granted under the 2019 Plan that are forfeited back to or repurchased by the Company because of a failure to vest.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock awards.</span></div><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="fact-identifier-639" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDc_bc226e1c-7462-49b7-8078-b667335ba922" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, outstanding awards were comprised of the following:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.750%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ifcbf9a3391e948e48670553130152f59_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-640" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzEtMS0xLTEtMTY2ODQ_e7f27b97-8ab8-47fe-bc9f-59b1baf82329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,074,858</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31c45a21c3d0472ab6ea23a4f224cfbc_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-641" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzEtMi0xLTEtMTY2ODQ_55921bb2-fb5b-44dd-beb7-2eeb17390d0f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,425,207</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement option awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icd51add8d0a94eeaa9c011e415bbac4a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-642" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzItMS0xLTEtMTY2ODQ_6e6cd4ad-775a-4aac-86e2-5dd0fc6545ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,760</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i530c634326904ca2a7f8ffa95df1bbd8_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-643" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzItMi0xLTEtMTY2ODQ_3afe5ac8-1f60-4e6c-9c25-8735ad287ac1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,761</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9831a006f77b4237af44fc5389d816f0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-644" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzMtMS0xLTEtMTY2ODQ_429a16a6-15c6-4f80-9884-676b3f723ff4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,004</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i1febabe6349142acb0a8f83cf9916ba9_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-645" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzMtMi0xLTEtMTY2ODQ_cf878810-ef2c-4818-ae7c-9352ec231f37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129,361</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i179edf8ed8864615a3d50b23fcd54cc1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="fact-identifier-646" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzQtMS0xLTEtMTY2ODQ_74c31dd5-66ae-4a85-92e4-5c87ffc2d563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ifa2202e685554aa7b28f5aff7494df0a_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="fact-identifier-647" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzQtMi0xLTEtMTY2ODQ_28acc177-c10b-4483-8508-51732c5f8b41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding awards</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i06813ca5a85147509b9b8c6443b909f4_I20211231" decimals="INF" name="blcm:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-648" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzUtMS0xLTEtMTY2ODQ_8e382b14-ed2c-401f-9cd0-4a120a8ae99d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,278,122</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icd89d8fbf2c2419cb132f0458660da5c_I20201231" decimals="INF" name="blcm:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-649" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmOTE1YTlmYzhlYjA0ZjM3YTY2YzRmODc3NWM5YTA2Zi90YWJsZXJhbmdlOmY5MTVhOWZjOGViMDRmMzdhNjZjNGY4Nzc1YzlhMDZmXzUtMi0xLTEtMTY2ODQ_492d4618-26f6-4e99-9ef7-23fb1c7f6f0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,640,829</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the share-based compensation awards is a significant accounting estimate that requires the use of judgments and assumptions that are likely to have a material impact on the financial statements. The fair value of option grants is determined using the Black-Scholes option-pricing model. Expected volatilities utilized in the model are based on historical volatility of the Companys common stock. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term is calculated as the midpoint between the weighted-average vesting term and the contractual expiration period also known as the simplified method.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="ie858147025a74334994f6ba3ac581d20" continuedat="i8a072b9f70254b51af8c99ffd09d2425" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="fact-identifier-651" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDA_9c4741e0-cb0d-414c-824b-2a7b086dddfe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the option grants has been estimated, with the following weighted-average assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-652" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzItMi0xLTEtMTY2ODQ_064b01f9-9906-4050-9d7d-1d415e8de642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,023,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-653" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzItNC0xLTEtMTY2ODQ_718d3a5c-efd2-4ba6-80a6-164356714a16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,352,595</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i74121680cdef41be8bf7bf100d5a65ef_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="fact-identifier-654" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzMtMi0xLTEtMTY2ODQ_90333536-da0b-45bd-96d6-3d319c083384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.80</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i2b9884a3e5eb4975a054f6c2b8dcaea5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="fact-identifier-655" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzMtNC0xLTEtMTY2ODQ_d79a083d-2d89-4e04-874b-4b715d269724" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.59</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-656" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzQtMi0xLTEtMTY2ODQ_6c17f453-52ff-4482-93e2-55d4487cbe78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.02</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-657" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzQtNC0xLTEtMTY2ODQ_06c7c8ba-1765-4a27-81c6-459e78d4c1d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-658" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzYtMi0xLTEtMTY2ODQ_9526175a-36f7-4864-8276-4e1f74d10e59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.92</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-659" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzYtNC0xLTEtMTY2ODQ_df50ec3e-f6e8-42e1-b228-8e966a62ae15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.82</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-660" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzctMi0xLTEtMTY2ODQ_a02628ef-39c2-40e9-865c-fd870cb0f1ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-661" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzctNC0xLTEtMTY2ODQ_2c38cdbe-4fac-4171-bfa7-36018d8efc29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-662" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzgtMi0xLTEtMTY2ODQ_646e723c-a77f-48e1-bf0c-6c190de56f09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.63</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-663" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzgtNC0xLTEtMTY2ODQ_c90ef197-4c2b-49ad-b7f2-a83fb5788234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.83</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="idf5532c48b3042409e8f6b4f458b93cd_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-664" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzktMi0xLTEtMTY2ODQ_d6333cd1-4a38-47ef-9bad-1385d4c0e08c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4540f64cd8a44cfc844aeb5274e5792d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-665" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTplYThhMWQ1Yjk5MTU0NTAxOTQ2MzlhZGY1Yjk2OGZkNS90YWJsZXJhbmdlOmVhOGExZDViOTkxNTQ1MDE5NDYzOWFkZjViOTY4ZmQ1XzktNC0xLTEtMTY2ODQ_0820a8f6-b71d-4eb5-9369-860d5fcf7cd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation Activity</span></div><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="fact-identifier-666" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDU_5625d089-8b38-4e4f-8e5f-f55354f71b0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for all stock plans during the year ended December 31, 2021 and 2020 as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ieae66221f10e47949897a952036d7680_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-667" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEtMi0xLTEtMTY2ODQ_6d2317e9-ebab-46c1-bc55-6b2c1be10ee7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">567,842</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ieae66221f10e47949897a952036d7680_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-668" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEtNC0xLTEtMTY2ODQ_8c24fa7e-3c78-42dd-b99a-68f09733cdb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76.25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d8309509e674155b9d4f0c57e5668c3_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-669" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEtNi0xLTEtMTY2ODQ_a9781a75-3c6f-4781-8dec-4e8ca0dd449c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.82</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieae66221f10e47949897a952036d7680_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-670" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEtOC0xLTEtMTY2ODQ_24c2a9d9-2d20-45ff-bfaa-364421cb705f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-671" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzItMi0xLTEtMTY2ODQ_040f36b1-97bd-4290-9dc7-a2584cb88386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,352,595</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-672" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzItNC0xLTEtMTY2ODQ_b1413cdb-7db6-4de7-9e92-ce058f86f6ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.59</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="fact-identifier-673" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzMtMi0xLTEtMTY2ODQ_e5661fad-78e8-41a3-9824-f2b483e5f098" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span><ix:nonfraction unitref="usdPerShare" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-674" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzMtNC0xLTEtMTY2ODQ_aaeb543c-d961-425d-8ad2-3f7c172cc53b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-675" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzQtMi0xLTEtMTY2ODQ_7b89f558-6b1c-43e2-89c5-c5714d21b8a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">409,469</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-676" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzQtNC0xLTEtMTY2ODQ_3a60b8c2-db74-4751-ac77-ed1795e40892" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29.86</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-677" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzUtMi0xLTEtMTY2ODQ_2f8da143-85cd-4c36-b423-cfe50a6f9e72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,510,968</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-678" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzUtNC0xLTEtMTY2ODQ_b0bbc9de-a0b8-44cd-81fe-4ab22e5f5150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.36</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-679" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzUtNi0xLTEtMTY2ODQ_b33070c1-a926-49cd-867b-a89260497011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.19</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-680" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzUtOC0xLTEtMTY2ODQ_bbff6337-bafc-4570-a477-6e6a4aa310e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">379</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-681" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzYtMi0xLTEtMTY2ODQ_ea983f8b-7170-4479-bbfe-190afd14713a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,023,000</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-682" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzYtNC0xLTEtMTY2ODQ_02f551e8-5df7-4f23-8a63-0b66abd2e682" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.80</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="fact-identifier-683" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzctMi0xLTEtMTY2ODQ_394fb942-8df9-4511-ae23-ccca6cc9d09e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span><ix:nonfraction unitref="usdPerShare" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-684" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzctNC0xLTEtMTY2ODQ_48911e72-c273-40a7-9c8d-089f75296313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-685" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzgtMi0xLTEtMTY2ODQ_f0214baa-a5a2-4508-ae47-94df21d1b085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">393,350</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-686" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzgtNC0xLTEtMTY2ODQ_34fe96ee-49cd-4831-9052-a84b57eb8f65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30.66</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-687" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzktMi0xLTEtMTY2ODQ_2324db9a-cab0-427c-954b-8ebeacbf6223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,140,618</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-688" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzktNC0xLTEtMTY2ODQ_c6faec4e-36cc-4d26-ae36-7f22da9a3d37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.01</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-689" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzktNi0xLTEtMTY2ODQ_7f254614-9a85-49f3-ac02-83630224bcfc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.48</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-690" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzktOC0xLTEtMTY2ODQ_6b8af7c7-2850-4b4d-a527-acdadb608fbc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-691" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEwLTItMS0xLTE2Njg0_7c6ee549-9ef3-4ac1-a618-8d1c5572f25b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">718,123</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-692" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEwLTQtMS0xLTE2Njg0_118d0cff-5472-4c35-b66f-0d4b9b08a9f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36.42</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-693" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEwLTYtMS0xLTE2Njg0_bbe1df08-0967-4e4c-b9db-28b4ca602b4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.98</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-694" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpmZTJhY2MyNDA0Mzg0NzZlYWEzMDkzNGRiMjM5YmI5MC90YWJsZXJhbmdlOmZlMmFjYzI0MDQzODQ3NmVhYTMwOTM0ZGIyMzliYjkwXzEwLTgtMS0xLTE2Njg0_2e5cc358-58e0-4c62-a462-ac4218a5e9a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="fact-identifier-695" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzkzNDU4NDg4NDY2OTM_582a7c50-25c0-4a24-a445-ab31036d91b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> options exercised or cash received for the year ended December&nbsp;31, 2021; the Company received cash of less than $<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-5" name="blcm:ProceedsFromStockOptionsExercisedLessThanAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-696" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzkzNDU4NDg4NDY2ODA_43dca501-2520-498d-9d7c-eacc6cb94c79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>&nbsp;million upon option exercises for year ended December&nbsp;31, 2020.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="i8a072b9f70254b51af8c99ffd09d2425" continuedat="ib730ca20db154764ba6b8ca0c85946e1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="fact-identifier-698" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMTA_a15cdea0-9393-4be5-823e-618247e3a93e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the options outstanding and exercisable at December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Exercisable</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i470cd8b3357a46c09250fbdf29b03991_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="fact-identifier-699" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjphOGI5ZmEwMzhkNTQ0OTNmYTIwY2U0YzE0NzFjN2IyOV80_9ca31ca0-2e18-4dec-8db5-522cffa54c17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.73</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i470cd8b3357a46c09250fbdf29b03991_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="fact-identifier-700" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjphOGI5ZmEwMzhkNTQ0OTNmYTIwY2U0YzE0NzFjN2IyOV8xMA_bd0dd133-d4c5-4654-915b-4d38ad38657d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.87</ix:nonfraction></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0a57fe3b57954d4c83f03d8769a5af5b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-701" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItMi0xLTEtMTY2ODQ_eb950db9-7e0d-44c9-9446-e73d09c0dfac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">215,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i470cd8b3357a46c09250fbdf29b03991_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-702" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItNC0xLTEtMTY2ODQ_237c4103-7ab9-4d0e-9a0f-7b466cbc2249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.89</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0a57fe3b57954d4c83f03d8769a5af5b_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-703" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItNi0xLTEtMTY2ODQ_a39ab049-d0af-4b85-81f9-b440277e870f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.81</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0a57fe3b57954d4c83f03d8769a5af5b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="0" id="fact-identifier-704" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItOC0xLTEtMTY2ODQ_22b09bfb-38cd-4ffa-b6d0-9337ccd46790" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i470cd8b3357a46c09250fbdf29b03991_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-705" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItMTAtMS0xLTE2Njg0_975dab35-c3fc-447f-9374-56fa0daf5495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0a57fe3b57954d4c83f03d8769a5af5b_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:fixed-zero" scale="0" id="fact-identifier-706" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzItMTItMS0xLTE2Njg0_7add3651-0173-4866-81d1-6d2c46265a3f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i321a29f91052497988a21cbd5d4abe98_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="fact-identifier-707" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjplNDJjNjMwN2U2YWQ0NzVjYTk1MmY0MWEwNzQ5NTkxMl80_0c163419-8db9-42b8-a053-94b1cc636173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.88</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i321a29f91052497988a21cbd5d4abe98_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="fact-identifier-708" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjplNDJjNjMwN2U2YWQ0NzVjYTk1MmY0MWEwNzQ5NTkxMl8xMA_bbe1fa45-1191-487c-b7d6-5e9448e60d53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.93</ix:nonfraction></span></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i71368a124d1f420287367ea7de54c757_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-709" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtMi0xLTEtMTY2ODQ_ef26ffad-1c03-4cf9-b1f1-7973c50ae822" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">665,000</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i321a29f91052497988a21cbd5d4abe98_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-710" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtNC0xLTEtMTY2ODQ_3eca2a36-eea8-432b-a4e3-228be84cb861" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.62</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i71368a124d1f420287367ea7de54c757_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-711" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtNi0xLTEtMTY2ODQ_0a86064f-0c8b-4bbd-bf05-fd30cc0f2b5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.88</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i71368a124d1f420287367ea7de54c757_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="0" id="fact-identifier-712" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtOC0xLTEtMTY2ODQ_06507a3c-9eec-4437-bce2-c5ca0a822bad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i321a29f91052497988a21cbd5d4abe98_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-713" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtMTAtMS0xLTE2Njg0_5ec9b814-3fc7-4fa6-802a-1b323f48817b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i71368a124d1f420287367ea7de54c757_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:fixed-zero" scale="0" id="fact-identifier-714" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzMtMTItMS0xLTE2Njg0_76c59a40-1ff2-437b-9ab5-e8513b19901c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i58f1d90f3233446581331846a4699635_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="fact-identifier-715" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkNmRjZjFhZDc5NWY0N2JmODYwZWRlODdhODk5MzczOF80_a4d7d0a9-250b-47a5-bc40-c122c478a4a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.94</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i58f1d90f3233446581331846a4699635_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="fact-identifier-716" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkNmRjZjFhZDc5NWY0N2JmODYwZWRlODdhODk5MzczOF8xMA_7812f603-3935-49de-a8cc-df1301943ef2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.01</ix:nonfraction></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2ec28ce16ad543e2bf23db163827b093_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-717" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtMi0xLTEtMTY2ODQ_632ee9ed-bae1-462b-96b2-dd76087329a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">506,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i58f1d90f3233446581331846a4699635_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-718" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtNC0xLTEtMTY2ODQ_7fe8f6a0-b816-4952-835b-e56092f58a90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.95</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i2ec28ce16ad543e2bf23db163827b093_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-719" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtNi0xLTEtMTY2ODQ_54923d92-eeca-4810-bf04-5143a45f480d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.97</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2ec28ce16ad543e2bf23db163827b093_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-720" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtOC0xLTEtMTY2ODQ_6748d471-7e9c-4e65-9391-cec826dff0fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">253,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i58f1d90f3233446581331846a4699635_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-721" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtMTAtMS0xLTE2Njg0_62559348-7e0a-47a8-9fed-d02ad5e05a20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.95</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i2ec28ce16ad543e2bf23db163827b093_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="fact-identifier-722" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzQtMTItMS0xLTE2Njg0_3b024b5c-074e-4388-b2b3-fd98168387d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.97</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ibee826079f8e4f15bdce1faa3872a89b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="fact-identifier-723" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo1YWI5MjA1MTU4M2U0OTA1ODYxMzI5ZWI3NDBlZmVmMF80_e6a16521-8e3c-44a3-93e8-b8f431513dce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.02</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="ibee826079f8e4f15bdce1faa3872a89b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="fact-identifier-724" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjo1YWI5MjA1MTU4M2U0OTA1ODYxMzI5ZWI3NDBlZmVmMF8xMA_8b4e9dcc-f64f-431b-8b4c-980ec8650ad3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.15</ix:nonfraction></span></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id2d02bf18ec4491188894537f5978a65_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-725" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtMi0xLTEtMTY2ODQ_45d4a4c1-2460-4e30-9353-e4c38b34d542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">475,076</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ibee826079f8e4f15bdce1faa3872a89b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-726" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtNC0xLTEtMTY2ODQ_3e0b1834-79fa-44cc-a662-7eb75a952223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.32</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id2d02bf18ec4491188894537f5978a65_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-727" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtNi0xLTEtMTY2ODQ_14632599-2398-4587-b692-0f6daad8a67c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.97</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id2d02bf18ec4491188894537f5978a65_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-728" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtOC0xLTEtMTY2ODQ_f6749b7b-65b9-4ae5-a35a-7ec307bfec71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">207,374</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ibee826079f8e4f15bdce1faa3872a89b_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-729" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtMTAtMS0xLTE2Njg0_3cf9ea48-6acd-497a-a4af-03a1b3f4c389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.15</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id2d02bf18ec4491188894537f5978a65_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="fact-identifier-730" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzUtMTItMS0xLTE2Njg0_d8c64495-51d2-4c9e-b62a-4c16cb6ef361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.97</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4159706212924c2db71ce2e3fecb58db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="fact-identifier-731" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkODA5YWNiNWJlZDc0ZmRlOGUyNzE4ZjQzOWYxOGVhMV80_72083005-9bcf-44d4-9204-5d0b685d8a01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.16</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i4159706212924c2db71ce2e3fecb58db_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="fact-identifier-732" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtMC0xLTEtMTY2ODQvdGV4dHJlZ2lvbjpkODA5YWNiNWJlZDc0ZmRlOGUyNzE4ZjQzOWYxOGVhMV8xMA_c5c1444a-fa99-49de-bb43-47bd80434b41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">234.70</ix:nonfraction></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i055b3841f68346ef8dadf5be51362c5c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-733" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtMi0xLTEtMTY2ODQ_752c27bc-ece5-4298-8173-76412b9ec220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">279,542</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4159706212924c2db71ce2e3fecb58db_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-734" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtNC0xLTEtMTY2ODQ_4a0b3cf8-1d97-483d-8c37-210255055974" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.82</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i055b3841f68346ef8dadf5be51362c5c_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-735" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtNi0xLTEtMTY2ODQ_89dd835f-936f-452a-ad86-89ad869b32ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84.39</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i055b3841f68346ef8dadf5be51362c5c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-736" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtOC0xLTEtMTY2ODQ_77a25e61-3c58-4367-ab26-6c201d09809d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,749</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4159706212924c2db71ce2e3fecb58db_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-737" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtMTAtMS0xLTE2Njg0_10f5ffd5-8d95-403a-97b0-0bbc69b6bd4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.71</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i055b3841f68346ef8dadf5be51362c5c_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="fact-identifier-738" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzYtMTItMS0xLTE2Njg0_ee4ad629-405f-4e5f-b084-68c36c3a429f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88.94</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-739" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctMi0xLTEtMTY2ODQ_5c2c1208-9054-41fb-8969-d4f08abd39d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,140,618</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-740" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctNC0xLTEtMTY2ODQ_da8bc541-fea5-44c6-a39c-1ada8cf672dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.48</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="fact-identifier-741" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctNi0xLTEtMTY2ODQ_404779ce-4763-4eb4-aeb7-796be3c88322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.01</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-742" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctOC0xLTEtMTY2ODQ_8eb90a17-e9fc-434b-ba62-ca4a9cc08761" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">718,123</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-743" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctMTAtMS0xLTE2Njg0_fe46717b-4d14-4cbe-9979-2c7c0095e11d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.98</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="fact-identifier-744" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo1YTc2MDRlNmI2MmY0MDJiODZkYmQ2MmNlZjdhM2IwZS90YWJsZXJhbmdlOjVhNzYwNGU2YjYyZjQwMmI4NmRiZDYyY2VmN2EzYjBlXzctMTItMS0xLTE2Njg0_2c81ccf2-ced1-4c55-aa99-d3ad1cef081d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36.42</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock" id="fact-identifier-745" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDE_1f86c8a8-a4c7-458f-bb76-a97438c1ae07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table summarizes the stock award activity for all restricted stock units during the year ended December 31, 2021:</span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Restricted Stock Awards and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Fair Value of Restricted Awards Vested (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="idefb4e4db80f469dabd2ece3778621d1_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-746" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzEtMi0xLTEtMTY2ODQ_1d7e78ad-3a70-4fbd-b319-c836168d9f54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,359</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="idefb4e4db80f469dabd2ece3778621d1_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-747" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzEtNC0xLTEtMTY2ODQ_ddadb9e0-1003-481e-9510-75e9861cdba7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92.29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idefb4e4db80f469dabd2ece3778621d1_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="fact-identifier-748" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzEtNi0xLTEtMTY2ODQ_69a1a4fa-2165-4278-a6cd-39d2a97bc7c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-749" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzItMi0xLTEtMTY2ODQ_b491b5ba-7578-4b6c-9530-0afbabe19e7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">239,023</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-750" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzItNC0xLTEtMTY2ODQ_016b8732-6e76-49ac-9e8a-d397e628c344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.70</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-751" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzMtMi0xLTEtMTY2ODQ_65d31064-019c-48da-af84-28d9add18f11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,309</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-752" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzMtNC0xLTEtMTY2ODQ_9a6a9b46-b43b-403e-a0e9-24ae564808ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">96.14</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="3" id="fact-identifier-753" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzMtNi0xLTEtMTY2ODQ_7a81c43e-a623-425b-a63e-3cb5ac36317e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="fact-identifier-754" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzMtOC0xLTEtMTY2ODQ_b024c357-01b7-4fab-95d1-230332a5dec7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">222</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-755" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzQtMi0xLTEtMTY2ODQ_316f818f-1482-41bc-bd41-1af975187536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,212</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5064785f80634863b0f4c9c2673da546_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-756" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzQtNC0xLTEtMTY2ODQ_cf90e985-3794-4ba7-9be5-2f7f295772da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.73</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i62438e1ebbc54cda81f31f2e249e5cc4_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-757" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzUtMi0xLTEtMTY2ODQ_ef8dd070-c57e-477e-a912-aea20ea40687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129,861</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i62438e1ebbc54cda81f31f2e249e5cc4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-758" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzUtNC0xLTEtMTY2ODQ_9a373c30-8e9c-4835-a122-2bea8bb11246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.59</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i62438e1ebbc54cda81f31f2e249e5cc4_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="fact-identifier-759" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzUtNi0xLTEtMTY2ODQ_1c98b776-0437-4c16-8229-98dfb746ef9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">458</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-760" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzYtMi0xLTEtMTY2ODQ_fbc159ae-8c1e-4489-8102-d01740ad2099" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136,626</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-761" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzYtNC0xLTEtMTY2ODQ_fd215ac6-5313-46e1-a85b-521942d896f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.54</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-762" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzctMi0xLTEtMTY2ODQ_7a5efdf1-b4c8-4258-8cb3-fda1d17d7d7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">126,477</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-763" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzctNC0xLTEtMTY2ODQ_3cfa0839-d363-4a9a-b1ac-034393d4f55d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.05</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="3" id="fact-identifier-764" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzctNi0xLTEtMTY2ODQ_fd7de906-4bde-4671-b520-88dbe4e58aa9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">413</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="fact-identifier-765" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzctOC0xLTEtMTY2ODQ_7228fca7-3a15-4a75-84ab-7f02bc05ccd7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">659</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-766" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzgtMi0xLTEtMTY2ODQ_4e95916f-ab14-41ae-88d5-343cc3655ab6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,506</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5948a95daefa4444a028a32b389dd760_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-767" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzgtNC0xLTEtMTY2ODQ_b7fb8284-8615-4de5-b051-bb7b158fed69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.85</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9837e2de40444a3da4cc7744f165c7fd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-768" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzktMi0xLTEtMTY2ODQ_4f07ecb2-1669-41dc-ba48-3631235df7d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,504</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i9837e2de40444a3da4cc7744f165c7fd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-769" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzktNC0xLTEtMTY2ODQ_ab7e40c0-d317-4b2b-8f5a-4aaa82ead045" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.06</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9837e2de40444a3da4cc7744f165c7fd_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="fact-identifier-770" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo4YjM3Njc2NDRiYTA0YmE0YTY0NjMyODk2NGVkNWEzYi90YWJsZXJhbmdlOjhiMzc2NzY0NGJhMDRiYTRhNjQ2MzI4OTY0ZWQ1YTNiXzktNi0xLTEtMTY2ODQ_a6392c1a-2584-4c50-b1ee-5245e93b5e0d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">205</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">2014 Employee Stock Purchase Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The 2014 Employee Stock Purchase Plan, the ESPP, provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase the Companys common stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to <span><ix:nonfraction unitref="shares" contextref="i00b53d27909f47cbab2d407eeb884583_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-771" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzY0NjY_ad3143e1-15fb-4297-b15f-26806a637892" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,000</ix:nonfraction></span> shares of the Companys common stock to participating employees and allows eligible employees to purchase shares of common stock at a <span><ix:nonfraction unitref="number" contextref="i6bd2fa016ad5485bb7b1576710652c92_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="fact-identifier-772" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzY2MDM_a8d84513-7a90-4bfb-b508-e0a92a6b7cf1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>% discount from the lesser of the grant date or purchase date fair market value. For the year ended December 31, 2020, there were <span><ix:nonfraction unitref="shares" contextref="idbf131eb73fd45b19f335f6d7c85f619_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-773" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzY1OTcwNjk3NzU2MzQ_2ad4f9e3-0b65-420c-b170-b7fc090ed5e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,975</ix:nonfraction></span> shares purchased by employees under the ESPP. The ESPP has been suspended since December 2020. As of December 31, 2021, there were <span><ix:nonfraction unitref="shares" contextref="i00b53d27909f47cbab2d407eeb884583_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-774" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzY1OTcwNjk3NzY1MTY_1a4e04d9-555c-450c-b7b4-688f975bc444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,488</ix:nonfraction></span> shares available for issuance under the ESPP.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="fact-identifier-775" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMDI_82cc0b86-1b5f-4ce0-b68b-b5370747c1fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity within the ESPP follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands except share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6bd2fa016ad5485bb7b1576710652c92_D20210101-20211231" decimals="-3" name="blcm:EmployeeStockPurchasePlanCashContributions" format="ixt:fixed-zero" scale="3" id="fact-identifier-776" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzItMi0xLTEtMTY2ODQ_3c61524b-a909-4d43-ad94-866a19571936" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idbf131eb73fd45b19f335f6d7c85f619_D20200101-20201231" decimals="-3" name="blcm:EmployeeStockPurchasePlanCashContributions" scale="3" id="fact-identifier-777" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzItNC0xLTEtMTY2ODQ_6b662aef-952f-47fb-bb35-e0a9b3de6ad6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">56</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6bd2fa016ad5485bb7b1576710652c92_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="fact-identifier-778" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzMtMi0xLTEtMTY2ODQ_eef76b16-b561-4f53-8772-55cbcace5a79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idbf131eb73fd45b19f335f6d7c85f619_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-779" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzMtNC0xLTEtMTY2ODQ_a2ebdd4e-1bc9-4d36-b3cf-99041f89fe2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">96</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds received by the Company for ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6bd2fa016ad5485bb7b1576710652c92_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="fact-identifier-780" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzUtMi0xLTEtMTY2ODQ_dd8e2c28-420a-4d5a-b22f-644ecdb5259b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idbf131eb73fd45b19f335f6d7c85f619_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="fact-identifier-781" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzUtNC0xLTEtMTY2ODQ_c42f9b1c-0438-4137-9704-a0782a7b6a87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average purchase price per common share </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i00b53d27909f47cbab2d407eeb884583_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" format="ixt:fixed-zero" scale="0" id="fact-identifier-782" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzYtMi0xLTEtMTY2ODQ_ba5c0e41-802e-4a8f-be78-4e587715eee5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5577f5996ca64249bfb81900a55916d2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="fact-identifier-783" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTo2YjI1ZTRiODAzZDY0NDJiYjFkMTJjMDQ1ZDA2MWYzNC90YWJsZXJhbmdlOjZiMjVlNGI4MDNkNjQ0MmJiMWQxMmMwNDVkMDYxZjM0XzYtNC0xLTEtMTY2ODQ_a6be6653-e27f-4960-bacb-9255ae90d779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.21</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="margin-top:3pt"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="ib730ca20db154764ba6b8ca0c85946e1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">Share-Based Compensation Expense</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="fact-identifier-785" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcyMTE_3cb40420-7780-4932-85d4-31aad45ea8c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Share-based compensation expense by classification for December 31, 2021 and 2020 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ifd8242ed350741b8bf827bd154cc8de6_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-786" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzItMi0xLTEtMTY2ODQ_c0097743-60b8-474b-861a-4806d1b07403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,275</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i081fe2a72cb64249bb7119c9e82e2a6e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-787" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzItNC0xLTEtMTY2ODQ_fb56fc05-d372-4ff5-a96b-97c1d8f55018" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,170</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if1c7fe4824dc40a385728be9a468220f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-788" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzMtMi0xLTEtMTY2ODQ_a0f5247c-bd2d-4115-99c5-260cbb8d62d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,164</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaebebeee6aed41b6a12ed261796cc1ab_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-789" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzMtNC0xLTEtMTY2ODQ_b556e076-ce3f-4944-92f2-a3bd1d7ec55d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,861</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-790" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzQtMi0xLTEtMTY2ODQ_dea2174d-bb55-4ace-8eec-5eb6fe35f7db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,439</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-791" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90YWJsZTpkNjM0Y2M4ZDA0YjU0ZTljOGVkNTJlZjRlMTg5Y2JiMS90YWJsZXJhbmdlOmQ2MzRjYzhkMDRiNTRlOWM4ZWQ1MmVmNGUxODljYmIxXzQtNC0xLTEtMTY2ODQ_88bfbfe4-7d38-4cd4-a5e4-e461625938ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,031</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, total compensation cost not yet recognized was $<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-792" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzY5ODE_71974e3c-ce9f-4511-98fe-1323720166cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.2</ix:nonfraction></span> million and the weighted-average period over which this amount is expected to be recognized is <span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="fact-identifier-793" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcwNzE_701bd798-5b1f-4203-8ba6-f1c7953d0d8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.52</ix:nonnumeric></span> years.  The aggregate fair value of options and restricted shares vesting in the years ended December 31, 2021 and 2020 was&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-794" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcxNzU_272a6cbb-fec3-4e8d-8ca1-d04cf485731a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.3</ix:nonfraction></span> million&nbsp;and&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-795" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTUvZnJhZzoxYmNiNjA4YTRjZmI0ZjA5ODI2NDZlZGQ5YjJlYTkxZi90ZXh0cmVnaW9uOjFiY2I2MDhhNGNmYjRmMDk4MjY0NmVkZDliMmVhOTFmXzcxODI_961949ec-34e7-4b8a-ae27-45d14b04535d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.8</ix:nonfraction></span> million, respectively.</span></div></ix:continuation></span><div style="margin-top:6pt"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="fact-identifier-796" continuedat="i739921d1b56c43fbb7171b1e5d89d224" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzExNDAz_c1ed522c-f6c9-42a1-a2e6-34941803b71e" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">COMMITMENTS AND CONTINGENCIES</ix:nonnumeric></span></span></div><div style="text-align:justify"><span><br></span></div><span><ix:continuation id="i739921d1b56c43fbb7171b1e5d89d224" continuedat="ibbe46c8882374a9797af6e2342857543" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development and Co-Commercialization Agreement - Adaptimmune Therapeutics plc</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2016, the Company entered into a Co-Development and Co-Commercialization Agreement with and Adaptimmune Therapeutics plc (Adaptimmune) in order to facilitate a staged collaboration to evaluate, develop and commercialize next generation T cell therapies. Under the Agreement, the parties agreed to evaluate the Companys GoTCR technology (inducible MyD88/CD40 co-stimulation, or iMC) with Adaptimmunes affinity-optimized SPEAR T cells for the potential to create enhanced TCR product candidates. Depending on results of the preclinical proof-of-concept phase, the parties expect to progress to a two-target co-development and co-commercialization phase. To the extent necessary, and in furtherance of the parties proof-of-concept and co-development efforts, the parties granted each other a royalty-free, non-transferable, non-exclusive license covering their respective technologies for purposes of facilitating such proof-of-concept and co-development efforts. In addition, as to covered therapies developed under the agreement, the parties granted each other a reciprocal exclusive license for the commercialization of such therapies. With respect to any joint commercialization of a covered therapy, the parties agreed to negotiate in good faith the commercially reasonable terms of a co-commercialization agreement. The parties also agreed that any such agreement shall provide for, among other things, equal sharing of the costs of any such joint commercialization and the calculation of profit shares as set forth in the Agreement. The Agreement will expire on a country-by-country basis once the parties cease commercialization of the T cell therapies covered by the Agreement, unless earlier terminated by either party for material breach, non-performance or cessation of development, bankruptcy/insolvency, or failure to progress to co-development phase. </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - Baylor</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2008, 2010, 2014 and 2016, the Company and Baylor College of Medicine (BCM) entered into license agreements pursuant to which the Company obtained exclusive rights to certain technologies and patent rights owned by BCM.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2014 license agreement, the Company is required to pay BCM a low annual maintenance fee on each anniversary of the agreement date. The Company is also required to make royalty payments in the low single digits, subject to certain annual minimums, on net sales of products covered by the license and, to the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is also required to pay BCM a percentage in the low double-digits on all non-royalty income received from sublicensing revenue.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the second quarter of 2021, the Company determined that $<span><ix:nonfraction unitref="usd" contextref="ie6c97dd59b684f59ae717bfca06c038a_D20190101-20191231" decimals="-5" name="blcm:SublicenseExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-798" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM4NDgyOTA3MTA3MjI_3cfeefaa-4d23-4849-bb1b-92173fec1b2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.6</ix:nonfraction></span>&nbsp;million of sublicense expense was incurred in 2019 through 2020 related to the Companys obligation to pay BCM a percentage of sublicense revenue earned by the Company under the 2014 license agreement. Management evaluated the impact of the adjustment and determined that the amount was immaterial to the consolidated financial statements for the current year and prior years. As such, the entire amount of $<span><ix:nonfraction unitref="usd" contextref="ia6bbc842116f4dadb9175bdacc0aeb63_D20210401-20210630" decimals="-5" name="blcm:SublicenseExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-799" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM4NDgyOTA3MTA3MDg_93c01a27-b734-4ea3-bda5-b24affe381f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.6</ix:nonfraction></span>&nbsp;million was recorded during the second quarter in 2021. During the third quarter of 2021, the Company earned additional sublicense revenue and, therefore, recorded additional sublicense expense of $<span><ix:nonfraction unitref="usd" contextref="i4490bf4fd09f4f5e83e18a46e04d0ec0_D20210701-20210930" decimals="-5" name="blcm:SublicenseExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-800" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM4NDgyOTA3MTA2OTQ_0d8972f8-2b84-4c42-95e0-00a027ff4e8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span>&nbsp;million.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - Agensys, Inc.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;10, 2015, the Company and Agensys, Inc. (Agensys), entered into a license agreement (the Agensys Agreement), pursuant to which (i)&nbsp;Agensys granted the Company, within the field of cell and gene therapy of diseases in humans, an exclusive, worldwide license and sublicense to its patent rights directed to prostate stem cell antigen 1 (PSCA) and related antibodies, and </span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="ibbe46c8882374a9797af6e2342857543" continuedat="i8a1b8110758b41f88e98085993a9ed71" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&nbsp;the Company granted Agensys a non-exclusive, fully paid license to the Companys patents directed to inventions that were made by the Company in the course of developing the Companys licensed products, solely for use with Agensys therapeutic products containing a soluble antibody that binds to PSCA or, to the extent not based upon the Companys other proprietary technology, to non-therapeutic applications of antibodies not used within the field. As consideration for the rights granted to the Company under the Agreement, the Company agreed to pay to Agensys a non-refundable upfront fee of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:LicenseCostsforRightsGrantedUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-802" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM2MDk_e8ac9d14-94f1-436d-9eb0-f673663f00c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span> million, which was included in license fee expense. The Company is also required to make aggregate milestone payments to Agensys of up to (i)&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:MilestonePaymentsforFirstLicensedProducts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-803" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM3NDY_e4af0f96-3fa4-4f0c-a260-230d9aa4e63e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5</ix:nonfraction></span> million&nbsp;upon the first achievement of certain specified clinical milestones for its licensed products, (ii)&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:MilestonePaymentsForEachLicensedProductAchievementOfClinicalMilestones" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-804" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM4NDk_48d66a43-af6a-4d2c-aabe-ce25536150a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span> million&nbsp;upon the achievement of certain specified clinical milestones for each licensed product, and (iii)&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:MilestonePaymentsForEachLicensedProductAchievementOfSalesMilestones" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-805" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzM5NTE_f52a3740-5fd6-46d2-81c9-581cc409c25a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75</ix:nonfraction></span> million&nbsp;upon the achievement of certain sales milestones for each licensed product. The Agreement additionally provides that the Company will pay to Agensys a royalty that ranges from the mid to high single digits based on the level of annual net sales of licensed products by the Company, its affiliates or permitted sublicensees. The royalty payments are subject to reduction under specified circumstances. These milestone and royalty payments will be expensed as incurred. Under the Agreement, Agensys also was granted the option to obtain an exclusive license, on a product-by-product basis, from the Company to commercialize in Japan each licensed product developed under the Agensys Agreement that has completed a phase 2 clinical trial. As to each such licensed product, if Agensys or its affiliate, Astellas Pharma, Inc., exercises the option, the Agensys Agreement provides that the Company will be paid an option exercise fee of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:LicenseAgreementExclusiveLicenseOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-806" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzQ4ODU_4812b27b-2e5f-4db4-ba1d-b9f5bdf039fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5</ix:nonfraction></span> million. In addition, the Agensys Agreement provides that the Company will be paid a royalty that ranges from the mid to high single digits based on the level of annual net sales in Japan of each such licensed product. If the option is exercised, the aggregate milestone payments payable by the Company to Agensys, described above with respect to each licensed product, would be reduced by up to an aggregate of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" decimals="INF" name="blcm:LicenseAgreementExclusiveLicenseOptionExercisedMaximumReductionInAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-807" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzUyOTI_578537c4-7c99-478e-a449-6da90bdc56ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65</ix:nonfraction></span> million&nbsp;upon the achievement of certain specified clinical and sales milestones. The Agensys Agreement will terminate upon the expiration of the last royalty term for the products covered by the Agensys Agreement, which is the earlier of (i)&nbsp;the date of expiration or abandonment of the last valid claim within the licensed patent rights covering any licensed products under the Agreement, (ii)&nbsp;the expiration of regulatory exclusivity as to a licensed product, and (iii)&nbsp;<span><ix:nonnumeric contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" name="blcm:LicenseAgreementTerminationPeriodAfterFirstCommercialSaleOfLicensedProduct" format="ixt-sec:duryear" id="fact-identifier-808" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzU3NTk_be880033-7b12-4894-9d9a-fc6e449c6a38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonnumeric></span> years&nbsp;after the first commercial sale of a licensed product. Either party may terminate the Agensys Agreement upon a material breach by the other party that remains uncured following&nbsp;<span><ix:nonnumeric contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" name="blcm:LicenseAgreementPeriodofNoticeofFailureonUncuredItems" format="ixt-sec:durday" id="fact-identifier-809" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzU5Mzk_46d71cdc-1317-4f7e-845b-3e5647c53508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60</ix:nonnumeric></span> days&nbsp;after the date of written notice of such breach (or&nbsp;<span><ix:nonnumeric contextref="ib492ce478a0c49ddb7dbdbef18efcba0_D20151210-20151210" name="blcm:LicenseAgreementPeriodOfNoticeOfFailureOnUncuredItemsFailureToMakePayments" format="ixt-sec:durday" id="fact-identifier-810" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzU5OTQ_188bbdbd-deb4-47cf-b243-3672ca083f47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days&nbsp;if such material breach is related to failure to make payment of amounts due under the Agensys Agreement) or upon certain insolvency events. In addition, Agensys may terminate the Agensys Agreement immediately upon written notice to the Company if the Company or any of its affiliates or permitted sublicensees&nbsp;commences an interference proceeding or challenges the validity or enforceability of any of Agensys patent rights. </span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - BioVec</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2015, the Company and BioVec Pharma, Inc. (BioVec) entered into a license agreement (the BioVec Agreement) pursuant to which BioVec agreed to supply the Company with certain proprietary cell lines and granted to the Company a non-exclusive, worldwide license to certain of its patent rights and related know-how related to such proprietary cell lines. As consideration for the products supplied and rights granted to the Company under the BioVec Agreement, the Company agreed to pay to BioVec an upfront fee of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:LicenseCostsforRightsGrantedUnderAgreement" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-811" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzY5ODE_caddb25d-6c60-4e28-971c-74bdaaae99c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span>&nbsp;within&nbsp;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzY5OTE_632c5823-5f58-4cb2-b266-e4f4f5e012c1"><span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementUpfrontFeePeriod" id="fact-identifier-812" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzY5OTE_632c5823-5f58-4cb2-b266-e4f4f5e012c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">ten</ix:nonnumeric></span></span>&nbsp;business days of the effective date of the BioVec Agreement and a fee of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:LicenseCostsDueUponFirstReleaseofProduct" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-813" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcwNjc_54ab5136-586c-4104-a33a-b100373a0e30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300,000</ix:nonfraction></span>&nbsp;within&nbsp;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcwNzc_e759e84a-050d-439c-80a0-b78dabfbc676"><span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementFirstReleaseFeePeriod" id="fact-identifier-814" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcwNzc_e759e84a-050d-439c-80a0-b78dabfbc676" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">ten</ix:nonnumeric></span></span>&nbsp;business days of its receipt of the first release of GMP lot of the products licensed under the BioVec Agreement. In addition, the Company agreed to pay to BioVec an annual fee of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:LicenseAgreementAnnualFee" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-815" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcyNjA_cf93441e-8fc0-4adf-9734-f462734f1d67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span>, commencing&nbsp;<span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementAnnualFeePeriodFromFirstINDFiling" format="ixt-sec:durday" id="fact-identifier-816" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzcyNzU_3d515bac-4eff-44be-b9b1-c25c83863533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days&nbsp;following the first filing of an Investigational New Drug Application (an IND filing), or its foreign equivalent, for a product covered by the license; with such annual fees being creditable against any royalties payable by the Company to BioVec under the BioVec Agreement. The Company also is required to make a&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:MilestonePaymentsforFirstLicensedProducts" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-817" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzc1OTE_c9d9d372-1054-433d-9427-157945968d8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">250,000</ix:nonfraction></span>&nbsp;milestone payment to BioVec for each of the first&nbsp;<span><ix:nonfraction unitref="product" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:MilestonePaymentsNumberOfInitialProducts" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-818" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzc2NDQ_1aa111be-8bde-43ad-96e3-6175c0aee75e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span>&nbsp;licensed products to enter into a clinical phase trial and one-time milestone payments of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:LicenseAgreementMilestonePaymentsuponRegistrationwithFDA" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-819" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzc3Mzc_d4564106-633c-4051-86a2-cb36542c0be9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span> million&nbsp;upon receipt of a registration granted by the Federal Drug Administration or European Medicines Agency on each of the Companys first&nbsp;<span><ix:nonfraction unitref="product" contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" decimals="INF" name="blcm:MilestonePaymentsNumberOfInitialProducts" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-820" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzc4NzQ_348a4f2d-8f9c-461e-a8d3-396a21440fef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span>&nbsp;licensed products. The BioVec Agreement additionally provides that the Company will pay to BioVec a royalty in the low single digits on net sales of products covered by the BioVec Agreement. The Company may also grant sublicensees under the licensed patent rights and know-how to third parties for limited purposes related to the use, sale and other exploitation of the products licensed under the BioVec Agreement. The BioVec Agreement will continue until terminated. The BioVec Agreement may be terminated by the Company, in its sole discretion, at any time upon&nbsp;<span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementTerminationNotice" format="ixt-sec:durday" id="fact-identifier-821" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzg0NDI_36490532-ee45-410b-9347-3fed687a0f1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">90</ix:nonnumeric></span> days written notice to BioVec. Either party may terminate the BioVec Agreement in the event of a breach by the other party of any material provision of the BioVec Agreement that remains uncured on the date that is&nbsp;<span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementPeriodofNoticeofFailureonUncuredItems" format="ixt-sec:durday" id="fact-identifier-822" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzg2NTQ_12488264-ef58-415a-b0c9-0222e5c0cae9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60</ix:nonnumeric></span> days&nbsp;after written notice of such failure or upon certain insolvency events that remain uncured following the date that is&nbsp;<span><ix:nonnumeric contextref="i850e911b14374e8896439c73c6dd8959_D20150610-20150610" name="blcm:LicenseAgreementPeriodafterInsolvencyEvent" format="ixt-sec:durday" id="fact-identifier-823" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMTgvZnJhZzo3Y2JiMjQ1ODk0N2U0NzRhYjliZmYxNTY3NzczN2E2ZS90ZXh0cmVnaW9uOjdjYmIyNDU4OTQ3ZTQ3NGFiOWJmZjE1Njc3NzM3YTZlXzg3NzU_0b60c7a3-ce0f-4211-bdf8-c770ce3b2bb7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days&nbsp;after the date of written notice to a party regarding such insolvency event. </span></div><div><span><br></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2019, Bellicum was served with a second amended complaint indicating that the Company had been added as an additional defendant in an ongoing civil tort lawsuit, captioned Kelly v. Childrens Hospital of Los Angeles et al., filed in the Los Angeles County Superior Court, Case No. BC681477. On July 10, 2019 plaintiffs filed a third amended complaint seeking unspecified monetary damages including punitive damages and alleging claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability - failure to warn, breach of express warranty and products liability design or manufacturing defect.  Bellicum filed a demurrer and motion to strike plaintiffs third amended </span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i8a1b8110758b41f88e98085993a9ed71" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">complaint, which were granted in part on August 5, 2020 with the Court dismissing (without prejudice) all claims against Bellicum with the exception of the breach of express warranty and products liability design or manufacturing defect causes of action.  The Court also granted Bellicums motion to strike plaintiffs claim for punitive damages.  On September 15, 2020, plaintiffs filed a fourth amended complaint alleging the same causes of action and damages against Bellicum as were pled in the third amended complaint.  On November 3, 2020, Bellicum filed a demurrer and motion to strike the fourth amended complaint, which is not currently set for hearing but will be rescheduled pursuant to a further order from the court.</ix:continuation></span></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="fact-identifier-825" continuedat="i57dc395af01b4c37a86014a7b4ea8570" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzIwMDA_fd7eff93-116a-4d8e-933b-087856199cd8" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">INCOME TAXES</ix:nonnumeric></span></span></div><span><ix:continuation id="i57dc395af01b4c37a86014a7b4ea8570" continuedat="i1481af908008454ca0cdea78a0bcfa4e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="fact-identifier-827" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzIwMDE_7211b19b-5a3f-4a3e-a298-dd98f52585fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between federal income taxes at the statutory U.S. federal income tax rate and the Companys income tax expense for the year is as follows: &nbsp;</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:61.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-828" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzEtMi0xLTEtMTY2ODQ_042d08c9-8545-4cc8-8220-f8797dad05ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,038</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-829" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzEtNC0xLTEtMTY2ODQ_101aa25b-edb0-4f77-b71f-ba3033f28826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,658</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="fact-identifier-830" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzItMi0xLTEtMTY2ODQ_f4d65886-2a34-47a3-b78c-e3ff3edb5f8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="fact-identifier-831" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzItNC0xLTEtMTY2ODQ_c0a6d48d-f1aa-4789-9166-a8e783b923c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="fact-identifier-832" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzMtMi0xLTEtMTY2ODQ_d6876a32-f8ed-41a2-ac2a-ee681c176cba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">780</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="fact-identifier-833" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzMtNC0xLTEtMTY2ODQ_a2aa029c-1c0b-4abc-981c-4cb4017e6698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">642</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering issuance costs and changes in fair value of warrants and private placement option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-834" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzQtMi0xLTEtMTY2ODQ_c619e41c-a0c1-4948-870f-2094e6a9df2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,176</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-835" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzQtNC0xLTEtMTY2ODQ_ce5437ca-f412-41d1-8a10-b6f70c42381c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,687</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax valuation allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-836" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzUtMi0xLTEtMTY2ODQ_69e8ba4c-d113-40e5-87d7-c8334cf7eecd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,718</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-837" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzUtNC0xLTEtMTY2ODQ_388e357e-3cef-4e41-b6c2-87089f427de1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,690</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="fact-identifier-838" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzYtMi0xLTEtMTY2ODQ_3e1fdba9-b7c1-4b1e-b130-9ad9bdd39fae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-839" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzYtNC0xLTEtMTY2ODQ_ebda2caa-c927-436f-a9aa-cf9967d9fa84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,187</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-840" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzctMi0xLTEtMTY2ODQ_aefd1e95-e62c-4116-82f4-1dee0c850131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-841" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTo2YzU0OWY5NmZmZGI0MDk1YTdiYmY2NzI1NDdjNjAzMi90YWJsZXJhbmdlOjZjNTQ5Zjk2ZmZkYjQwOTVhN2JiZjY3MjU0N2M2MDMyXzctNC0xLTEtMTY2ODQ_a5a6479b-36ad-4528-b308-f1d9928f312f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes, and the amounts used for income tax purposes. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="fact-identifier-842" continuedat="i5daf8359062a431f8300b4b1e8505ba4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzE5OTk_f608ae48-4a6c-41b8-8f5f-c7e640b4e957" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Significant components of the Companys deferred taxes as of December 31, 2021 and 2020 are as follows: </ix:nonnumeric></span></span></div><div style="margin-top:2pt;text-align:justify"><span><br></span></div><div><span><ix:continuation id="i5daf8359062a431f8300b4b1e8505ba4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carryforward</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-844" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzItMi0xLTEtMTY2ODQ_ee1d3651-98f4-40a9-a97e-bfac0c61cc53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,346</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-845" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzItNC0xLTEtMTY2ODQ_7a3a2c36-ebca-407f-b77e-3c2c62fe6f62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94,132</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:DeferredTaxAssetNonQualifiedStockOptions" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-846" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzMtMi0xLTEtMTY2ODQ_e6098564-39fc-4c68-a30e-99bc1fb8e750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,541</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:DeferredTaxAssetNonQualifiedStockOptions" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-847" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzMtNC0xLTEtMTY2ODQ_27b15d5e-ea40-46c0-81d8-deef0992ab5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,539</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-848" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzQtMi0xLTEtMTY2ODQ_1fc0fec7-cdc9-4969-a0c3-163cdd0662b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-849" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzQtNC0xLTEtMTY2ODQ_eae3a4e9-502c-4f05-8346-74836c02fcfd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,682</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-850" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzUtMi0xLTEtMTY2ODQ_61d686c2-f062-43fb-aac1-6c84b94bf427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,076</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-851" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzUtNC0xLTEtMTY2ODQ_38807874-2f23-4d5c-8012-73e9210a5692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,787</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="fact-identifier-852" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzYtMi0xLTEtMTY2ODQ_c40f8aa2-f5fc-4891-9391-dc71c152e645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-853" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzYtNC0xLTEtMTY2ODQ_f3955b8a-b9ee-4183-bff9-86cce822463c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">213</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="blcm:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-854" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzctMi0xLTEtMTY2ODQ_e2559eaf-5f70-4aed-a68b-a0cbd46743fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="blcm:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="fact-identifier-855" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzctNC0xLTEtMTY2ODQ_39213d66-e2a0-44d5-8c3c-3c8efea0b1a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">354</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="fact-identifier-856" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzgtMi0xLTEtMTY2ODQ_8e9a8d1c-f731-4aa5-a598-13de71f5a88f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-857" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzgtNC0xLTEtMTY2ODQ_b1646e50-2eb6-4344-aa9c-d919c4dd7041" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">976</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-858" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzktMi0xLTEtMTY2ODQ_8dd05695-ed64-4cde-860d-3069598e6ded" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,975</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-859" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzktNC0xLTEtMTY2ODQ_2c33addf-85ba-4179-8f56-9143b3db8aec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,257</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-860" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzEwLTItMS0xLTE2Njg0_1c1cf585-a65c-430d-b95c-d9c2b69b7c37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,975</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-861" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzEwLTQtMS0xLTE2Njg0_e30b941c-f072-4fbd-aaed-71ff84caf24e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,257</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-862" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzExLTItMS0xLTE2Njg0_49983cee-1e30-40c0-ab49-bbdd292babc6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-863" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTozY2FiOGFjNjZmOTg0MGVmYmM1ZGRhYTg2YTIwZWMzYi90YWJsZXJhbmdlOjNjYWI4YWM2NmY5ODQwZWZiYzVkZGFhODZhMjBlYzNiXzExLTQtMS0xLTE2Njg0_fa0c9a91-7756-42cc-aebf-08252ae3be7f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="fact-identifier-864" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzIwMDc_0d1d317a-adf0-4b2f-8379-3641ac2e6c5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards and research tax credits as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieaf683b96ef84367851ace784f569fdd_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-865" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzEtMi0xLTEtMTY2ODQ_8849c2f7-75fe-4db3-8fda-67c0c3be5119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">477,839</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if9cac21fa3564560b6a11612f4f5157e_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-866" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzEtNC0xLTEtMTY2ODQ_0de9e316-af05-4a17-93cc-1984a7480903" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">448,250</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i992c81554c22419c9fb83c9319dba987_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-867" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzItMi0xLTEtMTY2ODQ_10eb43af-3d19-400a-b8fd-27a815764a6d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i95535ea4bdc14a92b088e61d0092bc8a_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="fact-identifier-868" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzItNC0xLTEtMTY2ODQ_a28d8d61-f4e8-4fd3-a8ae-962a579d4242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal research tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieaf683b96ef84367851ace784f569fdd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-869" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzMtMi0xLTEtMTY2ODQ_02d3d51b-afce-43b1-b585-4182c53b925c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,985</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if9cac21fa3564560b6a11612f4f5157e_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-870" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzMtNC0xLTEtMTY2ODQ_682b4926-de80-45a0-af1b-f2c7dbd047f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,535</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas research tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i12df86319c3c4b788412c7e1c9748209_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-871" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzQtMi0xLTEtMTY2ODQ_f82d169c-cd82-4c84-b036-3bec3349e841" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,091</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibe8b1692698a4f07b46ede7dd7e20ae0_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-872" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90YWJsZTowYjM4ZTA1NDVmYWY0YjFjYjZhZDliZjU0NmY2MDVhOS90YWJsZXJhbmdlOjBiMzhlMDU0NWZhZjRiMWNiNmFkOWJmNTQ2ZjYwNWE5XzQtNC0xLTEtMTY2ODQ_427c2dd1-406d-4b86-b6a8-7ad160f6503d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,252</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $<span><ix:nonfraction unitref="usd" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-873" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzYwMw_4d90959e-23d6-4230-88fd-460a9864f3f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">228.4</ix:nonfraction></span> million of U.S. federal net operating loss carryovers that have no expiration date and the remaining begin to expire in 2025. The U.S. Federal and state research credits will begin to expire in 2028 and 2034 respectively.  No study has been performed on the research and development (R&amp;D) credits and gross R&amp;D credits in the amount of $<span><ix:nonfraction unitref="usd" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-874" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzkzNA_74768b0d-fbcb-4ee1-b9dd-65e5aaaf467a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17.8</ix:nonfraction></span> million could be limited based on review by the Internal Revenue Service.</span></div></ix:continuation></span><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><span><ix:continuation id="i1481af908008454ca0cdea78a0bcfa4e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Code Section 382 limits NOL and tax credit carry forwards when an ownership change of more than 50% of the value of the stock in a loss corporation occurs. Accordingly, the ability to utilize remaining NOL and tax credit carryforwards may be significantly restricted.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax asset will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during periods in which those temporary differences become deductible.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty surrounding the realization of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a <span><ix:nonfraction unitref="number" contextref="i0f186d28b811484ebb3e8a6a7ec9e242_I20211231" decimals="2" name="blcm:DeferredTaxAssetValuationAllowancePercentage" scale="-2" id="fact-identifier-876" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzIxOTkwMjMyNTc1ODA_a157a060-173e-45bc-8862-98be40e215a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction unitref="number" contextref="i236c04c5165044769887aa3cb89df57a_I20201231" decimals="2" name="blcm:DeferredTaxAssetValuationAllowancePercentage" scale="-2" id="fact-identifier-877" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzIxOTkwMjMyNTc1ODA_cbeba340-8ce0-48d6-87cc-fc6f8c425f9a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100</ix:nonfraction></span></ix:nonfraction></span>% valuation allowance on its net deferred tax assets at December 31, 2021 and 2020. The changes in the valuation allowance was an increase of $<span><ix:nonfraction unitref="usd" contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-878" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzE5MjY_a1f3c16a-18ff-40a7-8a29-aebe231048a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.7</ix:nonfraction></span> million and an increase of $<span><ix:nonfraction unitref="usd" contextref="i31abdc2095694632a1da4207c1d1f745_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-879" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjEvZnJhZzoyOGM4MzQxZjI4NDQ0ZWJjOTc4MzE3ZWU4OTQyNTM0Ni90ZXh0cmVnaW9uOjI4YzgzNDFmMjg0NDRlYmM5NzgzMTdlZTg5NDI1MzQ2XzE5NDg_e846c923-0d90-4262-a933-473da435db4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.7</ix:nonfraction></span> million for the years ended December 31, 2021 and 2020, respectively.</span></div></ix:continuation></span><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_124"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 - <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i9146c874a1d7449eba5143a27c6aff05_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="fact-identifier-880" continuedat="i982c8b40c69746528dbe66524150f393" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmRlNzFkYTNiMGQxZTRhNDFhMWFmZWEwNjFlMmQzZGQ2L3NlYzpkZTcxZGEzYjBkMWU0YTQxYTFhZmVhMDYxZTJkM2RkNl8xMjQvZnJhZzphN2EwMmIwNjRjMTE0ZWU1OWNkNmE5ODZkZTVmYjg5MS90ZXh0cmVnaW9uOmE3YTAyYjA2NGMxMTRlZTU5Y2Q2YTk4NmRlNWZiODkxXzE5NzE_56f00dde-4235-472f-9d6b-abde618834d4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SUBSEQUENT EVENTS</ix:nonnumeric></span></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i982c8b40c69746528dbe66524150f393" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">None.</ix:continuation></span> </span></div><div style="text-align:justify"><span><br></span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_127"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_130"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&nbsp;&nbsp;Controls and Procedures </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Principal Executive and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2021. The term disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companys management, including its Principal Executive and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Principal Accounting Officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Managements Annual Report on Internal Controls over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f) and 15d-15(f). Our internal control over financial reporting is designed under the supervision of our management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Companys internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Companys assets that could have a material effect on the Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including our Chief Executive Officer, has assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) in Internal Control-Integrated Framework. Based on those criteria and our evaluation,&nbsp;management has concluded that our internal control over financial reporting was effective as of&nbsp;December 31, 2021.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_133"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&nbsp;&nbsp;Other Information </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div><span><br></span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_1331"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_136"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&nbsp;III </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_139"></div><div style="padding-left:54pt;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the sections headed Election of Directors, Information about our Executive Officers and Section&nbsp;16(a)&nbsp;Beneficial Ownership Reporting Compliance in our definitive proxy statement for our Annual Meeting of Stockholders, or our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021, and is incorporated herein by reference.</span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_142"></div><div style="padding-left:54pt;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&nbsp;&nbsp;Executive Compensation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed Executive and Director Compensation in our Proxy Statement and is incorporated herein by reference. </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_145"></div><div style="padding-left:54pt;text-align:justify;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed Equity Benefit Plans and Security Ownership of Certain Beneficial Owners and Management in our Proxy Statement and is incorporated herein by reference. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&nbsp;201(d) of Regulation S-K will be set forth in the section headed Executive and Director Compensation in our Proxy Statement and is incorporated herein by reference. </span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_148"></div><div style="padding-left:54pt;text-align:justify;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&nbsp;&nbsp;Certain Relationships and Related Party Transactions, and Director Independence </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the sections headed Certain Relationships and Related Party Transactions and Election of Directors in our Proxy Statement and is incorporated herein by reference. </span></div><div style="text-align:justify"><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_151"></div><div style="padding-left:54pt;text-align:justify;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&nbsp;&nbsp;Principal Accounting Fees and Services </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed Principal Accounting Fees and Services in our Proxy Statement and is incorporated herein by reference.</span></div><div><span><br></span></div><div><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_154"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&nbsp;IV</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-51.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">ITEM 15. Exhibits, Financial Statements and Schedules </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(1) Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item 15 is set forth under Part II, Item 8 above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(2) Financial Statement Schedules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have omitted these schedules because they are not required, or are not applicable, or the required information is shown in the consolidated financial statements or notes thereto. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(3) Exhibits.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr style="height:6pt"><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000021/exh31-amendedandrestat.htm" tabindex="18">Amended and Restated Certificate of Incorporation, as amended by Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000021/exh31-amendedandrestat.htm" tabindex="18">s Quarterly Report Form 10-Q with the SEC on August 6, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514452822/d842482dex32.htm" tabindex="18">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrants Current Report on Form 8-K, filed with the SEC on August 5, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312519224579/d793259d8k.htm" tabindex="18">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrants Current Report on Form 8-K, filed with the SEC on August 5, 2019).</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514452822/d842482dex32.htm" tabindex="18">).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex31.htm" tabindex="18">Certificate of Designations, Preferences and Rights of Series 1 Redeemable Convertible Non-Voting Preferred Stock, Series 2 Redeemable Convertible Non-Voting Preferred Stock and Series 3 Redeemable Convertible Non-Voting Preferred Stock of Bellicum Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex31.htm" tabindex="18">s report on Form 8-K, filed with the SEC on August 19, 2019).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Reference is made to Exhibits <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000021/exh31-amendedandrestat.htm" tabindex="18">3.1</a> and <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312519224579/d793259d8k.htm" tabindex="18">3.2</a>.</span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514436933/d788220dex41.htm" tabindex="18">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-200328), originally filed with the SEC on November 18, 2014).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/a2015q4exh44bakerregrights.htm" tabindex="18">Registration Rights Agreement by and among the Registrant and Baker Brothers Life Sciences, LP, and two of its affiliated funds, dated January 15, 2016 (incorporated by reference to Exhibit 4.4 to Registrants Registration Statement on Form S-3 (File No. 333-209012), filed with the SEC on January 15, 2016).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex41.htm" tabindex="18">Form of Warrant issued in public offering (incorporated by reference to Exhibit 4.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex41.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex42.htm" tabindex="18">Form of Warrant issued in private offering (incorporated by reference to Exhibit 4.2 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/d793259dex42.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000007/exhibit47_descriptionofsec.htm" tabindex="18">Description of Description of Securities (incorporated by reference to Exhibit 4.7 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000007/exhibit47_descriptionofsec.htm" tabindex="18">s Current Report on Form 10K (File No. 001-36783), filed with the SEC on March 12, 2020.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312519224579/d793259dex101.htm" tabindex="18">Securities Purchase Agreement, dated August 16, 2019, by and among the Company and the institutional investors named therein, (incorporated by reference to Exhibit 10.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312519224579/d793259dex101.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312520283250/d57640dex41.htm" tabindex="18">Form of pre-funded warrant (incorporated by reference to Exhibit 4.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312520283250/d57640dex41.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783). filed with the SEC on November 2, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312520283250/d57640dex42.htm" tabindex="18">Form of warrant to purchase common stock (incorporated by reference to Exhibit 4.2 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000119312520283250/d57640dex42.htm" tabindex="18">s Current Report on Form 8-K (File No.001-36783), filed with the SEC on November 2, 2020).</a></span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex41.htm" tabindex="18">Form of Pre-Funded Warrant issued in private placement (incorporated by reference to Exhibit 4.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex41.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex42.htm" tabindex="18">Form of Accompanying Common Warrant issued in private placement (incorporated by reference to Exhibit 4.2 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex42.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex101.htm" tabindex="18">Securities Purchase Agreement dated August 16, 2019, by and among the Company, Baker Brothers Life Sciences, LP, and Boxer Capital, LLC (incorporated by reference to Exhibit 10.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521348507/d215852dex101.htm" tabindex="18">s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021).</a></span></div></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex101.htm" tabindex="18">Form of Indemnification Agreement by and between the Registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex101.htm" tabindex="18">s Registration Statement on Form S-1, as amended (File No. 333-200328), originally filed with the SEC on November 18, 2014).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex103.htm" tabindex="18">Bellicum Pharmaceuticals, Inc. 2011 Stock Option Plan and Forms of Incentive Stock Option Grant Agreement and Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-200328), originally filed with the SEC on November 18, 2014).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(A)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840319000058/exhibit102-2014equityincen.htm" tabindex="18">Bellicum Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrants Quarterly Report on Form 10-Q filed with the SEC on May 5, 2019). </a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(B)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104bxformofstoc.htm" tabindex="18">Form of Stock Option Grant Notice and Option Agreement under the 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4(B) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(C)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104cxformofstoc.htm" tabindex="18">Form of Stock Option Grant Notice and Option Agreement under the 2014 Equity Incentive Plan (with accelerated vesting) (incorporated by reference to Exhibit 10.4(C) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(D)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104dformofrestr.htm" tabindex="18">Form of Restricted Stock Award Notice and Restricted Stock Award Agreement under the 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4(D) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(E)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104eformofrestr.htm" tabindex="18">Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement under the 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4(E) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(F)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104fformofstock.htm" tabindex="18">Form of Stock Option Grant Notice and Option Agreement under the 2014 Equity Incentive Plan (Inducement Award)(incorporated by reference to Exhibit 10.4(F) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(G)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex104gformofstock.htm" tabindex="18">Form of Stock Option Grant Notice and Option Agreement under the 2014 Equity Incentive Plan (Non-Employee Director Form) (incorporated by reference to Exhibit 10.4(G) to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(A)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000119312521193361/d164967dex101.htm" tabindex="18">Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrants Quarterly Report on Form 8-K filed with the SEC on June 17, 2021).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(B)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/exhibit105b_2019equityince.htm" tabindex="18">Forms of stock option grant notice, stock option agreement and notice of exercise, and forms of restricted stock award notice and restricted stock award agreement under the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000021/exh101-directorcompens.htm" tabindex="18">Bellicum Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001358403/000135840320000021/exh101-directorcompens.htm" tabindex="18">s Quarterly Report on Form 10-Q filed with SEC on August 6, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/bellicum-ex107amendedincen.htm" tabindex="18">Incentive Award Program, as amended on February 19, 2018 (incorporated by reference to Exhibit 10.7 to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2018).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/exh43ceoemploymentagreement.htm" tabindex="18">Letter Agreement by and between the Registrant and Richard A. Fair, dated January 25, 2017 (incorporated by reference to Exhibit 10.43 to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1014.htm" tabindex="18">Notice of Expansion of Licensed Field to Obtain Additional Exclusive Rights (incorporated by reference to Exhibit&nbsp;10.14 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-200328), originally filed with the SEC on November 18, 2014).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1015.htm" tabindex="18">Amended and Restated License Agreement by and between the Registrant and ARIAD Pharmaceuticals, Inc., dated March 7, 2011 (incorporated by reference to Exhibit&nbsp;10.1  to the Registrants Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1016.htm" tabindex="18">Omnibus Amendment Agreement by and between Registrant and ARIAD Pharmaceuticals, Inc., dated October 3, 2014 (incorporated by reference to Exhibit&nbsp;10.2 to the Registrants Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1017.htm" tabindex="18">Exclusive License Agreement by and between the Registrant and Baylor College of Medicine, dated March 20, 2008 (incorporated by reference to Exhibit&nbsp;10.3  to the Registrants Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1018.htm" tabindex="18">Exclusive License Agreement by and between the Registrant and Baylor College of Medicine, dated June 27, 2010 (incorporated by reference to Exhibit&nbsp;10.4  to the Registrants Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1019.htm" tabindex="18">Cancer Research Grant Contract by and between the Registrant and the Cancer Prevention and Research Institute of Texas, dated July 27, 2011 (incorporated by reference to Exhibit&nbsp;10.5  to the Registrants Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000119312514416804/d788220dex1020.htm" tabindex="18">Exclusive License Agreement by and between the Registrant and Baylor College of Medicine, effective November 1, 2014 (incorporated by reference to Exhibit&nbsp;10.6  to the Registrants Quarterly Report on Form 10-Q filed with SEC on November 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840315000066/a2015q2exh102biovec.htm" tabindex="18">License Agreement by and between the Registrant and BioVec Pharma, Inc., dated as of June 4, 2015 (incorporated by reference to Exhibit 10.2 to the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840315000066/a2015q2exh102biovec.htm" tabindex="18">s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2015)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/a2015q4exh1033agensyslicag.htm" tabindex="18">Exclusive License Agreement by and between the Registrant and Agensys, Inc., effective as of December 10, 2015 (incorporated by reference to Exhibit 10.33 to the Registrants Annual Report on Form 10-K filed with the SEC on March 14, 2016).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/exh1041-adaptimmuneagreeme.htm" tabindex="18">Co-Development and Co-Commercialisation Agreement by and between the Registrant and Adaptimmune Limited, effective as of December 16, 2016 (incorporated by reference to Exhibit 10.41 to the Registrants Annual Report on Form 10-K filed with the SEC on March 13, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25^</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit1025mdaccassetpurch.htm" tabindex="18">Master Services Agreement Between The University of Texas M. D. Anderson Cancer Center and Bellicum Pharmaceuticals, Inc.</a></span></div></td></tr><tr style="height:6pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit1026charityemployme.htm" tabindex="18">Employment Agreement by and between the Registrant and Charity Scripture, dated December 1, 2021.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit211subsidiaries2021.htm" tabindex="18">Subsidiaries of the Registrant.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit231consentofey.htm" tabindex="18">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_160" tabindex="18">Power of Attorney. Reference is made to the signature page hereto.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit311-202110k.htm" tabindex="18">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/exhibit321-202110k.htm" tabindex="18">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance</span></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation</span></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition</span></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels</span></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation</span></td></tr></tbody></table></div><div style="padding-right:450pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:9.305%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit (indicated by [***]) have been omitted as the Registrant as determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to the Registrant if publicly disclosed.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">^</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit have been omitted (indicated by [***]) because the Company has determined that the information is not material and is the type that the Company treats as private or confidential.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_157"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ide71da3b0d1e4a41a1afea061e2d3dd6_7" tabindex="18">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. Form 10-K Summary</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br></span></div><div id="ide71da3b0d1e4a41a1afea061e2d3dd6_160"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tbody><tr><td style="width:1.0%"></td><td style="width:46.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bellicum Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 24, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard A. Fair</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Fair</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard A. Fair as his true and lawful attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorney-in-fact, or his substitute or substitutes may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard A. Fair</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard A. Fair</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Charles S. Grass</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles S. Grass</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Brown</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Brown</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jon P. Stonehouse</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jon P. Stonehouse</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James M. Daly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James M. Daly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stephen R. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen R. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Reid M. Huber, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reid M. Huber, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Judith Klimovsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Judith Klimovsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div>

</body>
</html>